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Abstract 
Diabetes mellitus is a complex disease characterised by chronic hyperglycaemia due to 
compromised insulin synthesis and secretion, or decreased tissue sensitivity to insulin, if not 
all three conditions. Endothelial dysfunction is a common complication in diabetes in which 
endothelium-dependent vasodilation is impaired. The aim of this study was to examine the 
involvement of TRPV4 in diabetes endothelial dysfunction. Male Charles River Wistar rats 
(350–450 g) were injected with 65mg/kg streptozotocin (STZ) intraperitoneally. STZ-injected 
rats were compared with naïve rats (not injected with STZ) or control rats (injected with 
10ml/kg of 20mM citrate buffer, pH 4.0–4.5), if not both. Rats with blood glucose 
concentrations greater than 16mmol/L were considered to be diabetic. As the results revealed, 
STZ-diabetic rats showed significant endothelial dysfunction characterised by impaired 
muscarinic-induced vasodilation, as well as significant impairment in TRPV4-induced 
vasodilation in aortic rings and mesenteric arteries. Furthermore, STZ-diabetic primary aortic 
endothelial cells (ECs) showed a significant reduction in TRPV4-induced intracellular 
calcium ([Ca2+]i) elevation. TRPV4, endothelial nitric oxide synthase (eNOS), and caveolin-1 
(CAV-1) were also significantly downregulated in STZ-diabetic primary aortic ECs and were 
later significantly restored by in vitro insulin treatment. Methylglyoxal (MGO) was 
significantly elevated in STZ-diabetic rat serum, and nondiabetic aortic rings incubated with 
MGO (100μM) for 12 hours showed significant endothelial dysfunction. Moreover, 
nondiabetic primary aortic ECs treated with MGO (100μM) for 5 days showed significant 
TRPV4 downregulation and significant suppression of 4-α-PDD-induced [Ca2+]i elevation, 
which was later restored by L-arginine (100μM) co-incubation. Incubating nondiabetic aortic 
rings with MGO (100μM) for 2 hours induced a spontaneous loss of noradrenaline-induced 
contractility persistence. Moreover, MGO induced significant [Ca2+]i elevation in Chinese 
hamster ovary cells expressing rat TRPM8 channels (rTRPM8), which was significantly 
inhibited by AMTB (1–5μM). Taken together, TRPV4, CAV-1, and eNOS can form a 
functional complex that is downregulated in STZ-diabetic aortic ECs and restored by insulin 
treatment. MGO elevation might furthermore contribute to diabetes endothelial dysfunction 
and TRPV4 downregulation. By contrast, MGO induced the loss of contractility persistence, 
possibly due to MGO’s acting as a TRPM8 agonist. 
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1. Chapter 1: General introduction 
1.1. Diabetes mellitus definition 
Diabetes mellitus (DM) is a complex disease characterised by chronic blood glucose 
elevation (hyperglycaemia) due to compromised insulin synthesis and secretion or declined 
tissue sensitivity to insulin, if not all three conditions (F. M. Ashcroft & Rorsman, 2012). In 
2015, the International Diabetes Federation (2015) reported that approximately 415 million 
people worldwide have diabetes and that DM accounted for approximately 5 million deaths, 
or one death every 6 seconds.  
1.2. Diabetes mellitus types 
Of all diabetes patients, approximately 10% are diagnosed with type-1-DM—that is, insulin 
dependent DM (T1DM)—which is mainly attributed to autoimmune aetiological factors such 
as plasma islet-cells antibodies that destroy pancreatic β-cells (American Diabetes 
Association, 2012; F. M. Ashcroft & Rorsman, 2012). Children aged less than 12 years 
comprise the majority of T1DM patients who require lifelong insulin treatment for their 
survival. However, two types of monogenic diabetes are commonly misdiagnosed as T1DM 
due to early symptoms detection: neonatal diabetes (ND), which is diagnosed in the first 6 
months of life, and maturity-onset diabetes of the young (MODY), which affects individuals 
aged less than 25 years (F. M. Ashcroft & Rorsman, 2012). Numerous therapeutic options are 
available to manage diabetes, including glibenclamide, which is a sulphonylurea capable of 
controlling 90% of cases of ND as well as MODY patients in general (F. M. Ashcroft & 
Rorsman, 2012). 
Approximately 90% of diabetic patients have type-2-DM (T2DM), which is regarded as a 
complex disease whose risk factors include genetic factors, lifestyle, age, obesity, pregnancy, 
and gender (Chao & Henry, 2010). Unlike T1DM, T2DM does not require its patients to 
receive insulin injections or pumps in order to survive, since insulin secretion is partially 
deficient or resisted, if not both, the latter primarily attributed to increased abdominal fat and 
obesity (American Diabetes Association, 2012; F. M. Ashcroft & Rorsman, 2012). Reduced 
insulin secretion derives from an altered insulin signalling cascade or reduced β-cell mass, if 
not both. However, studies remain inconclusive regarding the extent of β-cell mass reduction. 
As a case in point, an earlier study with 91 obese patients showed that approximately 65% of 
β-cell deficiency was associated with T2DM (Butler et al., 2003), whereas another concluded 
that only 10% of β-cell mass reduction was associated with the range of altered insulin 
signalling components that initiate diabetes (Del Guerra et al., 2005). 
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1.3. Insulin secretion 
Glucose-induced insulin secretion is a calcium-dependent cascade. Glucose-transporters-1 
(GLUT-1) uptake plasma glucose into pancreatic β-cells to generate ATP (F. M. Ashcroft & 
Rorsman, 2012), which is accompanied with ADP reduction and  ATP-sensitive potassium 
(KATP) channels closure (Arkhammar, Nilsson, Rorsman, & Berggren, 1987). Once KATP 
channels close, calcium ions (Ca
2+) flow in through corresponding channels and thereby 
initiate insulin exocytosis (Frances M Ashcroft, Harrison, & Ashcroft, 1984). However, 
glucose is not the only insulin release stimulator. As Figure 1 shows, lipids and proteins are 
also insulin secretagogues, as are other neurotransmitters and hormones, including incretins, 
which stimulate insulin secretion independently from Ca2+ (F. M. Ashcroft & Rorsman, 2012; 
Vilsbøll et al., 2008). 
Figure 1. Insulin release from pancreatic β-cells, which is Ca2+ dependent since GLUT-1 transporter uptake 
glucose is metabolised to stimulate the closure of potassium channels that triggers Ca2+ influx, whereas 
glucagon-like peptide-1 (GLP-1) stimulates insulin secretion independent from Ca2+; adapted from F. M. 
Ashcroft and Rorsman (2012). 
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1.3.1. Insulin signalling 
Insulin signalling is a complicated cascade that begins when insulin binds to its 
corresponding tyrosine kinase (TK)-coupled receptor, an insulin receptor (IR) that is 
phosphorylated to provide docking sites for intracellular proteins that function as insulin 
receptor substrates (IRS1-4) (Taniguchi, Emanuelli, & Kahn, 2006). Since it exerts TK 
activity, IR phosphorylates IRS1-4 to unveil an interactive sulfhydryl (SH2) domain 
responsible for activating phosphatidylinositol 3-kinase/protein kinase B (PI3K/PKB), as well 
as Ras-mitogen-activated protein kinase (MAPK) pathways that trigger approximately 40 
cellular targets for glucose uptake, protein synthesis, and vesicular trafficking (X. Jia & Wu, 
2007; Krüger et al., 2007; Taniguchi et al., 2006). Although ubiquitously expressed in the 
body, IRs are primarily expressed in metabolically active cells such as hepatocytes and 
adipocytes (Desbuquois et al., 1993), as well as in the hippocampus, where they are involved 
in cognition and memory (Ho et al., 2012). More specifically, endothelial IRs are involved in 
regulating vascular tone by mediating nitric oxide (NO) release and thus vasodilation 
(Federici et al., 2004). Insulin binding to IRS-1 stimulates endothelial nitric oxide synthase 
(eNOS) phosphorylation at serine-1177 and threonine-497 and thereby induces NO 
generation (Nigro et al., 2014), , as figure 2 illustrates. However, in T2DM, insulin resistance 
correlates to diabetes complications such as endothelial dysfunction (Mustafa, Sharma, & 
McNeill, 2009). 
Figure 2. Insulin-induced endothelial nitric oxide (NO) signalling cascade, in which insulin binds to insulin 
receptors (IR) phosphorylated to be further bound with insulin receptor substrate-1 (IRS-1) in order to activate a 
phosphatidylinositol 3-kinase/protein kinase B (PI3K/PKB) pathway that culminates with Akt phosphorylation. 
Akt phosphorylation activates endothelial nitric oxide synthase (eNOS), which generates NO as a means to 
achieve vasodilation (Shamsaldeen, Mackenzie, Lione, & Benham, 2016). 
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1.4. Diabetes complications 
Given its increasing prevalence, DM is forecast to affect approximately 600 million people 
worldwide by 2035 (DiabetesUK, 2014). Diabetes complications such as endothelial 
dysfunction, nephropathy, and neuropathic pain occur in both T1DM and T2DM patients, and 
approximately 50% of diabetics have demonstrated some of those complications at their 
initial diagnoses (M. Davies, Brophy, Williams, & Taylor, 2006; UK Prospective Diabetes 
Study Group, 1991). Diabetes complications compromise diabetic patients’ quality of life and 
contribute to significant economic burden (M. Davies et al., 2006). In 2011, for example, the 
UK National Health Services spent approximately £8 billion on managing diabetes 
complications and burdened the national treasury with a cost of approximately £24 billion, a 
figure that by 2035 is expected to reach approximately £40 billion, or 17% of the total 
expenditure on health resources (Hex, Bartlett, Wright, Taylor, & Varley, 2012). 
Furthermore, currently available diabetes therapies have several contraindications and pose 
adverse effects, and accordingly, the aim to efficiently manage diabetes complications 
remains unachieved (Virally et al., 2007). As such, new therapeutic strategies are required to 
manage diabetes complications and should focus on understanding the precise 
pathophysiology and selection or development of therapeutic options accordingly (Harden & 
Cohen, 2003). Among the numerous complications of diabetes, endothelial dysfunction is the 
chief focus of this research. Clarifying the physiology of endothelium-dependent vasodilation 
should provide a robust foundation for understanding the pathophysiology of endothelial 
dysfunction in diabetes. 
1.4.1. Endothelium-dependent vasodilation 
Blood vessels are primarily composed of three layers: the outer layer (tunica adventitia), the 
medial layer (smooth muscle cells, or tunica media), and the inner layer (endothelium or 
tunica intima) (C. W. Chen, Corselli, Peault, & Huard, 2012). The endothelium regulates 
vascular tone by releasing numerous vasodilators, including NO, prostaglandins (PG), and 
endothelium-derived hyperpolarising factor (EDHF), in addition to vasoconstrictors such as 
endothelin-1 (ET-1) and angiotensin II (Ang II) (Tabit, Chung, Hamburg, & Vita, 2010).  
On the whole, the endothelium mediates the transmission of electrical signals from one locus 
to remotely control vascular tone (Garland & Weston, 2011). 
NO in endothelial cells (ECs) is generated by way of endothelial NO synthase (eNOS), which 
oxidises L-arginine into L-citrulline (M. I. Lin et al., 2003). eNOS or NOS-3 is a 
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constitutively active enzyme in the ECs that can be further stimulated by receptor-dependent 
agonists that increase [Ca2+]i and compromise plasma membrane phospholipid symmetry 
(Cines et al., 1998; A. Dhar, Dhar, Desai, & Wu, 2010). eNOS is attached to the membranous 
caveolar protein, caveolin-1 (CAV-1), from which eNOS is displaced to become active 
through calcium calmodulin (CaM) binding (Adak, Wang, & Stuehr, 2000; H. Wang, Wang, 
Liu, Chai, & Barrett, 2009). NO diffuses to the vascular smooth muscle cells (VSMCs), 
where it activates the soluble guanylate cyclase (sGC) that generates cyclic guanosine-3,5-
monophosphate (cGMP) in order to achieve vasodilation (van den Oever, Raterman, 
Nurmohamed, & Simsek, 2010). cGMP inhibits the voltage-gated calcium channels (VGCC)-
mediated Ca2+ entry into the VSMCs to inhibit the vasoconstriction. At the same time, cGMP 
activates potassium channels such as BKca, KATP, and voltage-gated potassium channels 
(Kv), which induces membrane hyperpolarisation and vasodilation (Dong, Waldron, Cole, & 
Triggle, 1998; Murphy & Brayden, 1995b). cGMP also activates PKG, which in turn 
activates myosin light-chain phosphatase (MLCP) that dephosphorylates the myosin light 
chain (MLC) and causes further vasodilation (Poulos, 2006). NO reduces [Ca2+]i in the 
VSMCs by activating the sarcoplasmic and endoplasmic calcium ATPase (SERCA) pumps 
that uptake [Ca2+]i in order to fill cellular calcium stores and thereby inhibit the store 
operated calcium channels (SOCs) from inducing vasoconstriction (Cohen et al., 1999). 
Another NOS isoform, inducible NO synthase (iNOS), is induced by inflammatory mediators 
such as cytokines to release NO independent of Ca2+ (Kleinert, Pautz, Linker, & Schwarz, 
2004). Experimentally, iNOS expression can be induced by lipopolysaccharides (LPS), a 
bacterial cell wall component (Hattori, Hattori, & Kasai, 2003). A previous study showed that 
LPS-incubation reduces vascular contractility and thereby induces vascular relaxation in rat 
aortic strips denuded from the endothelium; such relaxation was mediated by the release of 
NO and the activation of calcium-activated potassium channels (Kca) channels in VSMCs 
(Hall, Turcato, & Clapp, 1996). Therefore, inducing iNOS expression might be associated 
with the activation of Kca that is responsible for the vasodilation associated with septic shock 
(Hall et al., 1996). Moreover, NO generated by iNOS was shown to inhibit cytokine-induced 
vasospasm in the coronary arteries of pigs (Fukumoto et al., 1997).  
In addition to NO, cyclooxygenase-1 (COX-1) in ECs metabolises arachidonic acid (AA) to 
produce prostacyclin, which is a potent vasodilator (Mitchell, Ali, Bailey, Moreno, & 
Harrington, 2008). AA is then liberated from the ECs membrane through the action of 
phospholipase A2 (PLA2) (Lambert, Pedersen, & Poulsen, 2006). Endothelial COX-1 
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initially metabolises AA into prostaglandin G2, which is then metabolised through the 
peroxidase activity of COX-1 into prostaglandin H2 (PGH2) (Mitchell et al., 2008). 
Afterward, PGH2 is metabolised into the vasodilator prostacyclin (PGI2) through 
prostaglandin G synthase (Mitchell et al., 2008). Prostacyclin mediates vasodilation by 
activating the KATP channels in VSMCs, which prompts membrane hyperpolarisation and, in 
turn, vasodilation (Jackson, Konig, Dambacher, & Busse, 1993). Moreover, prostacyclin 
binds to the prostacyclin receptor IP, a G-protein coupled receptor (GPCR) that activates the 
Gαs subunit that consequently activates adenylyl cyclase (AC), which converts endothelial 
ATP into cAMP. Otherwise, it can activate the Gαq subunit that further activates the 
membranous PLC to hydrolyse the membrane PIP2 into IP3 and DAG (Lawler, Miggin, & 
Kinsella, 2001). Accordingly, IP3 binds to the endoplasmic reticulum (ER) IP3-R to induce 
the release of Ca2+ from ER stores to mediate endothelium Ca2+ entry, which is a crucial step 
in initiating endothelium-dependent vasodilation (Murata et al., 2007). As another previous 
study showed, blocking BKca through iberiotoxin (25–50nM) prevented prostacyclin-
induced vasodilation and thereby revealed BKca involvement in aortic vasodilation in guinea 
pigs (Clapp, Turcato, Hall, & Baloch, 1998).  
Along with NO and prostacyclin, a third endothelial vasodilatory pathway is EDHF (G. Chen, 
Suzuki, & Weston, 1988). Previous studies have been conducted to identify the mechanism of 
action of EDHF and consequently revealed the involvement of a wide range of potassium 
channels. In eNOS knockout (KO) mice, acetylcholine-induced vasodilation was significantly 
inhibited by a physiological salt solution high in potassium (40mM) or iberiotoxin (100nM), 
which revealed BKca as an essential element of the EDHF pathway (A. Huang et al., 2000). 
Moreover, apamin (30nM), a selective SKca blocker, significantly inhibited EDHF-mediated 
vasodilation in rabbit mesenteric arteries treated with acetylcholine (Murphy & Brayden, 
1995a). Another study revealed IKca as an additional component of EDHF-mediated 
vasodilation, since charybdotoxin (0.3μM) inhibited acetylcholine-induced vasodilation in rat 
hepatic arteries, though such did not occur when charybdotoxin was substituted with 
iberiotoxin (0.1μM), which thereby revealed IKca involvement in mediating EDHF 
(Zygmunt & Högestätt, 1996). However, the role of KATP might not be essential to the EDHF 
pathway. Indeed, previous studies have shown that glibenclamide (5μM), a KATP blocker, did 
not inhibit hyperpolarisation induced by EDHF in rabbit mesenteric arteries (Murphy & 
Brayden, 1995a). In addition to the involvement of Kca channels, as numerous studies have 
revealed, epoxyeicosatrienoic acid (EET) is another essential component in the EDHF 
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pathway. In one such study, the metabolism of AA through cytochrome P450 epoxygenase 
proved to be the primary vasodilatory pathway in small epicardial arteries (Widmann, 
Weintraub, Fudge, Brooks, & Dellsperger, 1998). Another study showed that applying 5, 6-
EET to cultured rat ASMCs effected membrane hyperpolarisation similar to that of EDHF 
(Popp, Bauersachs, Hecker, Fleming, & Busse, 1996). At the same time, when the synthesis 
of 5, 6-EET, and 11, 12-EET and 14, 15-EET was inhibited by SKF 525a, AA-induced 
vasodilation became significantly inhibited in the bovine coronary artery, which highlighted 
EET derivatives as essential components of the EDHF pathway (Hecker, Bara, Bauersachs, & 
Busse, 1994; Rosolowsky & Campbell, 1993).  
However, the predominant role of each of the three aforementioned vasodilatory pathways 
differs according to blood vessel size. In a previous study, EDHF and the metabolism of AA 
through cytochrome P450 epoxygenase was the chief vasodilatory pathway in small 
epicardial arteries (Sandow & Hill, 2000; Widmann et al., 1998). By contrast, the NO 
pathway was identified as the primary mediator in large epicardial arteries (Widmann et al., 
1998). Such findings are consistent with the idea that the role of the EDHF pathway in 
mediating vasodilation is greater than that of NO in small vessels (Shimokawa et al., 1996). 
That dynamic might be attributed to expanded myoendothelial gap junctions in smaller 
arteries (e.g., mesenteric arteries), which furnish sites for electrical communication between 
the endothelium and vascular smooth muscle (VSM) (Sandow & Hill, 2000).  
Added to the three primary vasodilation pathways, at least 21 distinct transient receptor 
potential (TRP) channels have been recognised in VSMCs in studies involving Western 
blotting, reverse transcription polymerase chain reaction (RT-PCR), and 
immunohistochemistry (H. Y. Kwan, Huang, & Yao, 2007). TRP channels are ion channels 
that differ in their permeability to sodium (Na+), potassium (K+), and Ca2+ (Watanabe, 
Murakami, Ohba, Takahashi, & Ito, 2008), and most moderate Ca2+ conductance at a 
conductance ratio of P Ca2+/ P Na+ = 0.3–10 (Watanabe et al., 2008). VSMCs’ TRP channels 
include all TRPCs and TRPMs, in addition to TRPV1–TRPV4, TRPP1, and TRPP2 (H. Y. 
Kwan et al., 2007). Similar TRP were also found in the endothelium along with TRPA1, 
though not TRPM5 (Earley, Gonzales, & Garcia, 2010; H. Y. Kwan et al., 2007; Watanabe et 
al., 2008). As cation channels, TRP channels exert vascular tone regulation in both systemic 
and pulmonary circulations (Watanabe et al., 2008) and are involved in controlling VSMCs 
survival pathways by regulating Ca2+, Mg2+ and Na+ homeostasis, which is mediated by 
calcium-selective or -nonselective receptor-operated Ca2+ channels (ROCCs), if not both, that 
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stimulate VGCCs through Na+-mediated cell depolarisation (Watanabe et al., 2008). 
Sustained endothelium Ca2+ entry contributes to NO and PG generation and thereby 
vasodilation (D. X. Zhang et al., 2009). Notably, NO is among the vasodilators released in 
response to shear stress and TRPV4 activation (Sena, Pereira, & Seiça, 2013; Sukumaran et 
al., 2013). 
Numerous researchers have shown how TRP channels contribute to vascular tone regulation, 
as summarised in Table 1. 
Table 2 TRP channels contribution in vascular tone regulation 
TRP channel The vascular effect of TRP channel activation 
TRPC1 Endothelium independent vasodilation by BKca coupling (H.-Y. 
Kwan et al., 2009) and mediating ET-1-induced vasoconstriction 
(Bergdahl et al., 2003) 
TRPC2 Pseudogene (Vannier et al., 1999) 
TRPC3 Bradykinin-induced vasodilation mediated by endothelial TRPC3 
(C.-l. Liu, Huang, Nga, Leung, & Yao, 2006) and pyrimidine and 
ET-1-induced vasoconstriction mediated by TRPC3 (Peppiatt‐
Wildman, Albert, Saleh, & Large, 2007; Reading, Earley, Waldron, 
Welsh, & Brayden, 2005) 
TRPC4 Significant impairment of muscarinic-induced vasodilation by 
TRPC4 knockout (KO) (Marc Freichel et al., 2001) and TRPC4 
downregulation prevents stretch-induced vascular offset (Lindsey, 
Tribe, & Songu-Mize, 2008) 
TRPC5 TRPC5 is a SOC in dwarf rabbit’s VSMCs (S.-Z. Xu, Boulay, 
Flemming, & Beech, 2006), and TRPC5 nitrosylation provides 
positive feedback for TRPC5-induced Ca2+ influx in the 
endothelium (T. Yoshida et al., 2006) 
TRPC6 TRPC6 translocation activated by 11, 12-EET, which may contribute 
to vasodilation through endothelial Kca activation (Fleming et al., 
2007), and increased contractility provided by TRPC6 KO VSMCs 
(Dietrich et al., 2005) 
TRPC7 Vasopressin (AVP)-induced depolarisation in VSMCs contributed to 
TRPC7 and TRPC6 heteromultimeric channels (Maruyama et al., 
2006), and ET-1-induced vasoconstriction mediated by TRPC7 
(Peppiatt‐Wildman et al., 2007) 
TRPM1 Vascular effects yet to be investigated 
TRPM2 Oxidative stress-induced endothelial cells’ hyperpermeability and 
apoptosis mediated by TRPM2 (Hecquet, Ahmmed, Vogel, & Malik, 
2008) 
TRPM3 Vasoconstriction in murine arteries induced by TRPM3 (Naylor et 
al., 2010) 
TRPM4 Vasoconstriction induced by TRPM4 (Gonzales, Garcia, Amberg, & 
Earley, 2010; Reading & Brayden, 2007) 
TRPM6 Mg2+ influx into the VSMCs mediated by TRPM6, though the exact 
function of TRPM6 is unclear (Touyz et al., 2006) 
9 
 
TRPM7 Mg2+ influx into the VSMCs mediated by TRPM7 in response to Ang 
II (Touyz et al., 2006), and Mg2+ influx into the VSMCs mediated by 
TRPM7 to further mediate bradykinin endothelium-dependent 
vasodilation (Callera et al., 2009; Paravicini, Yogi, Mazur, & Touyz, 
2009) 
TRPM8 Vasodilation in pre-contracted mesenteric and thoracic aortic arteries 
induced by TRPM8 agonists (C. D. Johnson et al., 2009; Silva et al., 
2015), and endothelium independent vasodilation possibly induced 
by TRPM8 via BKca (A. I. Bondarenko, R.  Malli, & W. F. Graier, 
2011a; Earley, Heppner, Nelson, & Brayden, 2005) 
TRPP1 Blood shear stress-induced endothelial nitric oxide (NO) generation 
mediated by TRPP1 in a KO study (Nauli et al., 2008) 
TRPP2 Blood shear stress-induced endothelial NO generation partially 
mediated by TRPP2 in a KO study (AbouAlaiwi et al., 2009) 
TRPV1 Endothelium-dependent vasodilation through capsaicin ingestion (D. 
Yang et al., 2010), and vasoconstriction induced with TRPV1 
activated in C-fibres (Scotland et al., 2004) 
TRPV2 May contribute to vasoconstriction (Muraki et al., 2003) 
TRPV3 Endothelium-dependent vasodilation following treatment with 
carvacrol, a dietary TRPV3 agonist (Earley et al., 2010) 
TRPV4 Endothelium-dependent vasodilation through shear stress activation 
and independent vasodilation through BKca activation (Earley et al., 
2005; Earley et al., 2009) 
TRPA1 Significant reduction in propofol-induced vasodilation in TRPA1 
KO mice and with TRPA1 antagonism (Sinha, 2013) 
 
The variety of TRP channels expressions in ECs has been explained by two theories. First, 
different TRP channels are activated by different activators and hence endow ECs with 
different mechanisms for Ca2+ influx (X. Yao & Garland, 2005). For instance, TRPV4 is 
activated mechanically by blood flow shear stress (Köhler et al., 2006) and TRPM2 by ADP-
ribose, which oxidative stress (OS) releases from mitochondria (Desai & Clapham, 2005). 
Second, TRP channels activation might yield different functional responses according to 
channel properties, including the Ca2+ conductance profile, in addition to the level of 
expression at different vascular beds (X. Yao & Garland, 2005). TRPC5 is expressed 
predominantly in human coronary artery ECs, whereas human pulmonary arteries express 
TRPC4 (Yip et al., 2004). Such variation in TRP channels expression in different vascular 
beds is important for understanding the physiology and pathophysiology of ECs in different 
vascular regions (X. Yao & Garland, 2005). 
In vasodilatory pathways in general, when endothelial muscarinic receptors are activated, 
GPCR-bound AC converts the cytoplasmic ATP into cAMP, which in turn activates cAMP-
dependent protein kinase A (PKA) that phosphorylates and activates the ER’s IP3-R to 
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potentiate the release of Ca2+ from cellular stores (Bugrim, 1999). Moreover, cAMP was 
reported to enhance EDHF electrical signalling via the myoendothelial gap junction (Griffith, 
Chaytor, Taylor, Giddings, & Edwards, 2002). Endothelial muscarinic and prostacyclin 
GPCR activates membranous PLC to hydrolyse membrane PIP2 into IP3 and diacyl glycerol 
(DAG) (Everaerts, Nilius, & Owsianik, 2010; Miggin & Kinsella, 2002). The generated IP3 
binds to its corresponding IP3-R on the ER to facilitate the release of Ca2+, which is essential 
to activate IKca and SKca and thereby induce membrane hyperpolarisation, which becomes 
transmitted through myoendothelial projections (MEPs) and the myoendothelial gap junction 
to the VSM layer underneath (Bagher & Garland, 2014). Increased blood shear stress 
activates membrane bound PLA2, which generates AA from the membrane cholesterol, 
followed by a series of reactions that generate EETs, TRPV4 activators, and EDHF mediators 
(Earley et al., 2005; Hecker et al., 1994; Lambert et al., 2006; Rosolowsky & Campbell, 
1993). A previous study showed that TRPV4 forms a functional complex with BKca and 
ryanodine receptors (RyR) in the smooth muscle layer (Earley et al., 2005). RyR located on 
the sarcoplasmic reticulum (SR)—that is, the ER muscular equivalent in the smooth muscle 
layer— stimulates Ca2+ sparks that activate BKca to induce the hyperpolarisation of smooth 
muscle cell membrane and thus vasodilation (Earley et al., 2005). The activation of VSM’s 
TRPV4 elevates Ca2+ sparks and potentiates BKca activity to induce smooth muscle cells 
membrane hyperpolarisation and vasodilation (Earley et al., 2005). Moreover, the endothelial 
TRPV4-mediated Ca2+ influx activates IKca and SKca (Bagher et al., 2012; Ma et al., 2013). 
The activation of endothelial muscarinic receptors induces PI3K to phosphorylate Akt, which 
together with the CaM complex activates eNOS and ultimately generates NO (A. Dhar et al., 
2010). As Figure 3 shows, TRPV4 is involved in the activation of eNOS and in mediating 
muscarinic-induced endothelium-dependent vasodilation (Köhler et al., 2006). 
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Figure 3. Endothelial-dependent vasodilation pathways: nitric oxide (NO), prostacyclin (PGI2), and 
endothelium-derived hyperpolarising factor (EDHF). TRPV4-induced calcium (Ca2+) influx activates 
endothelial NO synthase (eNOS), small conductance calcium-activated potassium channels (SKca), and 
intermediate conductance calcium-activated potassium channels (IKca). By facilitating the potassium efflux and 
inducing hyperpolarisation, which is transmitted to the vascular smooth muscle (VSM), the result is 
hyperpolarisation as part of EDHF. The EDHF signal is involved in the activation of epoxygenase enzymes that 
generate epoxyeicosatrienoic acid (EET), which activate TRPV4 in the endothelium and VSM. VSM’s TRPV4-
induced Ca2+influx triggers large conductance calcium-activated potassium channels (BKca), while eNOS is 
activated to release NO, which diffuses to the VSM to activate cyclic guanylate mono phosphate (cGMP) that 
inhibits voltage-gated calcium channels and activates both potassium channels and myosin light chain 
phosphatase (MLCP) to induce vasodilation. PGI2 binds to the G-protein coupled receptor IP to induce 
adenylate cyclase (AC) and phospholipase C (PLC), and AC causes cyclic adenosine monophosphate to induce 
the release of calcium from endoplasmic reticulum (ER) cellular stores. PLC metabolises membranous 
phosphatidylinositol 4, 5- bisphosphate (PIP2) into inositol 1, 4,5- triphosphate (IP3) and diacyl glycerol 
(DAG), after which IP3 binds to the IP3 receptors (IP3-R) of the ER to cause the release of calcium and hence 
activate eNOS, SKca, and IKca. 
 
1.4.2. Endothelial dysfunction in diabetes 
Cardiovascular diseases refer to numerous pathological conditions that affect the heart or 
blood vessels, if not both, and with 31% of deaths worldwide each year, represent the greatest 
factor of mortality in humans (World Health Organization, 2015). 
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Diabetes mellitus is considered to be a metabolic and vascular disease, with compromised 
circulation due to endothelial dysfunction as a common complication (Sena et al., 2013). 
Diabetics are therefore prone to fungal infections and ulcers, nephropathy and retinopathy as 
a consequence of impaired vasodilation due to endothelial dysfunction (American Diabetes 
Association, 2012; A. Dhar et al., 2010; Sena et al., 2013).  
Endothelial dysfunction is a common diabetes complication in which endothelium-dependent 
vasodilation becomes impaired (Kolluru, Bir, & Kevil, 2012). The principal determinant of  
endothelial dysfunction is decreased NO bioavailability, with increased ET-1 biosynthesis as 
a close second (Bakker, Eringa, Sipkema, & van Hinsbergh, 2009). The primary factors 
govern the bioavailability of endothelial NO: the generation of NO from eNOS and the 
elimination of active NO (van den Oever et al., 2010). Numerous studies have revealed 
different pathways of accelerated NO elimination. As they have shown, under physiological 
circumstances, NO is produced from the dimeric eNOS that utilises L-arginine and molecular 
oxygen parallel to reducing nicotinamide adenine dinucleotide phosphate (NADPH) as a co-
substrate (M. I. Lin et al., 2003). This coupled oxidation reaction occurs in the presence of 
other cofactors, including flavin adenine dinucleotide (FAD), flavin mononucleotide (FMN), 
tetrahydrobiopterin (BH4) and calmodulin (Adak et al., 2000). However, uncoupled eNOS 
generates superoxide anions and other ROS without producing NO owing to the addition of 
NADPH-derived electrons to the molecular oxygen rather than the substrate L-arginine 
(Guzik et al., 2002). 
By inhibiting its synthesis or downregulating its synthesising enzyme, GTP cyclohydrolase I 
(GCH), BH4 downregulation contributes to eNOS uncoupling (Alp et al., 2003). Superoxide 
anions quench NO to produce peroxynitrite anions (ONOO-) that compromise NO 
bioavailability and oxidise BH4 to dihydrobiopterin (BH2), as well as suppress GCH 
expression and thereby reduce BH4 expression (Alp et al., 2003; Milstien & Katusic, 1999). 
Elevated BH2 reduces NO production in addition to aggravating eNOS uncoupling due to 
BH4 reduction (Alp et al., 2003; Milstien & Katusic, 1999). In a previous clinical study, BH4 
intra-arterial infusion (500μg/min) improved the endothelial function in diabetic patients, 
although such treatment did not significantly improve for non-diabetic volunteers (Heitzer, 
Krohn, Albers, & Meinertz, 2000). That study therefore concluded that endothelial 
dysfunction in T2DM might be attributed to the reduction in BH4 bioavailability (Heitzer et 
al., 2000). In another study, when human umbilical vein ECs were treated with high glucose 
concentration (30mM), the 26S proteasome activity significantly increased and yielded 
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ONOO--dependent GCH ubiquitination and degradation, which culminated with BH4 
deficiency (J. Xu et al., 2007). Such GCH degradation was accompanied by BH4 reduction in 
streptozotocin (STZ)-mice aortic homogenates, which indicated that GCH downregulation 
could cause diabetic BH4 downregulation (J. Xu et al., 2007). 
Asymmetric di-methyl arginine (ADMA) is an endogenous eNOS inhibitor which is 
metabolised to citrulline through dimethylaminohydrolase (DDAH) (Sena et al., 2013). In 
their clinical study with 135 T2DM patients, Krzyzanowska, Mittermayer, Wolzt, and 
Schernthaner (2007) found that approximately 50% of patients who experienced 
cardiovascular events were the same ones with plasma ADMA greater than 0.63μM. 
Accordingly, they postulated that ADMA could be used as a cardiovascular risk biomarker in 
diabetic patients (Cavusoglu et al., 2010; Krzyzanowska et al., 2007). At the same time, 
DDAH activity became significantly compromised in T2DM Sprague–Dawley rats and was 
accompanied with significant ADMA elevation and cGMP downregulation (K. Y. Lin et al., 
2002). Such compromised DDAH activity and cGMP downregulation were also reproduced 
in human ECs (HMEC-1) treated with high glucose concentration (25mM) (K. Y. Lin et al., 
2002). 
As the substrate for eNOS, L-arginine is metabolised through arginase to yield ornithine 
which is in turn metabolised through the urea cycle (Kim et al., 2009). Arginase upregulation 
or hyperactivity, if not both, compromises L-arginine availability to induce eNOS uncoupling 
that culminates with ROS production and suppressed NO generation (Kim et al., 2009). 
Plasma arginase-1 (i.e., approximately 0.3 ng/ml) and arginase-2 (i.e., approximately 0.2 
ng/ml) concentrations have been reported to be similar in T2DM patients and non-diabetic 
volunteers (Kashyap, Lara, Zhang, Park, & DeFronzo, 2008). However, plasma arginase 
activity was significantly higher in T2DM patients than non-diabetic individuals (Kashyap et 
al., 2008). Kashyap et al. (2008) also revealed that insulin infusion (80mU/m2) for 4 hours 
significantly reduced arginase activity in T2DM patients and even reached a normal level of 
activity (i.e., approximately 0.2μmol/ml/hr). In another study conducted with STZ-diabetic 
rats, both the activity and expression of arginase significantly increased in STZ-diabetic rats’ 
aortic rings, which showed significant endothelial dysfunction as a result (Romero et al., 
2008). Furthermore, treating bovine coronary ECs (BCECs) with a high glucose 
concentration (25mM) induced OS, which was accompanied with arginase upregulation 
(Romero et al., 2008). The 3-hydroxy-3-methyl-glutaryl-coenzyme A (HMG-CoA) reductase 
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inhibitor, simvastatin (5mg/kg) restored endothelial function in STZ-diabetic rats by 
suppressing arginase expression and activity (Romero et al., 2008). 
Endothelial dysfunction might also be attributed to the impairment of the eNOS signalling 
cascade that culminates with reduced NO production (Kolluru et al., 2012; Tabit et al., 2010). 
eNOS is activated via the activation of the PI3K/Akt system, from which Akt phosphorylates 
eNOS at serine 1177 residue and threonine 497 to induce NO generation (A. Dhar et al., 
2010; M. I. Lin et al., 2003). A previous research detected the attenuation of the 
PI3K/Akt/eNOS cascade in diabetes (Liang et al., 2009), namely that endothelial progenitor 
cells (EPCs) treated with advanced glycation end products (AGE) significantly suppressed 
Akt and eNOS phosphorylation accompanied with compromised NO release (Liang et al., 
2009). However, the peroxisome proliferator activated receptor-γ (PPAR-γ) agonist, 
rosiglitazone (10nM), induced Akt/eNOS upregulation, which was accompanied with 
improved NO release (Liang et al., 2009). Another NO pathway component is the TRPV4 
channel, which is highly expressed in the endothelium. Accordingly, by focusing on TRPV4 
channel involvement in diabetes endothelial dysfunction, this research seeks to clarify the 
physiological role of the TRPV4 channel in the endothelium in order to provide a robust 
foundation for explaining its pathophysiological contribution in endothelial dysfunction in 
diabetes. 
1.4.3. TRPV4 and endothelial dysfunction in diabetes 
Highly expressed in ECs, TRPV4 is a major vascular tone controller (Köhler et al., 2006). 
Although numerous researchers have suggested that TRPV4 is activated directly, others have 
demonstrated its indirect activation by way of mechanical stimulation or endothelium-derived 
5’,6’- EET (Christensen & Corey, 2007; Köhler et al., 2006). TRPV4 enhances Ca2+ influx to 
generate NO in addition to EDHF (Köhler et al., 2006). Moreover, TRPV1 and TRPV4 are 
central blood pressure (BP) regulators expressed in hypothalamic circumventricular organs 
such as organum vasculosum ligamentum terminals  (OVLT) (Liedtke & Friedman, 2003; 
Naeini, Witty, Séguéla, & Bourque, 2006). TRPV4 senses blood osmolarity in the OVLT and 
thereby triggers the release of vasopressin (AVP) through hypertonicity-induced cation 
depolarisation, which induces vasoconstriction and water retention (Liedtke & Friedman, 
2003; Mizuno, Matsumoto, Imai, & Suzuki, 2003). Furthermore, as KO mice studies have 
revealed, TRPV4 is essential in muscarinic-mediated endothelium-dependent vasodilation via 
a novel mechanism that involves Ca2+ influx by way of endothelium derived factor (11, 12 
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EET)-activated TRPV4 (Earley et al., 2005). Moreover, 11, 12 EET was shown to facilitate 
TRPV4 complex formation with RyR and BKca in VSMCs and thereby facilitate vasodilation 
(Earley et al., 2005). TRPV4-mediated Ca2+ influx involves cooperative gating through a 
four-channel cluster in MEPs  (Bagher & Garland, 2014). Such TRPV4 cooperative gating 
requires A-kinase anchoring protein (AKAP150) in MEPs to induce hyperpolarisation-
induced vasodilation through the activation of Kca, including BKCa, as several studies have 
(Bagher & Garland, 2014; Earley et al., 2005; M. Freichel et al., 2005). Pharmacological 
studies have shown the expression of TRPV4 channels as components of ECs in dilating 
mouse mesenteric arteries, rat aortic rings, and carotid arteries (Baylie & Brayden, 2011). H. 
Y. Kwan et al. (2007) hypothesised that dysfunction in TRPV4 contributes to endothelial 
dysfunction, while  Köhler et al. (2006) earlier provided initial evidence of the involvement 
in TRPV4 dysfunction in endothelial dysfunction when flow-induced vasodilation was 
abolished by TRPV4 blockers, ruthenium red, and the PLA2 inhibitor, arachidonyl 
trifluoromethyl ketone, in rat carotid arteries. A more recent study demonstrated TRPV4 
downregulation in STZ-rats’ mesenteric endothelium (Ma et al., 2013), which was 
accompanied with suppressed SKca, contributed to endothelial dysfunction (Ma et al., 2013). 
Moreover, TRPV4 downregulation was found to be involved in diabetic endothelial 
dysfunction and retinopathy (Monaghan et al., 2015). These studies provide a very robust 
foundation that correlates TRPV4 alteration with diabetes endothelium dysfunction. 
Taken together, all of those studies provide a very robust foundation for correlating TRPV4 
alteration with endothelium dysfunction in diabetes. Accordingly, since the aim of this 
research is to investigate the role of TRPV4 as a member of the TRPC family in endothelial 
dysfunction in diabetes, it should offer a further explanation of TRPC in order provide a 
better understanding of their role in the body.  
1.5. TRP channels 
When specific gene mutation caused visual impairment in Drosophila by disrupting Ca2+ 
entry in specific cells, the gene was termed TRP, which bioinformatics analysis showed had 
29 mammalian homologues (Pedersen, Owsianik, & Nilius, 2005; Ramsey, Delling, & 
Clapham, 2006). 
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1.5.1. TRP channels function 
TRP channels are ion channels that differ in their permeability to Na+, K+, and Ca2+ 
(Watanabe et al., 2008). Most TRP channels possess moderate Ca2+ conductance with a 
conductance ratio of P Ca2+/ P Na+ = 0.3–10 (Watanabe et al., 2008). Ca2+ performs essential 
diverse cellular functions as its baseline concentration (100nM) increases by up to 100-fold 
during cell excitation (Watanabe et al., 2008). Such a wide range of Ca2+ elevation is shown 
to be involved in different cellular activities at variable durations as for instance 
neurotransmission (short-term) as well as cell cycle regulation (long-term) (Watanabe et al., 
2008). Ca2+ is released from cellular storage, smooth ER, or its muscular analogue, SR, in 
response to G-protein coupled receptor-elaborated inositol triphosphate (GPCR-IP3). IP3 
binds to the corresponding ER’s IP3-receptor (IP3-R) or SR’s ryanodine receptor coupled 
with VGCCs (Huo, Lu, & Guo, 2010). Through specific channels, Ca2+ influx can perform 
specific cellular functions such as, the generation of cardiomyocytes action potential (AP), 
which is partly triggered through reversed Na+/Ca2+ exchanger-Ca2+ entry (Watanabe et al., 
2008). Moreover, ligand-activated cation channels (LGCs) are considered to be extracellular 
Ca2+ sources (Watanabe et al., 2008). Similarly, receptor-activated cation channels have a 
slower onset of action, which involves cellular signalling and second messenger activation to 
yield Ca2+ entry (Bootman, Berridge, & Roderick, 2002). Such a mechanism of action 
appears in SOCs such as TRPV4/TRPC1 heteromeric channels in the endothelium (Ma, 
Cheng, Wong, et al., 2011). Mechanical forces also facilitate Ca2+ entry through stretch-
activated Ca2+ channels (SACs) (Köhler et al., 2006). 
A few TRP channels, including TRPM3α1, TRPM4, and TRPM5 are more permeable to 
monovalent ions (e.g., P Ca2+/ P Na+ ˂ 0.05) (Pedersen et al., 2005). By contrast, other TRP 
channels are highly selective to Ca2+ (e.g., P Ca2+/ P Na+ ˃ 100) such as TRPM3α2, TRPV5, 
and TRPV6 (Pedersen et al., 2005; Watanabe et al., 2008). However, TRPM6 and TRPM7 
are permeable to Mg2+ and toxic heavy metals ions such as lead (Pb2+)  (Inoue, Jian, & 
Kawarabayashi, 2009; Ramsey et al., 2006). Permeability to such varied ions permeability 
among different TRP channels may be due to heterogeneous tetramer formation, since each 
subunit may provide distinct ion selectivity and permeability and thereby different channel 
properties (Ramsey et al., 2006). Cell response to TRP channels furthermore depends on the 
rate and amount of membranous TRP channels expression and the ability of cells to amplify 
TRP channels signals through the degree of the integrity of downstream cascade components 
(Winston, Toma, Shenoy, & Pasricha, 2001). TRP channels are involved in numerous 
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physiological and cellular functions, including sensory information transduction, visceral 
function modulation, cell growth, proliferation, and apoptosis (Inoue et al., 2009). Such a 
range of functions reflects TRP channels’ involvement in different cellular stages, from initial 
cascade signalling to the level of gene expression (Inoue et al., 2009). TRP channels are also 
signal amplifiers and integrators and thus cellular sensors and detectors, in which roles they 
provide numerous physiological functions, including growth cone guidance (Ramsey et al., 
2006). 
1.5.2. TRP channels topology 
Bioinformatics studies have identified TRP channels’ structural features with 6-
transmembrane (6-TM) domains of long cytosolic N- and C-termini (Mio et al., 2007). Those 
domains provide numerous protein-protein interaction motifs to yield a centralised, tetrameric 
ion-conducting pore, which is commonly located between the 5th and 6th TM domains 
(Pedersen et al., 2005). Moreover, the 6-TM domains share consensus homologous 25 
aminoacid residues of 6 invariable aminoacids called TRP box, in addition to pleckstrin 
homology domain (PHD) (Ferguson, Lemmon, Schlessinger, & Sigler, 1995; Nilius, Mahieu, 
Karashima, & Voets, 2007). Each PHD requires a complementary sequence from a relevant 
endogenous cognate activator and hence endows the TRP channels with polymodal activation 
properties, meaning that different TRP channels of different PHDs require different activators 
(Ramsey et al., 2006). Interestingly, as Figure 4 indicates, mammalian TRP families have 
approximately 20% sequence homology (Clapham, 2003). 
Figure 4. Transient receptor potential (TRP) channel topology of 6-TM domains, with a TRP box and other 
specific binding domains on N- and C-termini, protein kinase C (PKC), calmodulin kinase (CamK), and SH3 
(i.e., thiol domain); adapted from Pedersen et al. (2005). 
 
18 
 
1.5.3. TRP channels family 
As Figure 5 illustrates, human TRP (hTRP) channels are primarily categorised into 6 
subfamilies, each with distinct activation profiles (Inoue et al., 2009). 
Figure 5. Human transient receptor potential (TRP) channels family of 6 subfamilies (i.e, TRPC, TRPV, TRPM, 
TRPML, TRPP and TRPA1) adapted from Inoue et al. (2009).  
 
 TRPC 
The first identified mammalian TRP channels subfamily, simply called TRPC, exhibited 
approximately 40% homology to the TRPC of Drosophila (Wes et al., 1995). In general, 
TRPCs are canonically and classically activated channels (Ramsey et al., 2006). whose 
mechanism involves either DAG-mediated ROCCs or PLC-mediated store-operated cation 
channels (SOCCs) (Tseng et al., 2004; Venkatachalam, Zheng, & Gill, 2003). TRPCs are 
categorised into 3 groups according to their functionality and sequence alignment (Ramsey et 
al., 2006) as follows. 
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 TRPC1, TRPC4 & TRPC5 
TRPC1 forms heteromeric complexes with TRPC3, TRPC4 and TRPC5 to function as Gq/11 
ROCC (Strübing, Krapivinsky, Krapivinsky, & Clapham, 2001). Complexes with TRPC4 and 
TRPC5commonly appear in brain tissue, where they emit minor regulated outward-rectifying 
current and facilitate ion conductance (Strübing et al., 2001). TRPC5 homomeric channels 
are essential regulators of hippocampal growth cone morphology through PI3K, PI5K, and 
Rac cascades in response to growth factors (Greka, Navarro, Oancea, Duggan, & Clapham, 
2003; Ramsey et al., 2006). In particular, TRPC5 channel is activated by trivalent cations 
such as gadolinium (Gd3+) or at high extracellular Ca2+ concentration (e.g., 1.5mM) (Jung et 
al., 2003; F. Zeng et al., 2004). 
 TRPC3, TRPC6 and TRPC7 
TRPC3, TRPC6, and TRPC7 form a three-membered subfamily with approximately 80% 
sequence homology (Ramsey et al., 2006). The basal activities of TRPC3 and TRPC6 are 
controlled by glycosylated asparagine residues of S1–S4 extracellular loop domains (Dietrich 
et al., 2003), and those channels are stimulated by nonreceptor TK (i.e., Src and Fyn) and 
inhibited by PKC and PKG (Hisatsune et al., 2004; H.-Y. Kwan, Huang, & Yao, 2004; J Shi, 
Ju, Saleh, Albert, & Large, 2010; Vazquez, Wedel, Kawasaki, Bird, & Putney, 2004; 
Venkatachalam et al., 2003). By contrast, CaM positively regulates TRPC6 and negatively 
controls TRPC7 activities (J. Shi et al., 2004). 
 TRPC2 
Although an expressed pseudogene is a nonfunctional channel in humans (Vannier et al., 
1999), in rodents TRPC2 is DAG-activated and essential in pheromone signal transduction, 
as well as in fertilisation in both male and female mice (Liman, Corey, & Dulac, 1999; Lucas, 
Ukhanov, Leinders-Zufall, & Zufall, 2003). 
 TRPM 
TRPM is another TRP subfamily of 8 members named after TRPM1, which is activated with 
melastatin for what is called TRPM (Inoue et al., 2009). TRPM is classified into 3 groups as 
follows. 
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 TRPM1 and TRPM3 
TRPM1 is a prognostic marker since it is downregulated in malignant localised melanoma 
(Duncan et al., 1998), while as a chemically activated nonselective cation channel (NSCC), 
TRPM3 is expressed in different splice variants known as TRPM3α1–5 (Oberwinkler, Lis, 
Giehl, Flockerzi, & Philipp, 2005). Among them, TRPM3α1 is a monovalent selective ion 
channel, whereas TRPM3α2 is a divalent selective ion channel. However, both TRPM3α1 
and TRPM3α2 are constitutively active and inhibited by Mg2+ (Oberwinkler et al., 2005). 
Physiologically, TRPM3 is essential in the kidneys where it regulates Ca2+ homeostasis 
(Grimm, Kraft, Sauerbruch, Schultz, & Harteneck, 2003).   
 TRPM4 and TRPM5 
TRPM4 and TRPM5 channels are distinctively activated through elevated [Ca2+]i and 
considered to be highly monovalent selective (Launay et al., 2002; Ullrich et al., 2005). 
Heteromeric complexes with TRPM4 and TRPM5 channels control the myogenic 
vasoconstriction, since both channels exhibit a voltage-dependent deactivation at negative 
membrane potential (Earley, Waldron, & Brayden, 2004; Nilius et al., 2003). Moreover, 
TRPM5 is essential in the taste signalling pathway, since TRPM5 KO mice studies have 
demonstrated a significant absence of the bitter and sweet taste sensations (Y. Zhang et al., 
2003).  
 TRPM6 and TRPM7 
TRPM6 and TRPM7 are characterised by their distinct dual function as ion channels and 
serine and threonine protein kinase (PK) (Clark et al., 2008; Takezawa et al., 2004). The PK 
activity is chiefly regarded to the C-terminus of TRPM7 that is attributed to auto-
phosphorylation (Takezawa et al., 2004). TRPM6 is constitutively active and implicated in 
Ca2+ and magnesium (Mg+2) homeostasis, given its primary expression in the kidneys and 
intestine (Voets et al., 2004), TRPM7 is a mechanosensitive cation channel (MSCC) or 
chemically activated NSCC, if not both, that facilitates anoxia-induced brain cell death as a 
consequence of accumulated ROS (Aarts et al., 2003). 
 TRPM2 and TRPM8 
TRPM2 and TRPM8 share approximately 40% of sequence homology and both channels are 
MSCC and chemically activated NSCC (Inoue et al., 2009; Pedersen et al., 2005). TRPM2 is 
a cellular redox sensor that exists in two splice variants: the short (i.e., TRPM2S) and the 
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long (i.e., TRPM2L) which are co-localised in the plasma membrane (W. Zhang et al., 2003). 
TRPM2L is activated by ADP-ribose, which is released from mitochondria upon OS to 
induce cell death, while TRPM2S suppresses the OS-induced Ca2+ influx by way of  
TRPM2L (Perraud et al., 2005; W. Zhang et al., 2003). However, TRPM8 is an NSCC first 
discovered in prostate and represents an androgen-activated cation channel (Lei Zhang & 
Barritt, 2004). More recently, TRPM8 was found to be highly expressed in sensory neurons 
and implicated in cold-sensation (Andersson, Nash, & Bevan, 2007). In general, TRPM8 is 
expressed in both ECs and VSMCs in numerous vascular beds, including rat aorta, 
mesenteric arteries, femoral arteries, and tail artery (Earley, 2010; H. Y. Kwan et al., 2007). 
RT-PCR studies have shown showed that TRPM8 is the most expressed TRPM channel in 
VSMCs (Earley, 2010), while others have demonstrated that TRPM8-inudced vasodilation is 
partially endothelium-dependent (C. D. Johnson et al., 2009). Menthol and icilin, as TRPM8 
agonists induced vasodilation in pre-contracted mesenteric and thoracic aortic arteries (C. D. 
Johnson et al., 2009; Silva et al., 2015). A previous study conducted by X. R. Liu et al. 
(2013) indicated showed significant impairment in menthol-induced pulmonary artery 
vasodilation in pulmonary hypertensive rat model. Such impaired vasodilation was associated 
with TRPM8 downregulation in pulmonary artery ECs. Another recent study added that 
topical menthol gel (0.04-8.0%) enhanced skin blood flow through EDHF (Craighead & 
Alexander, 2016). The co-expression of TRPM8 and TRPV4 channels in the aortic 
vasculature was concluded as novel Ca2+ entry pathways that might control the systemic 
circulation by way of EDHF (Garland, Plane, Kemp, & Cocks, 1995; X. R. Yang, Lin, 
McIntosh, & Sham, 2006). 
TRPM8 can act through pathways other than TRPV4. For instance, endothelial muscarinic 
receptors stimulate PLC, an enzyme that hydrolyses membranous PIP2 into IP3 and DAG, 
from which IP3 can activate TRPV4 and bind to ER’s IP3-R to induce stored Ca2+ release 
(Everaerts et al., 2010). However, since TRPM8 is activated by the TRP-domain bound PIP2, 
upon the activation of muscarinic pathways and TRPV4 later on, TRPM8 might be inhibited, 
since its cytoplasmic activator, PIP2, is metabolised via PLC activation (B. Liu & Qin, 2005; 
Rohács, Lopes, Michailidis, & Logothetis, 2005). Previous studies have thus identified 
lysophosphatidylinositol as an extracellular mediator and an intracellular messenger that 
affects several ion channels, including BKCa and TRPM8 (D. A. Andersson et al., 2007; 
Bondarenko et al., 2011a; A. I. Bondarenko, R. Malli, & W. F. Graier, 2011b). Therefore, 
BKca might form a signalling complex with TRPM8 by taking advantage of 
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lysophosphatidylinositol, which suggests that TRPM8 and TRPV4 pathways might share 
BKca as a vasodilatory downstream target in the vasculature (Bondarenko et al., 2011a; 
Earley et al., 2005). 
 TRPML 
TRPML is a three-membered subfamily consisting of TRPML-1, TRPML-2, and TRPML-3 
and from which TRPML-1 mutation emerges to contribute to a progressive 
neurodegenerative disorder called mucolipidosis type IV (Pedersen et al., 2005; Sun et al., 
2000). Accordingly, all these members are called mucolipins (Ramsey et al., 2006). TRPML-
1 regulates endosomal and lysosomal trafficking and thus lysosomal degradation in proteins 
(LaPlante et al., 2002; LaPlante et al., 2004). TRPML-3 KO studies have furthermore shown 
the essential role of the channel in hearing and vestibulation, due to its expression in hair 
cells and stereocilia (H. Xu, Delling, Li, Dong, & Clapham, 2007). 
 TRPP 
TRPP is a four-membered subfamily consisting of TRPP1, TRPP2, TRPP3 and TRPP5 
(Inoue et al., 2009). TRPP2 mutation is implicated in autosomal polycystic kidney disease 
(APKD), a common genetic condition characterised by the formation of numerous kidney 
cysts that  culminates in kidney failure (Mochizuki, Wu, Hayashi, & Xenophontos, 1996). 
TRPP1 and TRPP2 form heteromeric complexes of calcium-permeable NSCC which is 
regulated by fluid flow through renal epithelial primary cilia and thus acts as a Ca2+ 
permeable ion channel (Delmas et al., 2004). 
 TRPV 
TRPV is a six-membered subfamily whose members are activated through vanilloid 
molecules such as capsaicin (Inoue et al., 2009). Accordingly, the channels are labelled with 
“V” and categorised into 2 groups (Inoue et al., 2009), as follows. 
 TRPV1-TRPV4 
These 4 members are MSCC and chemically activated NSCC (Inoue et al., 2009; Pedersen et 
al., 2005). TRPV1 is broadly expressed in the body and thereby implicated in numerous 
functions, including control of gastrointestinal tract motility and satiety, nociception and 
thermos-sensation activated at approximately 43°C (Davis et al., 2000; Rosenbaum, Gordon-
Shaag, Munari, & Gordon, 2004; X. Wang, Miyares, & Ahern, 2005). By contrast, TRPV2 
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exhibits approximately 50% homology with TRPV1 and is commonly found in the CNS, 
myenteric plexus, nodose ganglionm and keratinocytes where it is implicated in modulating 
the noxious heat sensation threshold activated at approximately 52°C (Caterina, Rosen, 
Tominaga, Brake, & Julius, 1999; Leffler, Linte, Nau, Reeh, & Babes, 2007). TRPV3 plays 
an essential role in thermosensation and thermal preferences, and its expression has been 
shown in keratinocytes and TRPV3 KO mice showing a lack of thermosensation activated at 
approximately 33°C (Moqrich et al., 2005; Peier et al., 2002). Lastly, TRPV4 initially named 
VR-OAC when discovered though sequence homology screening of the mammalian genome 
(Everaerts et al., 2010), is expressed ubiquitously and plays essential roles in endothelium-
dependent vasodilation  (Sukumaran et al., 2013). It is expressed in the distal convoluted 
tubule where it regulates the urine osmolality (Tian et al., 2004). Numerous researchers have 
suggested that TRPV4 is capable of direct and indirect activation through mechanical 
stimulation or second messengers such as endothelium-derived 5, 6-epoxyeicosatrienoic acid 
(5’, 6’-EET) (Liedtke & Friedman, 2003; Vriens et al., 2005).  
 TRPV5 and TRPV6 
Both TRPV5 and TRPV6 are constitutively active and have approximately 75% sequence 
homology (Inoue et al., 2009; Ramsey et al., 2006). Distinguished by their inwardly 
rectifying current with extremely high Ca2+ selectivity due to the negatively charged ring 
aspartate residue in selectivity controller pores (Pedersen et al., 2005; Voets et al., 2001), 
both channels are essential in controlling renal Ca2+ reabsorption and vitamin D-facilitated 
calcium absorption in the small intestine (J. Hoenderop et al., 2003; J. G. Hoenderop et al., 
2000; Nijenhuis, Hoenderop, Nilius, & Bindels, 2003).  
 TRPA1 
A single-membered subfamily of distinct 14 ankyrin repeats in the NH2 terminal (Story et al., 
2003), TRPA1 is a MSCC and a chemically activated NSCC which can be activated by  
organic TRPA1 agonist such as allicin from garlic or allyl isothiocyanate from mustard oil 
(Inoue et al., 2009; Macpherson et al., 2005). A recent research concluded that TRPA1 is a 
pivotal mediator for nociception and pain signalling in diabetic neuropathic pain (Eberhardt 
et al., 2012). 
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1.5.4. TRP channels’ mechanism of action 
Several researchers have classified TRP channels’ mechanisms of action differently for 
instance, according to the mechanism of activation (Clapham, 2003; Inoue et al., 2009), and 
the nature of activator (Ramsey et al., 2006). Classified according to the type of activator, 
TRP channels are categorised into 4 groups, as follows. 
 Receptor activation (i.e., GPCR and PKs) 
GPCR-activated PLC hydrolyses membranous phosphatidylinositol (4,5) bisphosphate (PIP2) 
into DAG and IP3 (Lawler et al., 2001). Consequently, IP3 binds to its corresponding smooth 
ER’s IP3-R to facilitate the release of Ca2+ from cellular stores (Murata et al., 2007). When 
ER Ca2+ stores are depleted, SOCs become activate to induce Ca2+ influx, as shown in 
TRPV4/TRPC1 heteromeric channels in the endothelium (Ma, Cheng, Wong, et al., 2011). At 
the same time, DAG activates PKC, which binds and activates TRPV4 to induce Ca2+ influx 
and thus endothelium-dependent vasodilation (Sonkusare et al., 2014). 
 Ligand activation 
TRP channels are activated by 4 primary types of agonists: exogenous small molecules, 
including capsaicin-activated chemosensors, such as TRPV1 (Benham, Davis, & Randall, 
2002); lipid metabolites such as 11, 12- EET, which activates TRPV4 to induce vasodilation 
(Earley et al., 2009); purine nucleotides or their metabolites, if not both, including β-
nicotinamide adenine dinucleotide (β-NAD+) and adenine diphosphoribose (ADP-ribose) 
which activate TRPM2 (W. Zhang et al., 2003); and inorganic ions such as Ca2+ (Ramsey et 
al., 2006), as a previous study concluded, [Ca2+]i directly activates TRPA1 conducted by 
(Zurborg, Yurgionas, Jira, Caspani, & Heppenstall, 2007). 
 Direct activation 
TRP channels are activated directly in polymodal fashion via, for instance, temperature 
variation or mechanical stress (Voets, Talavera, Owsianik, & Nilius, 2005). Such stimulators 
can indirectly trigger a second messenger that phosphorylates TRP channels, as shown in 
hypotonically-swollen TRPV4-expressing cells (Alessandri-Haber et al., 2003).  
 Store operated 
Excessive amplified cellular signalling depletes ER from its cellular Ca2+ stores, and thereby 
stimulates a compensatory TRP channels-induced Ca2+ influx through SOCs (Ramsey et al., 
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2006). Since the mechanism of SOCs is intertwined with ROCCs, when cellular Ca2+ stores 
are depleted and SOCs are activated, which is in turn associated with ROCC activation in 
order to maintain the cellular Ca2+ homeostasis as shown in TRPV4/TRPC1 heteromeric 
channels in vascular ECs (Ma, Cheng, Wong, et al., 2011).  
However, when classified according to their molecular mechanism of activation, TRP 
channels are divided into 3 categories as follows. 
 Bilayer dependent mechanism 
When the plasma membrane is stretched, its curvature increases and allosterically enhances 
hydrophobic molecule binding (Inoue et al., 2009). Once the plasma membrane is bound with 
hydrophobic molecules, the net effect of channel opening or closing depends on specific 
conformational changes and amphiphilic (i.e., amphipathic) molecule binding (Suchyna et al., 
2004). By extension, TRP channels blockers bind to the outer region of the channel which is 
consistent with the inward closure of the (Spassova, Hewavitharana, Xu, Soboloff, & Gill, 
2006). TRPC6 is regulated via that mechanism and thus contributes to vascular myogenic 
tone regulation, as Figure 6 shows (Spassova et al., 2006). 
Figure 6. Bilayer-dependent mechanism in TRP channels, in which the stretched membrane affords binding sites 
for amphiphilic molecules (black triangle) to govern the TRP channels gating as shown when it binds to the outer 
site and closes the channel; adapted from Inoue et al. (2009). 
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 Tethered mechanism 
Cytoskeletal proteins (e.g., integrin) form supportive structural scaffolds that are 
interconnected with intracellular components such as G-proteins that construct anchored 
frameworks with TM proteins (Inoue et al., 2009). Such mechanobiochemical integrity 
occurs in audio vestibular cells (i.e., tip-links), where head movement stimulates the 
steriocilia through strength-dependent deflection that culminates the activation of MSCC, as 
illustrated in Figure 7 (M. Andersson et al., 2007). 
 
Figure 7. The tethered mechanism involves cytoskeletal modification and thus cellular response in transient 
receptor potential (TRP) channels; adapted from Inoue et al. (2009). 
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 Mechanical biochemical conversion 
This category exhibits a slower mechanism of activation than the other mechanisms, since it 
involves the transconversion of mechanical forces into biochemical signals—for example, 
triggering enzymes and/or second messenger activation through membrane stretching (Inoue 
et al., 2009). Indeed, such a mechanism was found in TRPV4, which mediates vasodilation 
through NO and EDHF in response to shear stress, as shown in Figure 8 (Köhler et al., 2006). 
Figure 8. Mechanical biochemical conversion in transient receptor potential (TRP) channels. With mechanically 
generated second messengers that trigger the synergistic biochemical activation of TRP channels, blood flow 
shear activates membrane-bound phospholipase-A2 (PLA-2), which generates arachidonic acid (AA) from 
membrane cholesterol, followed by epoxygenase’s (EPO) production of epoxyeicosatrienoic acid (EET), which 
is a direct TRPV4 activator; adapted from Inoue et al. (2009).   
 
Recent studies have aimed to decipher the diabetes complications through investigating the 
molecular pathophysiology, one of which concluded that TRPA1 might play a major role in 
mediating diabetes neuropathic pain through methylglyoxal (MGO) (Eberhardt et al., 2012). 
Moreover, MGO induced significant endothelium impairment through inhibiting eNOS 
phosphorylation (A. Dhar et al., 2010). Since MGO effect on endothelium-dependent 
vasodilation and endothelial TRPV4 will be covered in this research. Therefore, introducing 
MGO into the next section will provide an insight toward its role in mediating diabetes 
complications.  
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1.6. MGO and diabetes 
Diabetes mellitus is associated with chronic hyperglycaemia, in which fasting blood glucose 
concentration exceeds 7mmol/L (125mg/dl) (Sheader, Benson, & Best, 2001). Approximately 
0.5% of glycolytic pathways generate electrophilic ROS such as MGO (Uchida, 2000). MGO 
generates AGE by reacting with various cellular and interstitial molecules such as proteins 
and phospholipids (Uchida, 2000). As a result of reacting with cellular molecules, MGO 
becomes trapped intracellularly and induces OS  (Kalapos, 2013), which in turn disrupts 
cellular membrane integrity in order to facilitate MGO leakage into circulation (Eberhardt et 
al., 2012; Kalapos, 2013; Sheader et al., 2001). At the same time, glycolysis-derived MGO 
interacts with cellular proteins and nucleic acid and hence accelerates AGE production and β-
cells cytotoxicity (Sheader et al., 2001). AGE act as ligands for their corresponding receptors, 
RAGE, which are multiligand receptors of the immunoglobulin superfamily expressed on 
different cell types, including ECs, VSMCs, and monocytes (Schmidt, Du Yan, Wautier, & 
Stern, 1999). Hyperglycaemia induces RAGE expression, which becomes normalised through 
GLO1 overexpression and thus reveals the contribution of MGO in inducing RAGE 
expression (D. Yao & Brownlee, 2010). 
MGO-derived hydroimidazolone is an AGE specifically recognised by RAGE that causes 
long-term diabetic complications by enhancing numerous signalling cascades, including c-
Jun N-terminal kinase (JNK) phosphorylation (p-JNK), which is associated with insulin 
resistance, pancreatic β-cells apoptosis, and atherosclerosis (Bennett, Satoh, & Lewis, 2003; 
Harja et al., 2008; Xue et al., 2014). Accordingly, MGO cytotoxicity exacerbates 
hyperglycaemia and DM complications (Sheader et al., 2001). Physiological human plasma 
MGO concentration is approximately 150nM and increases to fourfold in T2DM (Nicolay et 
al., 2006). 
However, MGO has not been significantly correlated to blood glucose concentration for 2 
technical reasons: the limited capacity to accurately measure total MGO, which is highly 
reactive and can damage sampled proteins or DNA, and the heterogeneity of participants’ 
backgrounds (Kalapos, 2013). 
1.6.1. MGO sources 
The 4 primary sources of MGO can be summarised as MGO sources= MGO carbohydrates + MGO 
lipids + MGO proteins + MGO exogenous (Shamsaldeen et al., 2016). As shown in Figure 9, MGO is 
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biosynthesised from 3 main integrated metabolic pathways: carbohydrates, lipid pathways, 
protein metabolism, and exogenous MGO. 
 Carbohydrates 
Reducing sugars react with proteins’ amino groups to generate Schiff’s bases that are 
structurally rearranged to form Amadori products, which are then subjected to a series of 
reactions to generate AGE (Uchida, 2000). Accordingly, MGO is generated primarily via 
phosphorylating glycolysis, which involves triose-phosphate enzymatic metabolism, the 
pentose phosphate shunt, sorbitol pathways such as xylitol metabolism, and glucoxidation 
(Kalapos, 2013). More specifically, triose-phosphate accumulation is involved in diabetic 
nephropathy, which emphasises the involvement of carbohydrate-generated MGO pathways 
in complications in diabetes. The pathway can also be inhibited by thiamine, as Figure 9 
illustrates (Hammes et al., 2003; Jadidi, Karachalias, Ahmed, Battah, & Thornalley, 2003). 
 Lipid pathways 
Lipid peroxidation of polyunsaturated fatty acids yields short hydrocarbon molecules of 
highly reactive aldehydes, such as ketoaldehydes, from which MGO is generated (Kalapos, 
2013). In particular, MGO is generated from the non-enzymatic and enzymatic metabolism of 
acetoacetate and acetone intermediates, respectively (Kalapos, 2013; Uchida, 2000). Triose-
phosphate is a common intermediate metabolite found in both lipolysis and glycolysis 
(Kalapos, 2013), whereas acetoacetate is a major ketone body (KB) elevated in T2DM 
patients’ plasma (Mahendran et al., 2013) Previous studies have found that diabetes is 
associated with increased lipolysis, the suppression of which improves insulin sensitivity and 
glucose use  (Arner & Langin, 2014; Lim, Hollingsworth, Smith, Thelwall, & Taylor, 2011). 
Moreover, plasma isopropyl alcohol (IP) is significantly increased (5mg/dl) in diabetic 
patients with ketoacidosis (Jones & Summers, 2000). Alcohol dehydrogenase metabolises 
acetone into IP via the reduction of NAD+ reduction into NADH. Therefore, as Figure 9 
shows, diabetes-accelerated lipolysis contributes to MGO elevation which can exacerbate the 
diabetes complications (Jones & Summers, 2000; Laffel, 1999). 
 Protein metabolism 
Numerous researchers revealed the susceptibility of tyrosine-, serine-, threonine- and glycine- 
rich proteins to oxidation (Kalapos, 2013; Uchida, 2000). Those aminoacid residues are 
enzymatically converted to MGO through acetone and aminoacetone intermediates (Kalapos, 
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2013; Uchida, 2000). In particular, aminoacetone intermediates are converted to MGO by 
semi-carbazide sensitive amine oxidase (SSAO), an enzyme that is elevated in diabetic 
patients’ plasma (Kalapos, 2013). A previous study with STZ-diabetic rats showed that 
protein catabolism increases by approximately 50% (Mitch et al., 1999), which is attributed 
to insulin resistance and increased glucocorticoids production in the STZ-diabetic rats as 
illustrated in Figure 9 (Mitch et al., 1999). 
 Exogenous MGO 
Processed sugar, protein, and fat-rich food, in addition to tobacco are the main exogenous 
sources of MGO (Uribarri et al., 2007). According to Banning (2005), coffee and whiskeys 
are also MGO-containing beverages. The average daily consumption of AGE is 16000kU 
AGE, which becomes exaggerated through processing at high temperatures (Goldberg et al., 
2004). For example, the AGE content of oven-fried chicken breast is 900kU/g, whereas that 
of boiled chicken breast is 100kU/g (Goldberg et al., 2004). When reduced sugars such as 
glucose interact with proteins’ free amino groups (i.e., Maillard reaction), N-substituted 
glycosylamine emerges (Martins, Jongen, & van Boekel, 2001). In the presence of water, N-
substituted glycosylamine undergoes Amadori rearrangement to yield the Amadori product 1-
amino-1-deoxy-2-ketose (Martins et al., 2001). The rearranged Amadori product is then 
degraded through 2,3 enolisation to form numerous carbonyl compounds, including those of 
acetol, pyruvaldehyde, and diacetyl (Martins et al., 2001), which interact with cellular amino 
acids to form aldehydes and α-aminoketones (Martins et al., 2001). Previous studies have 
found that Maillard reaction products are significantly increased in diabetics’ skin collagen as 
N6-carboxymethyllysine (CML), fructoselysine (FL), and pentosidine all of which are 
associated with accelerated aging (Dyer et al., 1993). Additionally, CML is significantly 
elevated in diabetic plasma, which becomes exacerbated when purely prepared AGE 
beverages are ingested (Jones & Summers, 2000). In another study, CML elevation was 
associated with eNOS downregulation and dysfunction, in addition to the stimulation of the 
release of vascular cells’ adhesion molecules (VCAM-1), which are all together contribute to 
vascular dysfunction (Uribarri et al., 2007).  
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Figure 9. Endogenous sources of methylglyoxal (MGO) from glucose, lipid, and protein metabolism. (A) The 
normal condition shows low MGO production from glycolysis, lipolysis, or proteolysis with major sources 
represented in bold arrows. (B) Diabetes is associated with increased MGO production from hyperglycaemia, 
accelerated lipolysis, and proteolysis, represented with thick borders and bold arrows, which are accompanied by 
compromised glyoxalase activity; DHAP = Dihydroxyacetone phosphate, GAPDH = Glyceraldehyde 3-phosphate 
dehydrogenase, SSAO = Semicarbazide-sensitive amino oxidase (Shamsaldeen et al., 2016). 
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1.6.2. MGO metabolism 
MGO is metabolised through two enzymatic systems: the glyoxalase (GLO) system 
consisting of glyoxalase 1 and 2 (GLO1 and GLO2, respectively) and, to a lesser extent, the 
aldose reductase system  (Kalapos, 2013). Both systems are GSH-dependent. The GLO 
system is the major metabolic pathway and involves GLO-1, the most MGO-detoxifying 
enzyme that converts MGO to D-lactate (Bierhaus et al., 2012; Kalapos, 2013). Since the 
sorbitol pathway contributes to 11% of glucose metabolism, bi-modal aldose reductase acts 
as aldehyde reductase instead of ketone reductase and thereby preferentially produces acetol 
(Kalapos, 2013). Accordingly, CYP2E1-converted acetol is further converted to MGO, which 
catalyses a futile cycle that depletes intracellular GSH and elevates acetol in diabetic plasma 
(Kalapos, 2013). 
1.6.3. MGO and insulin 
Insulin resistance is a complex condition in which physiologically normal insulin 
concentration becomes insufficient to mediate glucose uptake and usage due to insulin 
signalling disruption, which releases more insulin to meet the demand of tissues (S. Jia, H., 
Ross, & Wu, 2006; X. Jia & Wu, 2007). In their study on skeletal muscle L8 cells, 3T3-L1 
adipocytes, and H4-II-E hepatocytes, S. Jia et al. (2006) showed that MGO compromises 
insulin function by targeting insulin β-chain arginine residues through adding extra 126Da to 
the insulin molecule. Furthermore, another study conducted by X. Jia and Wu (2007) on 3T3-
L1 adipocytes revealed that MGO suppresses IRS-1 phosphorylation and PI3K.  
1.6.4. MGO and diabetes endothelial dysfunction 
Several authors have correlated MGO elevation to vascular dysfunction and end organ 
damage, including that of nephropathy (Chang, Wang, & Wu, 2005). Vascular dysfunction is 
a common complication in DM that often culminates in stroke and myocardial infarction (A. 
Dhar et al., 2010; Ruiter, Van Golde, Schaper, Stehouwer, & Huijberts, 2012). MGO inhibits 
eNOS activation by inhibiting the phosphorylation of serine 1177 residue, thereby prevents 
NO release and inducing endothelial dysfunction (A. Dhar et al., 2010). An earlier study on 
rat aortic smooth muscle cells (ASMCs) showed that MGO-induced vascular dysfunction was 
attributed to NO and hydrogen peroxide (H2O2) generation and hence induced ONOO
- 
formation, which compromises NO bioavailability (Chang et al., 2005). The overexpression 
of GLO-1 in STZ-diabetic rats moreover showed improved vascular function with MGO and 
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AGE reduction (Ruiter et al., 2012). However, treating ECs with MGO scavengers such as 
diacetyl cysteine restored vascular function (A. Dhar et al., 2010). 
MGO preferentially targets amino acids such as lysine to form Nε-carboxyethyl lysine (CEL) 
and the MGO-derived lysine–lysine dimer (MOLD), arginine to form 5-methylimidazolone, 
tetra-hydropyrimidine, and argpyrimidine, as well as a sulfhydryl group containing cysteine, 
which forms stabilised S-lactyl cysteine via keto-enol tautomerism to cause both CEL and 
MOLD elevation in diabetic serum (Uchida, 2000). In their immunohistochemical study, Oya 
et al. (1999) observed significant elevation in argpyrimidine in diabetic patients’ arteries, which 
stressed the implications of MGO in arterial injury as a complication of diabetes mellitus. 
In addition to those vascular complications, the lifespan of erythrocytes (RBC) is reduced in 
diabetes. As Nicolay et al. (2006) have shown, MGO concentration is significantly increased 
in diabetics’ RBC, putatively due to rapid GLO-dependent metabolism in the RBC that shifts 
the MGO gradient from the plasma to the RBC (Kalapos, 2013). Moreover, MGO 
accumulation in the RBC induces eryptosis, RBC suicidal death characterised by membrane 
blistering, and cell membrane phospholipid tangling accompanied with phosphatidylserine 
exposure that triggers cell apoptosis, which culminates in diabetic anaemia (Föller, Huber, & 
Lang, 2008). 
1.7. Aims and objectives 
Recent studies have shown that TRPV4 is downregulated in retinal microvascular 
endothelium (Monaghan et al., 2015) and that endothelial TRPV4 was downregulated in 
STZ-diabetic rats’ mesenteric arteries (Ma et al., 2013). TRPV4 is coupled and functionally 
regulated by CAV-1 (Saliez et al., 2008), which was shown to be coupled with eNOS, and 
both were downregulated in STZ-diabetic rats’ kidneys and bovine aortic ECs; accordingly, 
such downregulation was reversed by way of insulin treatment (Komers et al., 2006; H. 
Wang et al., 2009). In response to those findings, the aim of the present study was to 
investigate the influence of diabetes on the endothelium, with a chief focus on TRPV4 
function, by using STZ-diabetic rats’ aortic and mesenteric arteries. The experimental designs 
were devised according to three primary goals: 1) to investigate the effect of diabetes on 
muscarinic, TRPV4, and TRPM8 function in aortic ECs using appropriate agonists and 
antagonists, as well as to study downstream targets involved in vasodilation induced by 
muscarinic, TRPV4, and TRPM8 pathways; 2) to explore serum markers that might be 
associated with hyperglycaemia and diabetic endothelial dysfunction through enzyme-linked 
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immunosorbent assay (ELISA) studies; and 3) to apply a selected marker—namely, MGO—
to nondiabetic aortic rings and ECs in order to test the hypothesis that MGO contributes to 
endothelial dysfunction in diabetes.  
The objectives of this study were thus the following: 
1. To examine the effect of a muscarinic agonist (i.e., carbachol), TRPV4 agonists (i.e., 
RN-1747 and 4-αPDD), and a TRPM8 agonist (i.e., icilin) on pre-contracted thoracic 
aortic rings in the presence and absence of a TRPV4 antagonist (i.e., HC067047) and 
TRPM8 antagonist (i.e., AMTB); 
2. To investigate the involvement of NOS and BKca in the signalling cascade of 
muscarinic, TRPV4, and TRPM8 pathways in naïve aortic rings; 
3. To investigate the endothelium dependence of muscarinic, TRPV4-, and TRPM8-
induced vasodilation by removing (i.e., denuding) the endothelium in naïve aortic 
rings; 
4. To measure blood glucose concentration, body weight, serum MGO, and oxidised 
low-density lipoprotein (ox-LDL) with an ELISA analysis of STZ-diabetic and 
control rats; 
5. To investigate the influence of STZ-induced diabetes on muscarinic, TRPV4, and 
TRPM8-induced vasodilation in aortic rings and further examine any vascular 
dysfunction in mesenteric arteries (i.e., muscarinic and TRPV4), given the findings of 
a previous study with eNOS KO mice that revealed that NO plays a major role in 
mediating endothelium-dependent vasodilation in the aorta but not in mesenteric 
arteries (Chataigneau et al., 1999). Along similar lines, it also sought to describe 
TRPV4 function in primary aortic ECs through fura-2 Ca2+ imaging and laser 
scanning confocal microscopy (LSCM); 
6. To investigate the effect of MGO diabetic level on nondiabetic aortic rings, primary 
aortic ECs, and ASMCs to provide evidence of MGO implications in endothelial 
dysfunction in diabetes; 
7. To examine the effect of L-arginine on counteracting MGO diabetic-level effects, 
including (i) MGO-induced vascular dysfunction through organ bath experiments on 
pre-contracted naïve aortic rings treated with a carbachol concentration response 
curve, (ii) MGO-suppressed iNOS expression and total NO2 production in primary 
ASMCs treated with IFN-γ and LPS with sodium dodecyl disulphate (SDS)–
polyacrylamide gel electrophoresis (PAGE) Western blotting, and (iii) MGO-
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suppressed TRPV4-mediated [Ca2+]i in naïve primary ECs treated with TRPV4 
agonist (4-αPDD) with fura-2 Ca2+ imaging. 
8. To identify the effect of insulin treatment on TRPV4 function in STZ-diabetic ECs 
through fura-2 Ca2+ imaging and on the expression of TRPV4, CAV-1, and eNOS in 
primary aortic ECs through LSCM; and 
9. To investigate the acute effect of MGO on vascular tone through organ bath and 
FlexStation studies. 
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2. Chapter 2: General methodology: 
2.1. Animals and environmental conditions 
Male Wistar rats (Charles River) weighing 350–450g at baseline were housed in pairs in 
standard cages (Tecniplast 2000P) with sawdust (Datesand grade 7 substrate) and shredded 
paper wool bedding and provided with freely available water and food (5LF2 10% protein 
LabDiet). The room with the cages had a constant temperature of 22  2 C and a 12 hours 
light–dark cycle (lights on from 7:00 to 19:00). All tests were conducted under the light phase 
of that cycle.  
All experiments were approved by the institutional Animal Welfare and Ethics Review 
Committee, conducted in accordance with guidelines established by the Animals (Scientific 
Procedures) Act 1986 and European directive 2010/63/EU, and carried out under project 
licence PPL70/7732. 
2.2. Diabetes induction 
Diabetes inducers (i.e., diabetogenics) are experimental toxins, including alloxan and STZ 
(Lenzen, 2008). Despite resembling T1DM plasma insulin and blood glucose concentrations, 
diabetogenics induce β-cells necrosis, which is associated with initial insulin release, whereas 
in T1DM, β-cells dysfunction is attributed primarily to inflammatory and apoptotic factors 
such as interferon-γ (IFN-γ) and tumour necrosis factor-α (TNF-α) (Lenzen, 2008; Sheader et 
al., 2001). Numerous differences shift favour toward STZ, since alloxan is less stable at 
physiological conditions (pH 7.4, 37°C), in which it decomposes into alloxanic acid with a 
90- seconds half-life (t1/2), whereas STZ is more stable with a half-life of approximately 1 
hour (t1/2) (Szkudelski, 2001). Moreover, alloxan is highly hydrophilic and therefore less 
stable in aqueous solutions, in which it decomposes into another lipophilic derivative, 
butylalloxan, which distributes throughout a wide range of tissues’ cellular membranes and 
has been shown to accumulate in the tubular cells of kidneys, where in culminates in 
nephrotoxicity before inducing diabetes (Lenzen, 2008). By contrast, STZ is highly stable in 
aqueous media and induces diabetes according to its selective N-methyl-N-nitrosourea 
(MNU) moiety, which encourages STZ to act on only GLUT-2-expressing tissues such as 
pancreatic β-cells (Elsner, Guldbakke, Tiedge, Munday, & Lenzen, 2000). Alloxan induces 
diabetes by generating reactive oxygen species (ROS), which can be abolished if alloxan is 
kept oxidised (e.g., with dialuric acid), in which case ROS generation is omitted and thus 
unavailable to induce diabetes (Lenzen, 2008). Conversely, STZ induces diabetes through its 
MNU-coupled hexose C-2 (Lenzen, 2008). STZ is less lipophilic and hence less invasive than 
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alloxan and thus more dependent on GLUT-2, which facilitates STZ endocytosis into β-cells, 
where it alkylates O6-guanine DNA to induce cell necrosis (Elsner et al., 2000). STZ 
moreover induces nephrotoxicity and hepatotoxicity, since the kidneys and liver express 
GLUT-2 transporters (Schnedl, Ferber, Johnson, & Newgard, 1994). In sum, STZ-induced 
diabetes is attributed primarily to three targeted cellular components, starting with nicotine 
adenine dinucleotide (NAD+) depletion, which leads to impaired mitochondrial enzymatic 
function, mitochondrial genome damage, and β-cell dysfunction associated with inhibited 
gene expression, all to yield a net response of inhibited insulin biosynthesis and secretion, as 
well as impaired glucose metabolism (Akbarzadeh et al., 2007; Szkudelski, 2001). 
2.2.1. STZ-induced diabetes 
Male Charles River Wistar rats (approximately 350-450g) were injected with 65mg/kg STZ 
intraperitoneally (i.p., dose volume 10ml/kg). STZ-injected rats were compared to either 
naïve rats (non-injected) or controls, if not both, the latter of which were injected with 20mM 
of citrate buffer (pH 4.0–4.5, dose volume 10 m/kg). STZ was dissolved in pH 4.5 citrate 
buffer to a concentration of 6.5mg/ml (dose volume 10ml/kg for a dose of 65mg/kg i.p). The 
solution was kept in 4°C for 30 minutes and injected i.p. within 30–60 minutes after being 
prepared to enhance the efficacy and safety of dried STZ powder dissolved in sodium citrate 
solution. The period used (30–60 minutes) was based on the equilibrium between STZ 
anomers α and β, of which the highly toxic anomer, α, predominantly existed in the freshly 
prepared STZ. Therefore, anomer-equilibrated STZ solution was less toxic and more 
efficacious since the degradation rat of citrate-buffered STZ solution was 1%/day (de la 
Garza-Rodea, Knaän-Shanzer, den Hartigh, Verhaegen, & van Bekkum, 2010).  
Once injected, all STZ rats had a choice of 2% sucrose water or unmodified drinking water in 
their home cages for 48 hours in order to minimise the risk of hypoglycaemia. After 48 hours 
all STZ rats were supplied with extra unmodified drinking water to compensate for diabetic 
polydipsia. Home cages were changed more frequently due to polyuria. After injection, food 
was also changed from 10% protein (LabDiet 5LF2, EURodent Diet 10%) to a protein-rich 
diet (22% protein, LabDiet 5LF5, EURodent Diet 14%) in order to compensate for possible 
diabetes-induced protein loss. Blood glucose was measured before i.p. injection (i.e., baseline 
measurement) 2–7 days after i.p. injection as a means to confirm hyperglycaemia and lastly 
on the day of euthanasia (i.e., terminal measurement). Blood glucose was measured from a 
single drop of tail vein blood, obtained by a needle prick of conscious rats, using an  
Accu-Chek blood glucose monitor (Roche). Rats with blood glucose concentrations greater 
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than 16mmol/L (≥ 300mg/dl) were considered to be diabetic (i.e., hyperglycaemic) and 
included in the diabetes study. All experiments were powered to take into consideration the 
animals’ loss of 10% weight through the provision of sucrose water, a high-protein diet, and 
frequent home cage changes. 
2.3. Tissue determination, isolation and preparation 
All rats were euthanized according to the Schedule 1 procedure by CO2 asphyxiation, 
followed by cervical dislocation. Their thoracic aortas or mesenteric arteries, if not both, were 
rapidly removed and dissected into an oxygenated Krebs–Henseleit physiological solution 
(i.e., Krebs solution). 
2.3.1. Aortic rings and organ bath setup 
Aortic rings were isolated in an organ bath to facilitate the examination of the whole tissue 
isometric response following numerous treatments and conditions. A freshly isolated aorta 
was cut into approximately 2–3mm-wide rings after the surrounding connective tissue was 
removed. Each aortic ring was threaded by superior and inferior loops, so that the inferior 
loop was attached to a fixed hook and kept suspended in a Bennett isolated tissue vessel 
organ bath of 95% O2/5% CO2 Krebs solution (pH 7.4) at 37 ± 1°C. The superior loop was 
attached by a long terminal thread to the FT-100 force transducer under 1 g of tension force 
immediately after LabScribe software (iWORKS, version 1.817) was calibrated with a 
standard 1 g weight (measurement scale 0.25–2 g). An FT-100 force transducer transmitted 
the tissue responses to an iWORKS amplifier, which generated electrical signals to be 
recorded with LabScribe.  
For the purposes of viability, aortic rings were initially contracted with 123-mM potassium 
chloride Krebs solution (i.e., high-potassium Krebs) and relaxed through continuous washes 
with normal Krebs solution (Table 3) until reaching the baseline of approximately 1 g. 
Thereafter, aortic rings were left to equilibrate for 60–90 minutes with approximately 15- 
minutes washing intervals. 
Aortic rings were rubbed with a cotton thread to mechanically remove the endothelium. 
Afterward, the rings were contracted with noradrenaline (NA) (300nM) followed by 
carbachol cumulative concentration response curve (CRC, 30nM–300μM) to ensure the 
removal of the endothelium, since muscarinic-induced vasodilation is endothelium dependent 
(Furchgott & Zawadzki, 1980). 
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2.3.2. Mesenteric artery and myography 
Mesenteric arteries were examined in a four-channel myograph (DMT) to assess findings of 
aortic rings and to investigate whether pharmacological responses to the applied treatments 
differed. This procedure was based on a previous eNOS KO study with mice that revealed 
that NO plays a major role in mediating endothelium-dependent vasodilation in the aorta but 
not in mesenteric arteries  (Chataigneau et al., 1999). Mesenteric arteries were kept in 
myograph wells, where they were stretched and calibrated in cooperation with LabChart 7 
software. With a DMT 2000 stereomicroscope (magnification 4–40×), mesenteric arteries 
were gently cleaned and isolated. Mesentery was placed on a black background tray with the 
duodenum upward, thereby endowing the whole tissue with a C shape in order to position the 
vein toward the objective lens of the microscope, with the artery downward and proximal to 
the tray surface. Blood vessels were carefully cleaned and arteries isolated and kept in 
physiological solution. Mesenteric arteries were threaded with stainless steel wire 40-μm 
thick and stretched laterally and carefully, while the tension force was observed with 
LabChart software for calibration and zeroing purposes. Mesenteric arteries were treated with 
high-potassium Krebs solution to examine their viability by inducing VGCC-activated 
contraction. Once contraction plateaued, tissues were washed with normal Krebs solution to 
induce complete relaxation with zero contraction. Afterward, tissues were equilibrated for 
approximately 30 minutes before treatment. 
To examine the extent of vasoconstriction, aortic rings were treated with freshly prepared NA 
EC80 (300nM) mixed with ascorbic acid, and the contraction force was measured. The extent 
of vasoconstriction was determined with iWORKS version 1.817. Each value of the CRC was 
estimated regarding the baseline value and the value of the trace before adding the 
vasoconstrictor, which was approximately 1 g in aortic rings and 0mN in mesenteric arteries. 
The maximum contraction force was calculated as 100%, and the other contraction forces 
were normalised to the maximum contraction force as a percentage of maximum contraction 
considering the baseline to be 0%.  
To measure the extent of vasodilation, each value of the CRC was estimated regarding the 
baseline value and value of the trace before adding NA EC80, which was approximately 1 g in 
aortic rings and 0mN in mesenteric arteries. The NA EC80-induced contraction was 
normalised as 0% vasodilation. Each vasodilatory response was normalised as a percentage 
of the NA EC80-induced contraction, after which estimated values were subtracted from 0. 
The maximum vasodilation that reached 0 g tension force was -100% (Figure 10).  
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Figure 10. Representative trace of concentration response curve of carbachol (CC) after pre-contracting the 
aortic ring with noradrenaline (NA). 
 
Table 2 Krebs–Henseleit and high-potassium Krebs solutions components dissolved in 1 L of distilled water 
Chemical Supplier Concentration 
added (g/L) 
Molarity (M) 
Sodium chloride (NaCl) 
For high K+ Krebs 
Fisher Scientific, UK 6.9 
0 
118mM 
0mM 
Potassium chloride (KCl) 
For high K+ Krebs 
Fisher Scientific, UK 0.36 
9.2 
4.8mM 
123mM 
Potassium dihydrogen 
phosphate (KH2PO4) 
Fisher Scientific, UK 0.16 1.2mM 
Magnesium sulphate 
(MgSO4) 
Fisher Scientific, UK 0.29 2.4mM 
Sodium hydrogen 
carbonate (NaHCO3) 
Fisher Scientific, UK 2.1 25mM 
Calcium chloride (CaCl2) Fisher Scientific, UK 0.74 6.7mM 
Glucose (C6H12O6) Fisher Scientific, UK 2 10mM 
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2.3.3. Estimating noradrenaline (NA) concentration required for 80% of 
the maximum vasoconstriction (EC80) 
Naïve rats’ arteries (i.e., aorta and mesenteric) were treated with the NA CRC to induce 
vasoconstriction through final bath concentrations (10nM–10µM). Accordingly, EC80 was 
determined in terms of a nonlinear regression curve for robust fit using GraphPad Prism 5.0. 
Tissues were washed with normal Krebs solution for approximately 30–45 minutes with 5- 
minutes washing intervals before the next experiment commenced. 
All drugs were dissolved in a suitable vehicle and prepared according to the following 
equation: 
 
                (1) 
 
For example, the NA stock solution of 100mM was prepared by dissolving 8.3mg of NA in 
[83mg/(337g/mol/10)] = 2.4 ml of distilled water, which was the appropriate volume for 
estimating the required stock solution of NA. However, MGO was prepared by dissolving 
180 µl of MGO in 10 ml distilled water to yield 100mM. All stock solutions were prepared 
according to Equation (1) by being dissolved in the appropriate solvent (Table 3) and stored 
as 200 µl aliquots at -20°C, except MGO, which was stored at 2–8°C. 
2.3.4. Serum isolation 
Thoracic aortic blood was collected in a glass beaker, samples were left to coagulate at room 
temperature (25°C), and noncoagulated supernatant was collected in Eppendorf tubes. 
Afterward, samples were centrifuged at 13,000 rpm for 5 minutes at 25°C. Thereafter, the 
supernatant (i.e., serum) was collected in a new Eppendorf tube and stored immediately at  
-80°C to be analysed with ELISA and bicinchoninic acid (BCA) assay for total protein count 
(Section 2.8). 
2.4. Isolation of primary aortic ECs 
Primary aortic ECs were cultured to examine the expression level and localisation of TRPV4, 
eNOS, and CAV-1 under LSCM, while primary ECs were studied with a fura-2 Ca2+ imaging 
fluorescence microscope. All experiments were conducted to support tissue findings at the 
cellular level. Rat aortas were freshly isolated and plunged into sterile Hank’s balanced salt 
solution (HBSS), per the recommendations of Battle, Arnal, Challah, and Michel (1994), and 
Drug weight (mg) / (M. wt)/X) 
 
X= shift-log y of the stock’s e-y 
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primary cell isolation was performed in a laminar air flow cabinet. Aortas were transferred 
aseptically into another sterile tube containing sterile HBSS, a step which was repeated five 
times to ensure that all blood was washed from the aortas. Aortas were cleaned of connective 
tissue using autoclaved forceps and scissors and then cut into small rings 2–3mm in length 
(Battle et al., 1994; Ding, Gonick, & Vaziri, 2000). Afterward, aortic rings were transferred 
into a sterile tube containing warm medium 199 (10 ml) containing collagenase and agitated 
for 90 minutes at 37°C (Battle et al., 1994; Ding et al., 2000). The tube was returned to the 
laminar air flow cabinet and mixed with 1–2 ml new-born calf serum to halt collagenase 
activity (Ding et al., 2000). A wide mouth pipette was used to forcibly flush the aortic rings 
in order to dislodge any possible loosely hanging ECs (Ding et al., 2000). Aortic rings were 
then transferred to a new sterile falcon tube and mixed with sterile HBSS for ASMC isolation 
(Section 2.4). The medium 199 containing new-born calf serum, collagenase, and ECs was 
then centrifuged for 5 -minutes at 10000 rpm at 25°C (Battle et al., 1994). The supernatant 
was discarded, and the small pellet containing ECs was resuspended in 3 ml of collagenase-
free media 199 (Ding et al., 2000). The resuspended pellet was then plated in a collagen-
coated t-25 flask later left in the incubator (95% O2, 37°C) for 25–30 minutes (Dolman, 
Drndarski, Abbott, & Rattray, 2004). Primary aortic ECs were expected to attach more 
quickly than ASMCs or fibroblasts (Battle et al., 1994). Accordingly, the flask was examined 
at approximately 5- minutes intervals under a light microscope to ensure ECs adherence, 
since the recommended initial adhering incubation is approximately 25–30 minutes (Dolman 
et al., 2004). The medium was then aspirated, and recently adhered cells were washed twice 
with HBSS to remove any possible impurities, debris, or ASMCs (Battle et al., 1994). The 
flask was then added with complete Dulbecco’s modified Eagle’s medium (DMEM, 3 ml) 
containing horse serum (15%) and foetal calf serum (4%), ECs growth factor 75μg/ml, and 
heparin powder (0.005% w/v) in addition to streptomycin-penicillin 1× (Battle et al., 1994; 
Ding et al., 2000). After 3 days, half of the medium (approximately 1.5 ml) was changed and 
left for another 3 days. Within 5 days, clusters of ECs emerged, as illustrated in Figure 11. 
Cell culture flasks were next coated with collagen. Briefly, rat tail collagen (type I, 10 mg) 
was dissolved in glacial acetic acid (10 ml) in small autoclaved glass bottles (final volume of 
0.1 g%). The solution was then gently mixed with 1.1 ml chloroform (1% v/v), which settled 
at the bottom, and the autoclaved glass bottle was subjected to U/V light for 25 minutes 
before being left in 4°C overnight. Afterward, the collagen solution was transferred to a new 
small autoclaved glass bottle without the chloroform, which was left at the bottom to be 
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discarded. The required amount of collagen coat was 4 ml for the t-25 flask; thus, 0.7 ml of 
collagen stock was added to the HBSS (3.3 ml). The collagen coat was then added to the t-25 
flask and subjected to U/V light before being transferred to the incubator (95% O2, 37°C) 
overnight. Thereafter, the collagen coat was aseptically aspirated, and the flask was washed 
twice with HBSS before cells were added (Sitterley, 2008a). 
Figure 11. Primary aortic endothelial cell cluster shown in T-25 flask coated with collagen after 5 days of 
isolation from rat aorta through collagenase digestion (400×). 
 
2.5. Isolation of primary ASMCs 
Primary ASMCs were examined to investigate the expression level of proteins of interest, 
iNOS, and TRPV4 through SDS–PAGE Western blotting. During ECs isolation, aortic rings 
were kept in a sterile tube with HBSS, and aortic rings were cut longitudinally and flipped so 
that the internal layer of the explants stuck to the flask’s bottom. The flask was then mounted 
vertically and added to the complete DMEM mixture (3 ml) with foetal calf serum (15%) and 
streptomycin penicillin 1×. The flask was left vertically in the incubator (5% CO2, 37°C) for 
90 minutes so that the medium was not in direct contact with the explants. Thereafter, the 
flask was gently placed horizontally so that the explants were not detached from the flask 
surface. The medium was kept unchanged, and after 3 days, half of it (approximately 1.5 ml) 
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was changed and left for another 3 days. Within 5 days, clusters of smooth muscle cells were 
observed, as Figure 13 shows  (Kenagy, Hart, Stetler-Stevenson, & Clowes, 1997). 
Figure 12. Primary aortic smooth muscle cells (ASMCs); an aortic explant denuded from endothelium and 
adventitia (the dark side of the picture) was plated in t-25, and spindle-shaped ASMC growth started at day 4 
(400×). 
2.6. Calcium imaging with fura-2 
Measuring the Ca2+ influx in primary ECs was an elegant method for examining the viability 
of the isolation technique and to correlate the findings with other in vitro and in vivo studies. 
The method used calcium-sensitive fluorescent probes such as fura-2, a dye that shows 
changes in its fluorescent properties when it binds to Ca2+ (Morgan & Thomas, 1999). Fura-2 
is applied as acetoxymethyl (AM) ester that enhances the dye’s membrane permeability. 
Once the dye crosses the cellular membrane, intracellular esterase enzymes remove the ester 
moiety to yield the hydrophilic fura-2 that has become trapped intracellularly. Therefore, the 
process can concentrate the dye to approximately 100-fold the initial extracellular 
concentration of the AM ester (Morgan & Thomas, 1999). Fura-2 is a dual excitation dye that 
emits fluorescence at a wavelength of 510nm. The intracellular fura-2 exists in two forms: the 
free fura-2, which is excited at 380nm to emit fluorescence, and the Ca2+ bound fura-2, which 
is excited at 340nm to emit fluorescence at 510nm (Morgan & Thomas, 1999). Accordingly, 
upon Ca2+ influx, Ca2+ binds to fura-2, which is excited at 340nm to emit fluorescence at 
510nm by ratiometric recording (Iredale & Dickenson, 1995). 
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Primary ECs were digested with trypsin and seeded on autoclaved glass coverslips 0.16–0.19-
mm thick coated with poly-L-lysine to enhance the adherence of ECs. Briefly, autoclaved glass 
coverslips were placed in a sterile 6-well plate, covered with poly-L-lysine, and left in the 
incubator overnight (Sitterley, 2008b). Afterward, the extra poly-L-lysine was aspirated, and 
the coverslips were washed with Hank’s buffer (HB) containing 5.6mM of KCl, 138mM of 
NaCl, 4.2mM of NaHCO3, 1.2mM of NaH2PO4, 2.6mM of CaCl2, 1.2mM of MgCl2, 10mM of 
glucose, and 10mM of HEPES with a pH of 7.4  (Smith, Proks, & Moorhouse, 1999). The 
autoclaved coated glass coverslips were then seeded with primary ECs (200μl) and left in the 
incubator (5% CO2, 37°C) for 3–5 hours, after which the cells were observed under a light 
microscope to ensure their adherence. Thereafter, the wells were mixed with complete ECs 
media (2 ml) and left in the incubator (5% CO2, 37°C) overnight. The ECs were washed, and 
the media with or without treatments were changed until the ECs become confluent (i.e., at 
approximately 70%). ECs were next washed three to five times with HB before being treated 
with fura-2AM solution, composed of HB with fura-2AM (5 µM), 2% pluronic F-127, and 2% 
foetal bovine serum (FBS), per the recommendations of A. J. Huang et al. (1993); (Ma, Cheng, 
Wonga, et al., 2011). The ECs were incubated with fura-2AM solution in the dark at room 
temperature for 45–60 minutes (Ma, Cheng, Wonga, et al., 2011). Afterward, the coverslips 
were extensively washed with HB for 5-7 times to remove the extracellular fura-2AM and 
incubated with HB containing 2% FBS in the dark at room temperature for 30 minutes to 
enhance the hydrolysis of intracellular fura-2AM. Thereafter, the coverslips were washed for 
5 times with HB before starting the experiment was begun (A. J. Huang et al., 1993) and placed 
under the Nikon Eclipse TE200 epifluorescence microscope (40×). A drop of immersion oil 
(type NF, nd= 1.515, Nikon) was mounted on the lens to enhance image resolution by 
correcting the refraction index and collecting more diffracted orders using the scientific image-
processing IPLab software version 4.04. The coverslips were subjected to an experiment lasting 
600 seconds that included a frame-shot every 10 seconds for 60 frames per experiment. 
2.7. Laser scanning confocal microscopy 
Confocal microscopy is an optical imaging method with three-dimensional sectioning 
capability widely applied in biomedical sciences to study fixed or living objects with a 
fluorescent probe. Modern confocal microscopes are relatively easy to operate and have been 
integrated in many multiuser imaging facilities. Among the different types of confocal 
microscopes is the LSCM, which provides a better resolution than the conventional light 
microscope (theoretical maximum resolution of 0.2μm), but less than the transmission 
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electron microscope (0.1nm). LSCM imaging starts by bathing the entire specimen in laser 
light; sensitive photomultiplier tube detectors are used, as well as scanning mirrors controlled 
by a computer to improve the imaging process. Image improvement also involves confining 
the illumination and detection to a single point in the specimen with limited diffraction 
through an objective lens with scanning devices. Therefore, regions of interests (ROI) 
labelled with fluorescence light-emitting probes are detected by a photomultiplier behind a 
pinhole to construct an image with imaging software (Goy & Psaltis, 2012). 
2.7.1. Primary aortic ECs imaging 
Primary ECs were seeded on autoclaved poly-L-lysine coated glass coverslips 0.16–0.19-mm 
thick and grown to reach approximately 70% confluency. ECs were labelled with acetylated 
low-density lipoprotein (Dil-Ac-LDL). Briefly, the coverslips were washed five times with 
HBSS, and ECs were washed with serum-free DMEM and incubated with Dil-Ac-LDL 
(10μg/ml in serum-free media) in the incubator for 4 hours. The coverslips were then washed 
with HBSS five times before being incubated with paraformaldehyde (4%) in the dark at 
room temperature for 1 hours to fix the cells. Afterward, the ECs were permealised with 
Triton-X100 (0.5% in HBSS) incubation for 10 minutes in the dark at room temperature. The 
coverslips were again washed with HBSS three times, after which the ECs were incubated 
with rabbit primary antibody for TRPV4, eNOS, or CAV-1 in blocking solution composed of 
phosphate buffer saline (pH 7.4), bovine serum albumin (BSA, 1%), and foetal calf serum 
(FCS, 2%) (1:100) overnight at 4°C. Thereafter, cells were again washed five times with 
HBSS before being incubated with the fluorescent goat secondary anti-rabbit antibody 
(1:1,000) for 2 hours at room temperature. The coverslips were yet again washed five times 
with HBSS and mounted on a microscope glass slide with a drop of mounting media 
containing DAPI, which stained the nucleus blue. ECs were visualised with Nikon C1 CLSM 
and EZ-C1 silver version 3.9 software. Primary aortic ECs were characterised under the laser 
confocal microscope (488nm), characterised as ROI red fluorescence staining less than 
650nm and by the presence of the DAPI-stained nucleus, and visualised under 480nm. The 
protein of interest—namely, TRPV4, CAV-1, or eNOS—was probed indirectly through a 
secondary fluorescence antibody and visualised under a 515-nm wavelength. From each 
coverslip, four cells were selected and analysed. The images were then uploaded to ImageJ 
1.46r software for quantitative analysis with the split-channel function and with ‘Colour’ 
selected on the image menu. Thereafter, each cell was selected and analysed with the measure 
function of the analyse menu. 
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2.8. BCA assay and SDS-PAGE Western blotting 
Western blotting, or protein blotting, is a fundamental technique in biomedical sciences that 
detects a protein of interest from a complex protein population extracted from cell or tissue 
lysates. Protein detection is based on three aspects: gel electrophoresis, which separates 
proteins according to their size as they travel through the resolving gel; the transfer of the 
separated proteins to a membrane; and protein probing with a selective antibody visualised 
through an imaging system such as enhanced chemiluminescence (ECL), per the 
recommendations of Kurien and Scofield (2006).  
ASMCs were washed with ice-cold HBSS three times followed by hot lysis buffer at 95°C 
(lysis buffer pH 7.4, 24mg of Tris-HCl, 200mg of SDS in 20-ml deionised distilled water 
with protease inhibitor cocktail of 1μl/ml). Afterward, cells were scrapped with lysis buffer to 
form cell lysates collected in Eppendorf tubes and sonicated for 30 seconds with ultrasound 
water bath three times with 10-seconds intervals in between. Afterward, Eppendorf tubes 
were transferred in heating blocks and heated at 95°C for 5 minutes before being centrifuged 
at 10000 rpm for 5 minutes. The supernatant was collected for BCA assay and Western 
blotting. For Western blotting, cells lysates were added with bromophenol blue (5x) by ratio 
of 4:1 and kept in -80°C. 
BCA assay is a colorimetric analytical method that is applied to determine the protein 
concentration in a sample (Bainor, Chang, McQuade, Webb, & Gestwicki, 2011). BCA assay 
is based on measuring the formation of cuprous ions (Cu+) from cupric ions (Cu+2) through 
the Biuret complex formed in alkaline solutions of proteins using BCA (Olson & Markwell, 
2007). The first reaction culminates with the interaction of copper and BCA with the amino 
acids cysteine, cystine, tryptophan, and tyrosine in the protein (Olson & Markwell, 2007). 
Thereafter, the BCA reagent forms a complex with Cu+ that yields a purple Cu+1(BCA)2 
chromophore of an optimum absorbance at the 562-nm wavelength (Bainor et al., 2011). The 
test tube protocol requires only two reagents, and the relationship between protein 
concentration and absorbance is nearly linear (Olson & Markwell, 2007) over a wide working 
range (0–40nM/100μl), as shown in Figure 13. 
Accordingly, BCA assay was initially conducted on a standard curve estimated from eight 
standard solutions of different concentrations obtained from BSA stock solution in deionised 
distilled water (1% w/v).  
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In a nonsterile 96-well plate, samples and standards were added as 5μl triplicates. To unify 
the vehicle, 5μl of lysis buffer was added to the standard wells, whereas 5μl of distilled water 
was added to each sample’s well. BCA reagents A and B were mixed in a ratio of 9.8:0.2, of 
which 100μl was added into each well. The plate was shaken for 45 minutes and samples 
were read at 620nm using an Ascent Multiskan plate reader and software, version 2.6 
(Thermo Labsystems Oy). 
Figure 13. Bicinchoninic acid (BCA) assay standard curve, estimated from eight different BSA standard 
solutions (0–4μg/μl) loaded in 96-well plates treated with BCA reagents A and B mixture and shaken at room 
temperature before being read at the 620-nm wavelength. 
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2.8.1. Western blotting 
The Western blotting gel chambers were prepared from 8% acrylamide resolving gel [2.66 ml 
of 30% acrylamide, 2.5 ml of Tris-HCl, pH 8.8 (1.5M), 100μl of SDS 10%, 100μl of 
ammonium persulfate 10%, and 6μl of tetramethylethylenediamine (TEMED), all in 4.64 ml 
deionised distilled water] and stacking gel [0.52 ml of 30% acrylamide, 1 ml of Tris-HCl, pH 
6.8 (0.5M), 40μl of SDS 10%, 20μl of ammonium persulphate 10% and 4μl of TEMED, all in 
2.44 ml deionised distilled water]. The Western blotting gel glass chambers were placed in a 
loading tank containing tank buffer [Tris-HCl (0.025M), glycine 0.192M, and SDS 0.1% in 
deionised distilled water]. The gels were loaded with 20-μg proteins calculated from BCA 
assay and run at 20m amp/gel current using a Thermo–Fisher PowerPack for approximately 
60 minutes. Once samples reached the bottom of the resolving gel front, the gels were 
mounted on polyvinylidene difluoride immobilon-P transfer membranes of 0.45 µm pore size 
in a semidry transfer chamber, subjected to 25 mV for 20 minutes and added with transfer 
buffer [Tris-HCl (4.8mM), glycine (3.9mM) and SDS (0.00375%), pH 8.3 in deionised 
distilled water with freshly added methanol (20%)]. Briefly, the membrane was mounted on 
three Whatmann filter papers, and the gel was placed atop the membrane and topped with 
another three Whatmann filter papers, so that the membrane was between the gel and the 
positive side of the semidry chamber. Afterward, the membrane was incubated with blocking 
buffer for 2 hours on a shaker [blocking buffer: Tris-HCl (1mM), NaCl (10mM), Tween-20 
(0.1% v/v) in deionised distilled water, pH 7.5] and added with bovine serum albumin (5% 
w/v). The gels were then mixed with Coomassie Blue to ensure that the proteins were 
transferred to the membrane, after which the blocking buffer was removed and the membrane 
incubated on a shaker with primary antibody in blocking buffer overnight at 4°C. Thereafter, 
the membrane was washed with washing buffer [Tris-HCl (1mM), NaCl (10mM) and Tween-
20 (0.1% v/v)] in deionised distilled water, pH 7.5) three times for 15 minutes (net washing 
time: 45 minutes). The secondary antibody in blocking buffer was added to the membrane on 
a shaker for 2 hours the membrane was washed with washing buffer three times for 15 
minutes (net first washing time: 45 minutes). Lastly, the membrane was treated with ECL 
detection reagents A [p-coumaric acid (25 µl, 90mM)] + luminol (50 µl, 250mM) in 5 ml of 
Tris-HCl (100mM), pH 8.5] and B [3 µl of 30% H2O2 in 5 ml of Tris-HCl (100mM), pH 8.5) 
and left on the shaker for 5 minutes. The protein of interest was detected using a Thermo 
Scientific MYECL imager. Western blotting results were quantified with densitometric 
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analysis, which is based on comparing the band density of the protein of interest (i.e., iNOS 
or TRPV4) to that of the loading control protein (i.e., β-actin). 
2.9. Data analysis 
All experimental data are presented as mean ± standard error mean (SEM). The number of 
different experiments conducted from different batches (i.e., animals or cell passages) is 
referred to as the group size (N), whereas the number of repeats within the same experimental 
batch is termed as n. Therefore, data subjected to statistical analysis have at least N= 3 and n= 
6 when data showed consistency and robust reproducibility; however, most data were 
collected from sample sizes of N= 4 and n= 8.  
Griess assay, BCA assay, and ELISA analysis were conducted by loading each sample in 
triplicate, except with ox-LDL ELISA, in which samples were loaded in duplicate, as 
recommended by the manufacturers. Technical repeats were conducted to ensure the 
reliability of the produced values. 
Data analysis was performed with GraphPad Prism 5.0 software to determine the level of 
significance. When the level of probability (p) was less than 0.05 (*), 0.01 (**), or 0.001 
(***), the effect of the difference was deemed significant. Two-way analysis of variance 
(ANOVA) was conducted to examine the effect of two independent variables in specific 
experiments (e.g., organ bath studies), in terms of the effect of treatment (e.g., STZ or another 
incubation) in addition to the effect of the applied drug concentration (i.e., x-axis), as detailed 
in Chapters 3 and 4). Significance observed with two-way ANOVA was presented on the side 
of the graph next to the last concentration (i.e., time point), whereas post hoc significance 
was shown on the top of the specific concentration or time point. By contrast, one-way 
ANOVA was conducted to examine the effect of a single independent variable on more than 
two groups—for instance, when iNOS expression was examined in the presence of MGO 
with and without L-arginine (Chapter 6) and the effect of insulin on STZ-diabetic ECs 
compared with naïve nondiabetic ECs (Chapter 5). A two-tailed Student’s t-test was applied 
to examine the effect of a single independent variable on two groups—for example, when 
TRPV4 expression in ASMCs was compared (Chapter 6) and when the effect of AMTB was 
studied in terms of MGO-induced intracellular calcium elevation in CHO cells (Chapter 7). 
Paired or matched analysis was conducted when the same sample was subjected to two 
different conditions, such as with STZ-diabetic ECs treated with insulin (Chapter 6) and 
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when CHO and rTRPM8 cells were compared to CHO and rTRPM8 cells incubated with 
AMTB (Chapter 7). 
2.10. Chemicals and drugs 
Table 3 Chemical and drug suppliers, solvents used, and specifications 
Chemical Supplier Specification Solvent  
Streptozotocin 
(STZ) 
Sigma Chemical, St. Louis, 
MO, USA 
≥98.0% high performance 
liquid chromatography 
(HPLC), 
M.wt= 265.22g/mol 
pH 4.5,  
20-mM 
citrate 
buffer 
Noradrenaline 
(NA) 
Sigma Chemical Min. 99%,  
M.wt= 337g/mol 
Distilled 
water 
(DW) 
Carbachol 
(CC) 
Sigma Chemical Min. 98% (TLC), 
M.wt= 182.65g/mol 
DW 
Methylglyoxal 
(MGO) 
Sigma Chemical 40% (w/v) in H2O DW 
L-NG-Nitro-L-
arginine methyl 
ester hydrochloride 
(L-NAME) 
Sigma Chemical ≥98.0% (TLC), 
M.wt= 269.69g/mol 
DW 
RN-1747 
 
Tocris Bioscience, Bristol, 
UK 
10 mg 
M.wt= 395.87g/mol 
Dimethyl 
sulfoxide 
(DMSO) 
4α-Phorbol 12,13-
didecanoate 
(4αPDD) 
Sigma Chemical 1mg  
M.wt= 672.93g/mol 
DMSO 
HC067047 Tocris Bioscience 
 
10 mg 
M.wt= 471.15g/mol 
DMSO 
RN-1734 Sigma Chemical 10mg 
M.wt= 353.31g/mol 
 
DMSO 
Icilin Tocris Bioscience 10mg  DMSO 
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M.wt= 311.3g/mol 
AMTB 
hydrochloride  
Tocris Bioscience 10 mg 
M.wt= 430.99g/mol 
DW 
Lipopolysaccharides 
 
Sigma Chemical 100 mg 
from Escherichia coli 
0111:B4 
DW 
Collagenase Sigma Chemical 50mg from Clostridium 
histolyticum, sterile-
filtered for general use, 
type I-S, 0.2-1.0 FALGPA 
units/mg solid, ≥125 
CDU/mg 
Serum-free 
media 199 
or 
Dulbecco’s 
modified 
Eagle’s 
medium 
(DMEM) 
Endothelial cell 
growth supplement  
Sigma Chemical 15mg from bovine 
pituitary 
Complete 
DMEM 
media 
Heparin sodium salt  Sigma Chemical 10mg from porcine 
intestinal mucosa (25 KU) 
Complete 
DMEM 
media 
Collagen  Sigma Chemical 10mg  
from rat tail  
Bornstein and Traub Type 
I, powder, BioReagent, 
suitable for cell culture 
Acetic acid 
(100%) 
Poly-L-lysine 
solution  
 
Sigma Chemical 50 ml  
M.wt= 150000-
300000g/mol, 0.01%, 
sterile-filtered, 
BioReagent, suitable for 
cell culture 
 
Luminol  Sigma Chemical, St. Louis, 
MO, U.S.A 
5g 
M.wt= 177.16g/mol 
DMSO 
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p-Coumaric acid 
 
 
Sigma Chemical 5g 
M.wt= 164.16g/mol 
DMSO 
Carestream® 
Kodak® 
autoradiography 
GBX developer/ 
replenisher 
Sigma Chemical 1 gallon DW 
Carestream® 
Kodak® 
autoradiography 
GBX fixer/ 
replenisher 
Sigma Chemical 1 gallon  DW 
Ionomycin  Sigma Chemical Calcium salt (1 mg) from 
Streptomyces conglobatus 
 M.wt= 47.07g/mol 
DMSO 
Iberiotoxin 
 
 
 
Sigma Chemical 10 µg 
recombinant from 
Mesobuthus tamulus  
M.wt= 4,248.86g/mol 
DMSO 
L-arginine  Sigma Chemical 
 
 25 g 
 M.wt= 174.20 
DW 
DMEM (1×) liquid 
(low glucose) 
Invitrogen Gibco 
Fisher Scientific 500 ml 
[with L-Glutamine 
1,000mg/L D-glucose 
sodium pyruvate 25mM 
HEPES] with L-
glutamine, D-glucose, 
sodium pyruvate, HEPES 
Invitrogen Gibco 
 
New-born bovine 
calf serum 
Fisher Scientific 100 ml  
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Thermo Scientific 
HyClone 
Horse serum Fisher Scientific 100 ml 
[Origin: New Zealand] in 
plastic container, E-Z 
hold, Invitrogen Gibco 
 
Antibiotic–
antimycotic solution 
Fisher Scientific 100 ml 
100×, 10000U/ml 
penicillin G, 10000 µg/ml 
streptomycin, 25µg/ml 
amphotericin B 
(Fungizone), Thermo 
Scientific HyClone  
 
Trypsin solution Fisher Scientific 100 ml 
2.5% (10×) without EDTA 
or phenol red Thermo 
Scientific HyClone 
 
Medium 199  Fisher Scientific 
 
 
500 ml 1× liquid [with 
Earle’s salts L-glutamine]  
Invitrogen Gibco 
 
Hyperfilm ECL  Fisher Scientific 18 × 24cm  
Hank’s Balanced 
Salt Solution 
(HBSS) 
Fisher Scientific 500ml 
10× liquid [without phenol 
red sodium bicarbonate] 
without phenol red (ce) 
Invitrogen Gibco 
 
Membrane filter  Fisher Scientific Immobilon-P transfer 
membranes 0.45 µm, pore 
size 265mm × 3.75m 
 
Protein assay 
reagent B 
Fisher Scientific 25 ml 
BCA, Thermo Scientific 
Pierce 
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Protein assay 
reagent A 
Fisher Scientific 1 L 
BCA Thermo Scientific 
Pierce 
 
Fura-2, AM 
 
Life Technologies Cell permeant (20 × 50 
µg) 
DMSO 
Pluronic® F-127 Life Technologies 0.2 µm filtered (10% 
solution in water, 30 ml) + 
A11 
 
Biotinylated Protein 
Ladder Detection 
Pack 
New England Biolabs 650 µL  
Antibiotin New England Biolabs 1 ml 
HRP-linked antibody 
 
Interferon-γ (IFN-γ) Merck 
Chemicals 
10μg (1000000 U) 
Rat, Recombinant, E. coli 
Sterile 
distilled 
water 
(SDW) 
Anti-SM22 alpha 
antibody  
Abcam Polyclonal rabbit anti-rat 
(100 µg) 
SDW 
Anti-TRPV4 
antibody  
Abcam Polyclonal rabbit anti-rat 
(100 µl) 
 
Anti-iNOS antibody  Abcam Polyclonal rabbit anti-rat 
(200 µl) 
 
Anti-rabbit antibody Abcam Goat IgG H&L (Biotin), 1 
mg 
SDW 
Caveolin-1 antibody  Thermo–Fisher Scientific  Polyclonal rabbit anti-rat 
antibody (100 µl) 
 
 
eNOS antibody Thermo–Fisher Scientific Polyclonal rabbit anti-rat 
antibody (100 µl) 
 
TRPV4 antibody Thermo–Fisher Scientific Polyclonal rabbit anti-rat 
antibody (100 µl) 
 
56 
 
Mounting medium Vector Laboratories With DAPI (10 ml), 
VECTASHIELD HardSet 
 
Fluorescein 
antibody  
Vector Laboratories Goat anti-rabbit IgG (1.5 
mg) 
 
Rat oxidised low-
density lipoprotein 
enzyme-linked 
immunosorbent 
assay (ELISA) kit 
H2bioscience 96 assays  
OxiSelect 
Methylglyoxal 
(MGO) Competitive 
ELISA kit 
Cambridge Bioscience Rat selective 96 assays  
Acetylated low-
density lipoprotein 
(Dil-Ac-LDL) 
Bioquote Limited 200 µg Serum-free 
DMEM  
Sodium nitrite 
(NaNO2) 
Fisher Scientific 500 g (≥97%) 
M.wt = 69g/mol 
DDW 
Griess A  Sulphanilamide (1% v/v)  5% 
phosphoric 
acid 
Griess B  Naphthyl ethylenediamine 
dihydrochloride  
(0.1% v/v) 
DDW 
Chloroform  Sigma Chemical 500 ml (≥99.5%) 
M.wt= 119.38g/mol 
 
Hydrochloric acid Fisher Scientific  2.5 L 
M.wt= 36.46g/mol 
 
Ammonium 
persulfate 
Fisher Scientific 25 g 
M.wt= 228.19 
DDW 
NNN’N’-
tetramethylethylene
diamine  
VWR Chemicals, 
Auckland, New Zealand 
25 ml 
M.wt= 116.21g/mol 
DDW 
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(TEMED) 
Hygromycin B 
from Streptomyces 
hygroscopicus 
Sigma Chemical M.wt = 527.52 
  
 
MEM 
AQmedia 
Acrylamide National Diagnostics, 
Yorkshire, UK 
450 ml 
30% acrylamide, 0.8% 
bis-acrylamide stock 
solution (37.5:1) 
DDW 
Sodium dodecyl 
disulphate (SDS) 
Fisher Scientific 500 g (99% min) 
M.wt= 288.38g/mol 
DDW 
Glycine Fisher Scientific 500 g (98%) 
M.wt= 75.07g/mol 
DDW 
Insulin Sigma Chemical 100mg from bovine 
pancreas 
M.wt= 5733.49g/mol 
Hydrochlor
ic acid  
pH 2-3 
Probenecid Sigma Chemical 25g 
M.wt= 285.36g/mol 
DDW 
Acetic acid  Sigma Chemical 2.5 L (≥99%) 
M.wt= 60.05g/mol 
(A6283) 
 
HEPES Sigma Chemical BioPerformance Certified, 
≥99.5% (titration), cell 
culture tested 
M.wt= 238.8g/mol 
DW 
Minimum essential 
medium eagle 
(MEM AQMedia) 
Sigma Chemical With Earle’s salts, L-
alanyl-glutamine, and 
sodium bicarbonate, 
liquid, sterile-filtered, 
suitable for cell culture 
 
Anti-phospho p38 
MAPK 
Cell Signalling Polyclonal rabbit anti-rat 
antibody (200 µl) 
 
Anti-phospho Akt Cell Signalling Polyclonal rabbit anti-rat 
Antibody (100 µl) 
 
1. Introduction :  
2. Methodology : 
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3. Chapter 3: The effect on muscarinic, TRPV4 and TRPM8 agonists on rat 
aortic rings 
3.1. Introduction 
Blood vessels are primarily composed of three layers: the outer layer (tunica adventitia), the 
medial layer (smooth muscle cells, or tunica media), and the inner layer (endothelium or 
tunica intima) (C. W. Chen et al., 2012). The endothelium is composed of endothelial cells 
(ECs) and sub-endothelial layer forming a relatively impermeable layer that separate the 
passive diffusion of the circulation’s components to the supplied tissues (M. G. Davies & 
Hagen, 1993).  
The endothelium regulates vascular tone by releasing numerous vasodilators, including NO, 
PG, and EDHF, in addition to vasoconstrictors such as ET-1 and Ang II (Tabit et al., 2010). 
NO is among the vasodilators released in response to shear stress and TRPV4 activation 
(Sena et al., 2013; Sukumaran et al., 2013). NO in ECs is generated by way of eNOS, which 
oxidises L-arginine into L-citrulline (M. I. Lin et al., 2003). eNOS or NOS-3 is a 
constitutively active enzyme in the ECs that can be further stimulated by receptor-dependent 
agonists that increase [Ca2+]i and compromise plasma membrane phospholipid symmetry 
(Cines et al., 1998; A. Dhar et al., 2010). NO diffuses to VSMCs where it activates the sGC 
that generates cGMP to yield vasodilation (van den Oever et al., 2010). cGMP inhibits the 
voltage-gated calcium channels (VGCC)-mediated Ca2+ entry into the VSMCs to inhibit the 
vasoconstriction. At the same time, cGMP activates potassium channels such as BKca, KATP, 
and Kv, which induces membrane hyperpolarisation and vasodilation (Dong et al., 1998; 
Murphy & Brayden, 1995b). cGMP also activates PKG, which in turn activates MLCP that 
dephosphorylates the MLC and causes further vasodilation (Cohen et al., 1999).  
In addition to NO, COX-1 in ECs metabolises AA to produce prostacyclin, which is a potent 
vasodilator (Mitchell et al., 2008). AA is liberated from the ECs membrane through the action 
of PLA2 (Lambert et al., 2006). Prostacyclin mediates vasodilation by activating the BKca,  
KATP channels in VSMCs, which prompts membrane hyperpolarisation and, in turn, 
vasodilation (Clapp et al., 1998; Jackson et al., 1993). Moreover, prostacyclin induces the 
release of Ca2+ from ER stores to mediate endothelium Ca2+ entry, which is a crucial step in 
initiating endothelium-dependent vasodilation (Murata et al., 2007).  
In addition to NO and prostacyclin, the 3rd endothelial vasodilatory pathway is the EDHF (G. 
Chen et al., 1988), which involves SKca, IKca, BKca and EET as essential elements in 
mediating vasodilation (Hecker et al., 1994; A. Huang et al., 2000; Murphy & Brayden, 
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1995a; Popp et al., 1996; Rosolowsky & Campbell, 1993; Widmann et al., 1998; Zygmunt & 
Högestätt, 1996). 
In addition to the three mentioned pathways, Western blotting, RT-PCR and 
immunohistochemistry studies recognised at least 20 distinct TRP channels in the VSMCs 
and the endothelium (Earley et al., 2010; H. Y. Kwan et al., 2007; Watanabe et al., 2008). As 
cation channels, TRP channels exert vascular tone regulation in both systemic and pulmonary 
circulations (Watanabe et al., 2008). Highly expressed in ECs, TRPV4 induces NO and 
EDHF release and thereby controls the vascular tone (Köhler et al., 2006). Furthermore, 
TRPV4 is essential in muscarinic-mediated endothelium-dependent vasodilation via a novel 
mechanism that involves Ca2+ influx and by way of endothelium derived factor (11, 12 EET)-
induced   TRPV4 complex formation with RyR and BKca in VSMCs and thereby facilitate 
vasodilation (Earley et al., 2005). In addition to TRPV4, TRPM8 is expressed in both ECs 
and VSMCs in numerous vascular beds, including rat aorta, mesenteric arteries, femoral 
arteries, and tail artery (Earley, 2010; H. Y. Kwan et al., 2007). The co-expression of TRPM8 
and TRPV4 channels in the aortic vasculature was concluded as novel Ca2+ entry pathways 
that might control the systemic circulation by way of EDHF (Garland et al., 1995; X. R. Yang 
et al., 2006). 
Therefore, as mentioned in section 1.7, the main objectives this chapter were to investigate 
the relationships between muscarinic receptors, TRPV4 and TRPM8 channels through organ 
bath studies using aortic rings from Wistar rats. Moreover, the dependence of these three 
pathways on NO was investigated through incubating the rings with the NOS blocker, L-
NAME. Further studies were conducted to investigate the involvement of BKca in the 
vasodilatory pathways induced by muscarinic agonist (carbachol), TRPV4 agonist (4-αPDD) 
and TRPM8 agonist (icilin). These investigations were conducted using the selective BKca 
blocker, iberiotoxin. Lastly, carbachol-, 4-αPDD-, and icilin-induced vasodilation was 
investigated after endothelium removal to investigate the endothelium-dependent vasodilation 
in muscarinic, TRPV4, and TRPM8 pathways. 
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3.2. Materials and methods 
Organ bath studies were conducted to examine the muscarinic, TRPV4 and TRPM8-induced 
vasodilation through inhibiting TRPV4 and/or TRPM8, or inhibiting selected downstream 
cascade components such as NOS and BKca. Additionally, the endothelium was removed 
(denuded endothelium) to examine the endothelium-dependence of the muscarinic, TRPV4 
and TRPM8 pathways. Fresh aortic rings were isolated and prepared as mentioned in section 
2.3.1. To examine the vasodilation of an agonist, the tissue was initially contracted with NA 
(300nM) which was found as the EC80 (Figure 14). The extent of vasoconstriction and 
vasodilation was calculated as mentioned in general methodology section 2.3.2. 
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3.3. Results 
3.3.1. NA EC80 determination 
NA EC80 was estimated to spare the time for prospective experiments by curtailing NA 
concentration response curve (CRC) to avoid possible tissue damage or desensitisation 
through repeated maximum contraction as described in section 2.3.3. 
When NA CRC experiments were analysed, the mean maximum contraction force (Emax) 
was 0.468 ± 0.041g obtained from 9 different rats (N= 9) from which 36 aortic rings were 
studied (n= 36) which were then normalised to the maximum response to yield an EC80 of 
FBC= 629.2 ± 86.7nM. However, when NA (629nM) was applied as a single dose, it yielded 
100% vasoconstriction. NA (300nM) showed EC80 submaximal response Emax= 0.468 ± 
0.04g, 100 ± 13.5% was achieved with NA final bath concentration (FBC) = 300µM (Figure 
14).  
 
Figure 14. Noradrenaline (NA) concentration response curve in rat aortic rings. NA-induced vasoconstriction in 
gram scale (a). NA-induced vasoconstriction normalised to the maximum response % (b). Data is shown as 
mean ± SEM (N=9). 
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3.3.2. TRPV4 and TRPM8 antagonists’ studies 
As the vehicle for TRPV4 agonists (RN-1747 and 4-αPDD) and TRPM8 agonist (icilin) is 
DMSO, therefore, DMSO CRC was applied to investigate whether DMSO has an effect on 
vascular tone. DMSO stock solution 100% w/v which is equivalent to 12.8M was diluted by 
1:1000 serial dilutions. DMSO did not show significant difference on vascular tone when 
compared to NA-induced contraction (N=3, p ≥ 0.05, DMSO Emax= -3.6 ± 2.3% vs NA-
induced contraction, Emax= 0.00 ± 2.4%) (Figure 15). 
Figure 15. Dimethyl sulfoxide (DMSO) effect on NA-induced vasoconstriction in aortic rings. Non significance 
is represented as ns p ≥ 0.05 analysed through one-way ANOVA vs NA-induced contraction (N= 3), Data is 
shown as mean ± SEM. 
These studies were conducted to estimate the required concentration of the antagonist to 
block the targeted channel, whether TRPV4 (HC067047 and RN-1734) or TRPM8 (AMTB). 
As a previous study conducted by L. Zhang, Papadopoulos, and Hamel (2013) revealed that 
HC067047 is a competitive antagonist of TRPV4 and an unpublished findings from Professor 
Stuart Bevan’s laboratory in Wolfson centre for age related diseases revealed that AMTB is a 
competitive TRPM8 antagonist (Unpublished data). Therefore, pA2 was estimated for each 
antagonist through constructing a Schild plot. pA2 is the negative logarithm of the molar 
concentration of an antagonist which reduces the effect of a dose of agonist to that of half the 
dose (Tallarida, Cowan, & Adler, 1979). pA2 measures the affinity of a competitive 
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antagonist to a certain receptor. The presence of an antagonist shifts the concentration 
response curve rightward as more agonist is required to exert a certain response (Tallarida & 
Murray, 1987). 
 TRPV4 antagonist 
Thoracic aortic rings were incubated with 3 different concentrations of TRPV4 antagonist 
(HC067047); 1µM, 1nM and 1pM for 60 minutes. Afterward, the aortic rings were contracted 
with NA (300nM) and relaxed with TRPV4 agonist, RN-1747 CRC. pA2 was obtained 
graphically as shown in Figure 16a&b and 17. The time period selected (60 minutes) was 
more than stated by Jin, Berrout, Chen, and O’Neil (2012) who stated that HC067047 
(100nM) pre-incubation for 5 minutes was sufficient to block the effect of TRPV4 selective 
agonist, GSK1016790A in mouse cortical duct collect cells (M1 cells). In Figure 17b, the 
maximum control RN-1747-induced vasodilation was re-calculated as 100% to obtain an 
accurate pA2 using the Schild plot. The Schild plot represents the relationship between log 
(DR-1) and –log antagonist concentration (the ratio of the dose of agonist to produce a 
specific effect (e.g., half maximal effect) in the presence of the antagonist to the dose of 
agonist required in the absence of the antagonist is calculated). The obtained relationship was 
approximately linear revealing surmountable antagonism where pA2= 8.75 (Figure 17). 
HC067047 showed significant effect on RN-1747-induced vasodilation at the highest applied 
concentration (1μM) [N=3, ns p ≥ 0.05, HC067047 (1pM) EC50= 28.9 ± 10.5nM Emax= -
41.2 ± 9.5%, HC067047 (1nM) EC50= 54.3 ± 39.5nM and Emax= -44.1 ± 4.4% and N=4 * p 
˂ 0.05 HC067047 (1μM) EC50= 103.7 ± 42.0nM and Emax= -26.8 ± 4.2% vs RN-1747 
without HC067047 EC50= 46.7 ± 35.3nM and Emax= -52.6 ± 3.9%] (Figure 16a). The 
control response was calculated as 100% and each antagonist data were calculated according 
to the maximum concentration of the corresponding control data (Figure 16b). HC067047 
showed significant effect on RN-1747-induced vasodilation at the highest applied 
concentration [N=3, ns p ≥ 0.05, HC067047 (1pM) EC50= 25.8 ± 10.8nM and Emax= -75.8 ± 
17.8%, HC067047 (1nM) EC50= 46.1 ± 32.9nM and Emax= -80.3 ± 7.7% and N=4, * p ˂ 
0.05, HC067047 (1μM) EC50= 65.8 ± 24.6nM and Emax= -50.82 ± 7.0% vs RN-1747 
without HC067047 EC50= 37.7 ± 28.8nM and Emax= -100.0±0.00%] (Figure 16b). 
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Figure 16. TRPV4 agonist (RN-1747) concentration response curve in the presence of three different 
concentrations of TRPV4 antagonist (HC067047). RN-1747-induced vasodilation normalised to noradrenaline 
EC80 submaximal contraction (a). RN-1747-induced vasodilation normalised to RN-1747 only-induced 
vasodilation (b). Analysed through two-way ANOVA with Bonferroni post-hoc test. Significance is represented 
as *** p ˂ 0.001 compared with RN-1747 without HC067047. Data is shown as mean ± SEM (RN-1747, N= 4, 
HC067047 1pM+RN-1747, N= 3, HC067047 1nM+RN-1747, N= 3 and HC067047 1μM+RN-1747, N= 4). 
Table 4 Schild plot parameters for TRPV4 antagonists (HC067047) applied against TRPV4 agonist (RN-1747) 
Antagonist concentration 
(HC067047) M 
-log 
HC067047 
Dose ratio 
(DR) 
Log 
(DR-1) 
EC50 (nM) Emax % 
Control - - - 37.7 ± 28.8 100.0 ± 0.0 
1pM 12 1.14 -0.85 25.8 ± 10.8 75.8 ± 17.8 
1nM 9 (1.64)1 
-0.2 
46.1 ± 32.9 80.3 ± 7.7 
1μM 6 7.46 0.81 65.8 ± 24.6 50.82 ± 7.0 
1 Estimated from the original data set (not from the 100% recalculated data) 
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Figure 17. Schild plot for TRPV4 antagonist (HC067047) versus TRPV4 agonist (RN-1747). pA2 is the point of 
intersection at x-axis and is graphically estimated as 8.75.   
 TRPM8 antagonist 
Naïve aortic rings were incubated with 3 different concentrations of TRPM8 antagonist 
(AMTB); 1µM, 100nM and 1nM for 60 minutes. Afterward, the aortic rings were pre-
contracted with NA (300nM) and relaxed with TRPM8 agonist, icilin CRC. pA2 was 
obtained graphically as shown in Figure 18a&b and 19. The incubation period (60 minutes) 
was more than what was applied by Lashinger et al. (2008) when they incubated hTRPM8 
HEK293 cells with AMTB (1nM-100μM) for 10 minutes. In Figure 18b, the maximum 
control icilin-induced vasodilation was re-calculated as 100% to obtain an accurate pA2 using 
the Schild plot. The Schild plot represents the relationship between log (DR-1) and –log 
antagonist concentration. The obtained relationship was approximately linear revealing 
surmountable antagonism where pA2= 10.4. 
AMTB showed significant effect on icilin-induced vasodilation at the highest applied 
concentration (1μM) [N=3, ns P ≥ 0.05, AMTB (1pM) EC50= 238.7 ± 92.2nM and Emax=  
-72.6 ± 12.2%, AMTB (1nM) EC50= 3.8 ± 3.1μM and Emax= -71.2 ± 11.2% and *** 
P˂0.001 AMTB (1μM) EC50= 13.6 ± 3.4μM and Emax= -34.1 ± 10.5% vs icilin without 
AMTB EC50= 223.4 ± 125.6nM and Emax= -83.8 ± 2.0%] (Figure 18a). The control response 
was calculated as 100% and each antagonist data were calculated according to the maximum 
concentration of the corresponding control data. AMTB showed significant effect on icilin-
y = -0.2883x + 2.5383
R² = 0.98 if y=0
x= -2.54/-0.29
pA2= x= 8.75
-1
-0.5
0
0.5
1
12345678910111213
lo
g 
(D
R
-1
)
-log antagonist
Schild plot for (HC067047)
66 
 
induced vasodilation at the highest applied concentration (1μM) [N=3, ns P ≥ 0.05, AMTB 
(1pM) EC50= 246.1 ± 95.7nM and Emax= -86.5 ± 14.1%, AMTB (1nM) EC50= 3.9 ± 2.2μM 
and Emax= -85.2 ± 14.0% and *** P ˂ 0.001, AMTB (1μM) EC50= 13.3 ± 3.5μM and 
Emax= -40.1 ± 11.6% vs icilin without AMTB EC50= 228.6 ± 131.5nM and Emax= -100.0 ± 
0.0%] (Figure 18b). 
Figure 18. TRPM8 agonist (icilin) concentration response curve in the presence of three different concentrations 
of TRPM8 antagonist (AMTB). Icilin-induced vasodilation normalised to noradrenaline EC80 submaximal 
contraction (a). Icilin-induced vasodilation normalised to icilin only-induced vasodilation (b). Analysed through 
two-way ANOVA with Bonferroni post-hoc test. Significance is represented as * p ˂ 0.05 and *** p ˂ 0.001 vs 
icilin without AMTB. Data is shown as mean ± SEM (Icilin, N= 3, AMTB 1pM+icilin, N=3, AMTB 1nM+icilin, 
N=3 and AMTB 1μM+icilin, N=3). 
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Table 5 Schild plot parameters for TRPM8 antagonists (AMTB) applied against TRPM8 agonist (Icilin) 
Antagonist 
concentration 
(AMTB) M 
-log AMTB Dose ratio 
(DR) 
Log (DR-1) EC50 (μM) Emax % 
Control - - - 0.23 ± 0.13 100.0 ± 0.0 
1pM 12 1.08 
-1.08 
0.25 ± 0.01 86.5 ± 14.1 
1nM 9 22.5 
1.33 
3.9 ± 2.2 85.2 ± 14.0 
1μM 6 41.7 
1.61 
13.3 ± 3.5 40.1 ± 11.6 
 
 
Figure 19. Schild plot for TRPM8 antagonist (AMTB) versus TRPM8 agonist (Icilin). pA2 is the point of 
intersection at x-axis and is graphically estimated as 10.4. 
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3.3.3. Carbachol-induced vasodilation in the presence of TRPV4 and 
TRPM8 antagonists 
Carbachol-induced vasodilation was studied to examine the effect of blocking TRPV4 and/or 
TRPM8. These studies were conducted through utilising the TRPV4 antagonist (HC067047) 
and the TRPM8 antagonist (AMTB). 
 TRPV4 antagonist did not significantly influence carbachol-induced 
vasodilation 
Carbachol-induced vasodilation was examined before and after incubating the aortic ring 
with HC067047 (1μM). HC067047 was added for 1 hour before the aortic rings were 
constricted with NA (300nM) followed by carbachol CRC (30nM-300μM). TRPV4 
antagonism did not show significant effect on carbachol CRC (p ≥ 0.05). HC067047 did not 
show significant effect of carbachol-induced vasodilation (N=4, ns p ≥ 0.05, EC50= 2.0 ± 
1.23μM and Emax= -64.0 ± 5.5% vs carbachol only EC50= 1.02 ± 0.84μM and Emax= -
76.1±3.0%) (Figure 20). 
Figure 20. Carbachol cumulative concentration response curve in the presence and absence of TRPV4 
antagonist (HC067047) (1μM). Analysed through two-way ANOVA with Bonferroni post-hoc test (ns p ≥ 0.05) 
compared with carbachol in the absence of HC067047. Data is shown as mean ± SEM (Carbachol, N= 4, 
HC067047 1μM+carbachol, N=4). 
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 TRPM8 antagonist (AMTB) significantly compromised carbachol-
induced vasodilation 
Carbachol-induced vasodilation was examined in the presence and absence of AMTB (1μM). 
The antagonist was added for 1 hour before the aortic rings were contracted with NA 
(300nM) followed by carbachol cumulative concentration response curve (30nM-300μM). 
TRPM8 antagonism showed significant effect on carbachol CRC (*** p ˂ 0.001) with 
significant reduction in carbachol-induced vasodilation (N=4, ns p ≥ 0.05, EC50= 2.7 ± 1.7μM 
vs carbachol only EC50= 1.8 ± 1.05μM, and ** p ˂ 0.05, Emax= 59.0 ± 10.4% vs carbachol 
only Emax= 80.8 ± 13.8%) (Figure 21). 
Figure 21. Carbachol cumulative concentration response curve in the presence and absence of TRPM8 
antagonist (AMTB) (1μM). Analysed through two-way ANOVA with Bonferroni post-hoc test. Significance is 
shown as ** p ˂ 0.01 and *** p ˂ 0.001 compared with carbachol in the absence of AMTB. Data is shown as 
mean ± SEM (Carbachol, N= 4, AMTB 1μM+carbachol, N=4). 
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 TRPM8 antagonist (AMTB) and TRPV4 antagonist (HC067047) 
significantly compromised carbachol-induced vasodilation 
Carbachol-induced vasodilation was examined in the presence and absence of both AMTB 
(1μM) and HC067047 (1μM). Both antagonists were added for 1 hour before the aortic rings 
were contracted with NA (300nM) followed by carbachol CRC curve (30nM-300μM) (Figure 
22). The co-incubation of AMTB and HC067047 showed significant effect on carbachol 
CRC (*** p ˂ 0.001) with significant reduction in carbachol-induced vasodilation (N=4, ns p 
≥ 0.05, EC50= 3.1 ± 1.1μM vs carbachol only EC50= 3.9 ± 2.2μM, and * p ˂ 0.05, Emax= -
44.3 ± 9.4% vs carbachol only Emax= -72.7 ± 6.9%) (Figure 22). 
Figure 22. Carbachol cumulative concentration response curve in the presence and absence of both TRPM8 
antagonist (AMTB) (1μM) and TRPV4 antagonist (HC067047) (1μM). Analysed through two-way ANOVA 
with Bonferroni post-hoc test. Significance is shown as ** p ˂ 0.01 and *** p ˂ 0.001 compared to carbachol in 
the absence of AMTB and HC067047. Data is shown as mean ± SEM (Carbachol, N= 4, AMTB 
1μM+HC067047 1μM+carbachol, N= 4). 
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When comparing the effect of the application of both AMTB and HC067047 to the effect of 
each antagonist on the carbachol-induced vasodilation, there was significant change induced 
by the additional treatment (* p ˂ 0.05). To investigate whether TRPM8 antagonism through 
AMTB added a significant effect to TRPV4 antagonism on carbachol-induced vasodilation, 
AMTB and HC067047 co-incubation (green) was compared with HC067047 incubated aortic 
rings (pink) through one-way ANOVA to investigate the treatment effect. Accordingly, 
TRPV4 antagonism showed non-significant effect on carbachol-induced vasodilation in the 
presence AMTB (green) when compared to the effect of HC067047 alone (pink) (N=4, ns p ≥ 
0.05 EC50= 3.1 ± 1.0μM and Emax= 44.3 ± 9.4% vs EC50= 2.0 ± 1.2μM and Emax 65.0 ± 
5.5%) (Figure 23). Similarly, to investigate whether TRPV4 antagonism through HC067047 
added a significant effect to TRPM8 antagonism on carbachol-induced vasodilation, AMTB 
and HC067047 co-incubation (green) was compared with AMTB incubated aortic rings 
(orange) through one-way ANOVA to investigate the treatment effect. Accordingly, 
HC067047 showed non-significant effect to AMTB (green) when compared to AMTB 
incubated artic rings (orange) (N=4, ns p ≥ 0.05 EC50= 3.1 ± 1.0μM and Emax= 44.3 ± 9.4% 
vs EC50= 2.7 ± 1.7μM and Emax 65.0 ± 5.5%) (Figure 23). 
Figure 23. Carbachol-induced vasodilation in the presence of either TRPV4 antagonist (HC067047) or TRPM8 
antagonist (AMTB) or both of the antagonists. Significance is shown as * p ˂ 0.05 analysed through one-way 
ANOVA with Tukey post-hoc test. 
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3.3.4. TRPV4-induced vasodilation in the presence of TRPM8 antagonist 
TRPV4-induced vasodilation was studied through examining the effect of blocking TRPM8. 
These studies were conducted through utilising TRPM8 antagonist (AMTB). 
 TRPM8 antagonist (AMTB) did not show significant effect on TRPV4-
induced vasodilation 
TRPV4-induced vasodilation was examined in the presence and absence of AMTB (1μM). 
AMTB (1μM) was added for 1 hour before the aortic rings were contracted with NA 
(300nM) followed by 4-αPDD cumulative concentration response curve (3pM-3μM). AMTB 
(1μM) showed significant effect on 4-αPDD CRC (ns p ≥ 0.05) without showing significant 
effect on 4-αPDD-induced vasodilation in Bonferroni post-hoc test (N=4, EC50= 142 ± 
89.6nM and Emax= -90.9 ± 2.8% vs 4-αPDD only EC50= 156.3 ± 96.4nM and Emax= -
74.3±8.2%) (Figure 24). 
Figure 24. 4-αPDD cumulative concentration response curve in the presence and absence of TRPM8 antagonist 
(AMTB) (1μM). Analysed through two-way ANOVA (ns p ≥ 0.05) with Bonferroni post-hoc test (ns p ≥ 0.05) 
compared with 4-αPDD only. Data is shown as mean ± SEM (4α-PDD, N= 4, AMTB 1μM+4α-PDD, N= 4). 
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3.3.5. TRPM8-induced vasodilation in the presence of TRPV4 antagonist 
TRPM8-induced vasodilation was studied through examining the effect of blocking TRPV4. 
These studies were conducted through utilising TRPV4 antagonist (HC067047). 
 TRPV4 antagonist did not show significant effect on TRPM8-induced 
vasodilation 
TRPM8-induced vasodilation was examined before and after incubating the aortic ring with 
HC067047 (1μM). HC067047 was added for 1 hour before the aortic rings were contracted 
with NA (300nM) followed by icilin cumulative concentration response curve (3nM-30μM). 
HC067047 (1μM) did not show significant effect on icilin CRC (p ≥ 0.05). Icilin-induced 
vasodilation was not significantly affected through HC067047 incubation (N=3, Emax= -68.6 
± 13.1% vs icilin only Emax= -72.9 ± 8.4%) (Figure 25). 
Figure 25. Icilin cumulative concentration response curve in the presence and absence of TRPV4 antagonist 
(HC067047) (1μM). Analysed through two-way ANOVA with Bonferroni post-hoc test (ns p ≥ 0.05) compared 
with icilin in the absence of HC067047. Data is shown as mean ± SEM (Icilin, N= 3, HC067047 1μM+icilin, 
N= 3).  
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3.3.6. Nitric oxide synthase involvement in carbachol, TRPV4 and 
TRPM8-induced vasodilation 
The role of NO and NOS in the muscarinic, TRPV4 and TRPM8-induced vasodilation was 
investigated through inhibiting NOS through incubating the freshly isolated aortic rings with 
L-NG-Nitro-L-arginine methyl ester (L-NAME) (100μM). 
 L-NAME significantly reduced carbachol-induced vasodilation 
Carbachol-induced vasodilation was examined in the presence and absence of NOS inhibitor, 
L-NAME (100μM). L-NAME was added for 30 minutes before the aortic rings were 
contracted with NA (300nM) followed by carbachol cumulative concentration response curve 
(30nM-300μM). L-NAME significantly influenced carbachol CRC (*** p ˂ 0.001) with 
significant reduction in carbachol-induced vasodilation (N=4, *** p ˂ 0.001, Emax= -11.3 ± 
1.6% vs carbachol only Emax= -68.4 ± 2.3%). However, EC50 was not significantly 
influenced through L-NAME incubation (N=4, ns ˃ 0.05, EC50= 12.6 ± 1.6μM vs carbachol 
only EC50= 2.2 ± 1.7μM) (Figure 26). 
Figure 26. Carbachol cumulative concentration response curve in the presence and absence of the non-selective 
NOS inhibitor, L-NAME (100μM). Analysed through two-way ANOVA with Bonferroni post-hoc test. 
Significance is shown as *** p ˂ 0.001 compared with carbachol in the absence of L-NAME. Data is shown as 
mean ± SEM (Carbachol, N= 4, L-NAME 100μM+carbachol, N= 4). 
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 L-NAME significantly influenced TRPV4-induced vasodilation 
TRPV4-induced vasodilation was examined in the presence and absence of L-NAME 
(100μM). L-NAME was added for 30 minutes before the aortic rings were contracted with 
NA (300nm) followed by 4-αPDD cumulative concentration response curve (3pM-3μM). L-
NAME significantly influenced 4-αPDD (*** p ˂ 0.001) with significantly compromising 4-
αPDD-induced vasodilation (N=4, *** p ˂ 0.001, EC50= 1.5 ± 1.0μM vs 4-αPDD only EC50= 
5.2 ± 3.4nM). Emax did not show significant difference (ns p ≥ 0.05, Emax in the presence of 
L-NAME= -87.4 ± 2.2% vs 4-αPDD only Emax= -90.7 ± 4.7%) (Figure 27). 
Figure 27. 4-αPDD cumulative concentration response curve in the presence and absence of NOS inhibitor (L-
NAME) (100μM). Analysed through two-way ANOVA with Bonferroni post-hoc test. Significance is shown as 
*** p ˂ 0.001 compared with 4-αPDD in the absence of L-NAME. Data is represented as mean ± SEM (4α-
PDD, N= 4, L-NAME 100μM+4α-PDD, N= 4). 
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 L-NAME did not show significant effect on TRPM8-induced vasodilation 
TRPM8-induced vasodilation was examined in the presence and absence of L-NAME 
(100μM). L-NAME was added for 30 minutes before the aortic rings were contracted with 
NA (300nM) followed by icilin cumulative concentration response curve (3nM-30μM). L-
NAME did not show significant effect on icilin-induced vasodilation (N=6, ns p ≥ 0.05, 
EC50= 21.3 ± 9.7μM and Emax= -94.0 ± 2.4% vs icilin only EC50= 7.5 ± 4.2μM and Emax= -
79.4 ± 6.4%) (Figure 28). 
Figure 28. Icilin cumulative concentration response curve in the presence and absence of NOS inhibitor (L-
NAME) (100μM). Analysed through two-way ANOVA with Bonferroni post-hoc test (ns p ≥ 0.05) compared 
with icilin in the absence of L-NAME. Data is represented as mean ± SEM (Icilin, N= 4, L-NAME 
100μM+icilin, N= 4). 
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3.3.7. The large conductance calcium-dependent potassium channels 
(BKca) involvement in carbachol, TRPV4 and TRPM8-induced 
vasodilation 
The role of BKca in the carbachol, TRPV4 and TRPM8-induced vasodilation was 
investigated through inhibiting BKca by incubating the freshly isolated aortic rings with 
iberiotoxin (1-10nM). 
 Iberiotoxin significantly compromised carbachol-induced vasodilation 
Carbachol-induced vasodilation was examined in the presence and absence of BKca blocker, 
iberiotoxin (1nM). Iberiotoxin was added for 1 hour before the aortic rings were contracted 
with NA (300nM) followed by carbachol cumulative CRC (30nM-300μM). Iberiotoxin 
showed significant effect on carbachol CRC (*** p ˂ 0.001) with significant reduction in 
carbachol-induced vasodilation (N=4, ns p ≥ 0.05, EC50= 1.5 ± 1.0μM vs carbachol only 
EC50= 0.3 ± 0.19μM, and ** p ˂ 0.001 Emax= -57.3 ± 3.5% vs carbachol only Emax= -87.9 
± 7.6%) (Figure 29). 
Figure 29. Carbachol cumulative concentration response curve in the presence and absence of BKca blocker 
(iberiotoxin) (1nM). Analysed through two-way ANOVA with Bonferroni post-hoc test. Significance is shown 
as ** p ˂ 0.01 and *** p ˂ 0.001 compared with carbachol-induced vasodilation in the absence of iberiotoxin. 
Data is represented as mean ± SEM (Carbachol, N= 4, iberiotoxin 1nM+carbachol, N= 4). 
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 Iberiotoxin significantly reduced TRPV4-induced vasodilation 
TRPV4-induced vasodilation was examined in the presence and absence of iberiotoxin (1nM 
& 10nM). Iberiotoxin was added 1 hour before the aortic rings were contracted with NA 
(300nm) followed by 4-αPDD cumulative CRC (3pM-3μM). Iberiotoxin (10nM) 
significantly compromised 4-αPDD-induced vasodilation (*** p ˂ 0.001) (N=4, * p ˂ 0.05, 
EC50= 403.7 ± 101.4nM vs 4-αPDD only EC50= 25.1 ± 14.1nM). Maximum vasodilation 
showed significant difference (* p ˂ 0.05, Emax= -46.2±12.0% vs 4-αPDD only Emax= -
81.4±5.7%) (Figure 30a). However, iberiotoxin (1nM) did not show significant effect on 
TRPV4 function. Iberiotoxin (1nM) showed significant effect on 4-αPDD potency (N=2, * p 
˂ 0.05, EC50= 3.0 ± 1.5nM vs 4-αPDD only EC50= 38.4 ± 18.0nM). However, iberiotoxin 
(1nM) did not show significant effect on the maximum vasodilation (N=2, p ≥ 0.05, Emax= -
92.4 ± 5.0% vs 4-αPDD only Emax= -93.7 ± 2.2%) (Figure 30b). 
Figure 30. 4-αPDD cumulative concentration response curve in the presence of BKca blocker (Iberiotoxin) 
(1nM & 10nM). Analysed through two-way ANOVA with Bonferroni post-hoc test. Significance is represented 
as * p ˂ 0.05 and *** p ˂ 0.01 compared with 4-αPDD only. Data is represented as mean ± SEM (4-αPDD, N= 
4, iberiotoxin 10nM+4-αPDD, N= 4 and iberiotoxin 1nM+4-αPDD, N= 2). 
 
79 
 
 Iberiotoxin showed significant effect on TRPM8-induced vasodilation 
TRPM8-induced vasodilation was examined in the presence and absence of iberiotoxin 
(1nM). Iberiotoxin was added for 1 hour before the aortic rings were contracted with NA 
(300nM) followed by icilin cumulative CRC (3nM-30μM). Iberiotoxin showed significant 
effect on icilin-induced vasodilation (* p ˂0.05) (N=3, ns p ≥ 0.05, EC50= 6.6 ± 1.9μM vs 
icilin only EC50= 5.7 ± 2.5μM, and * p ˂0.05 Emax= -40.1 ± 5.7% vs carbachol only Emax= 
-82.7 ± 6.9%) (Figure 31). 
Figure 31. Icilin cumulative concentration response curve in the presence and absence of BKca blocker 
(Iberiotoxin) (1nM). Analysed through two-way ANOVA with Bonferroni post-hoc test. Significance is 
represented as * p ˂ 0.05 versus icilin only CRC. Data is represented as mean ± SEM (Icilin, N= 3, iberiotoxin 
1nM+icilin, N= 3).  
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3.3.8. Endothelium involvement in carbachol, TRPV4 and TRPM8-
induced vasodilation 
Since, NOS inhibition showed significant compromise of the muscarinic and TRPV4-induced 
vasodilation, but not TRPM8-induced vasodilation. Endothelium denuding was proposed as a 
strategy to investigate the role of endothelium components including eNOS and whether the 
targeted receptors or channels are expressed in the tunica media. 
 Endothelium denuding showed significant suppression of carbachol-
induced vasodilation 
Aortic rings were rubbed with a cotton thread to mechanically remove the endothelium. 
Afterward, the aortic rings were contracted with NA (300nM) followed by carbachol 
cumulative CRC (30nM-300μM). Endothelium denuding showed significant reduction in 
carbachol-induced vasodilation (N=5, *** p ˂ 0.001, Emax= -16.6 ± 4.8% vs intact 
endothelium carbachol induced-vasodilation Emax= -68.4 ± 2.3%)  (Figure 32). However, 
the EC50 was not significantly influenced (N=5, p ≥ 0.05, EC50= 3.8 ± 0.6μM and vs intact 
endothelium carbachol induced-vasodilation EC50= 1.8 ± 1.1μM) (Figure 52). 
Figure 32. Carbachol cumulative concentration response curve when endothelium was denuded. Analysed 
through two-way ANOVA with Bonferroni post-hoc test. Significance is shown as *** p˂0.001 versus 
carbachol-induced vasodilation in intact endothelium aortic rings. Data is represented as mean ± SEM 
(Carbachol, N= 5, denuded endothelium + carbachol, N= 5). 
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 Endothelium denuding showed significant suppression of TRPV4-
induced vasodilation 
After confirming the removal of the endothelium through the significant impairment of 
carbachol-induced vasodilation (Figure 32), the aortic rings were contracted with NA 
(300nM) followed by 4-αPDD cumulative CRC (3pM-3μM). Endothelium denuding showed 
significant reduction in 4-αPDD-induced vasodilation (*** p ˂ 0.001). Endothelium 
denuding significantly compromised 4-αPDD-induced vasodilation (N=4, * p ˂ 0.05 
maximum vasodilation -58.7 ± 9.5% vs intact endothelium 4-αPDD-induced maximum 
vasodilation -89.3 ± 4.0%). However, endothelium denuding did not show significant 
influence on 4-αPDD potency (N=4, ns p ≥ 0.05, EC50= 7.5 ± 2.9nM vs intact endothelium 
with 4-αPDD-induced vasodilation EC50= 5.4 ± 3.5nM) (Figure 33). 
Figure 33. 4-αPDD cumulative concentration response curve when endothelium was denuded. Analysed 
through two-way ANOVA with Bonferroni post-hoc test. Significance is shown as * p ˂ 0.05 and *** p ˂ 0.01 
versus 4-αPDD-induced vasodilation in intact endothelium aortic rings. Data is represented as mean ± SEM (4α-
PDD, N= 4, L-denuded endothelium+4α-PDD, N= 4). 
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 Endothelium denuding did not show significant suppression of TRPM8-
induced vasodilation 
After confirming the removal of the endothelium through the significant impairment of 
carbachol-induced vasodilation (Figure 32), the aortic rings were contracted with NA 
(300nM) followed by icilin cumulative CRC (3nM-30μM). Endothelium denuding showed 
significant reduction in icilin-induced vasodilation (** p ˂ 0.01). However, Bonferroni post-
hoc test did not show significant difference among the applied concentrations (N=3, ns p ≥ 
0.05, EC50= 5.3 ± 3.2μM and maximum vasodilation -67.4±9.67% vs intact endothelium 
icilin-induced vasodilation EC50= 1.3 ± 0.7μM and maximum vasodilation -82.1 ± 1.3%) 
(Figure 34). 
Figure 34. Icilin cumulative concentration response curve when endothelium was denuded. Analysed through 
two-way ANOVA with Bonferroni post-hoc test versus icilin-induced vasodilation in intact endothelium aortic 
rings. Data is represented as mean ± SEM (Icilin, N= 3, denuded endothelium+icilin, N= 3). 
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3.3.9. Experiments visual summary 
The conducted experiments are summarised in the following figure where the arrow is 
stemmed from the blocked channel (TRPM8              cc-induced vasodilation, means the 
effect of blocking TRPM8 on carbachol-induced vasodilation). 
Figure 35. Chapter 3 experiments summary. The arrows are stemmed from the blocked channels/cellular 
components and labelled with the correspondent figure. 
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3.4. Discussion 
In this chapter, firstly, consensus EC80 of NA (300nM) (Figure 14) was estimated which was 
similar to what was found previously (Verbeuren et al., 1986).  Such experiment was 
conducted to spare the time for further experiments instead of constructing NA CRC for 
every tissue which might stress the tissue upon cumulative repeated contractions. 
Antagonists’ studies were conducted to estimate the pA2 and to prove that the applied 
concentrations are relevant to block the targeted channel. Therefore, when HC067047 (1μM) 
was applied for 1 hour incubation period, it showed significant suppression with EC50= 103.7 
± 42.0nM and Emax= 26.8 ± 4.2% vs RN-1747 without HC067047 EC50= 46.7 ± 35.3nM and 
Emax= 52.6 ± 3.9% (Figure 16). pA2 was calculated and estimated as 8.7 which was around 
the value estimated through previous research where pA2= 7.8 (L. Zhang et al., 2013). 
Previous studies showed that the efficacy of RN-1747 (EC50= 4.1µM) is similar to 4-αPDD 
(EC50= 4.4µM) against rat TRPV4 (Vincent & Duncton, 2011). However, RN-1747 activates 
human TRPV1 with 25% of the capsaicin’s Emax and antagonises TRPM8 (Vincent & 
Duncton, 2011). Therefore, the residual RN-1747-induced vasodilation might be attributed to 
TRPV1 activation. By contrast, 4-αPDD is a small phorbol ester molecule that activates 
TRPV4 selectively (Vincent & Duncton, 2011). 
TRPM8 antagonist, AMTB showed significant effect on icilin-induced vasodilation at the 
highest applied concentration (1μM). Therefore, when AMTB (1μM) was applied for 1 hour 
incubation period, it showed significant suppression with EC50= 13.6 ± 3.4μM and Emax= 
34.1 ± 10.5% vs icilin without AMTB EC50= 223.4 ± 125.6nM and Emax= 83.8 ± 2.0% 
(Figure 18). Icilin is a TRPM8 agonist (EC50= 7µM) that was shown to activate TRPA1 when 
applied to hTRPA1 expressing Xenopus laevis oocytes at 100µM (Sherkheli, Gisselmann, 
Vogt-Eisele, Doerner, & Hatt, 2008; Sherkheli et al., 2010). Accordingly, icilin vasodilation 
might include some paradoxical pathways to TRPM8, through TRPA1 activation in the 
presence of the selective TRPM8 antagonist, AMTB. AMTB’s pA2 was estimated 
graphically= 10.4 (Figure 19). To the best of our knowledge and according to the AMTB 
manufacturers’ email, there has not been any published data regarding AMTB’s pA2 
(Lefevre, 2016). 
Carbachol studies were conducted to examine the endothelium function where muscarinic 
receptors (M3) mediate eNOS phosphorylation and hence causes NO-dependent vasodilation 
(A. Dhar et al., 2010). The cross studies were conducted to investigate the involvement of 
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TRPV4 and TRPM8 in the muscarinic-induced vasodilation. Accordingly, TRPV4 inhibition 
through HC067047 (1μM) did not significantly influence the carbachol-induced vasodilation 
as shown in Figure 20. However, previous data showed significant effect of HC067047 
(1μM) on acetylcholine-induced vasodilation in mouse cerebral arteries (D. X. Zhang et al., 
2009). This might be attributed to species or vascular bed differences, if not both. However, 
AMTB (1μM) significantly decreased carbachol induced vasodilation (Figure 21). Blocking 
TRPV4 and TRPM8 showed further inhibition of carbachol-induced vasodilation with EC50= 
3.1 ± 1.1μM and Emax= 44.3 ± 9.4% vs carbachol only EC50= 3.9 ± 2.2μM and Emax= 
72.7±6.9% (Figure 22). When compared together, there was not significant difference among 
blocking TRPV4 alone (EC50= 2.0 ± 1.2μM and Emax= 65.0±5.5%), TRPM8 alone (EC50= 
2.7 ± 1.7μM and Emax 65.0 ± 5.5%) or both TRPV4 and TRPM8 (EC50= 3.1 ± 1.0μM and 
Emax= 44.3 ± 9.4%), suggesting that TRPV4 or TRPM8, if not both, might be involved in 
muscarinic-induced vasodilation (Figure 23). These findings suggested that carbachol, 
TRPV4 and TRPM8 might play major roles in mediating vasodilation. 
Furthermore, TRPV4 cross studies were conducted which showed that TRPM8 has a 
significant effect on TRPV4 CRC without showing significant effect on any of the applied 4-
αPDD concentrations (Figure 24). Moreover, TRPM8-induced vasodilation was studied 
through treating the freshly isolated rat aortic rings with icilin. HC067047 did not show a 
significant effect on TRPM8-induced vasodilation (Figure 25). Therefore, these findings 
confirm the selectivity of each applied blocker at the applied concentrations. 
Further investigation on the muscarinic, TRPV4 and TRPM8 pathways included L-NAME 
studies. L-NAME is a non-selective blocker of NOS that competes with L-arginine, the NOS 
substrate required to generate NO (Buxton et al., 1993). The aortic rings were cleaned from 
the connective tissue including the removal of the outer vascular layer, adventitia neurons 
that express neuronal nitric oxide synthase predominantly. Moreover, the VSMCs express 
iNOS  that generates synthesise NO independent from CaM complex and phosphorylation 
(Arnal, Dinh-Xuan, Pueyo, Darblade, & Rami, 1999; Lüscher & Barton, 1997). However, 
eNOS is the predominant NOS isoform in the endothelium and it generates NO through a 
signalling cascade that requires CaM complex and enzyme phosphorylation to become active 
(Lüscher & Barton, 1997). Therefore, L-NAME treatment was hypothesised to inhibit eNOS 
as it is the constitutively expressed NOS isoform found in the endothelium (Cines et al., 
1998).  
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Muscarinic endothelial vasodilation was NO-dependent, as eNOS inhibition with L-NAME 
showed significant suppression of carbachol-induced vasodilation (Figure 26). Moreover, 
TRPV4-induced vasodilation through 4-αPDD was also NO-dependent, however, other 
significant vasodilation pathways might be involved as the concentration response curve in 
the presence of L-NAME was surmountable with Emax of approximately 90% (Figure 27). 
By contrast, NO might not play a major role in TRPM8-induced vasodilation, as icilin 
treatment was not significantly affected by L-NAME incubation (Figure 28). These findings 
suggest that muscarinic and TRPV4 vasodilatory effects are NO-mediated, however TRPM8 
exerts its vasodilation effect through different pathways. Therefore, although blocking 
TRPM8 with or without TRPV4 showed significant effect on muscarinic vasodilatory 
pathway (Figure 21 & 30), the intracellular pathway of TRPM8-induced vasodilation was not 
NO-dependent (Figure 28).  This suggests TRPM8 as an extra signalling pathway to 
muscarinic-induced vasodilation. Moreover, muscarinic and TRPV4 vasodilatory pathways 
might share eNOS as a major vasodilatory intracellular component since both pathways were 
significantly inhibited by L-NAME (Figure 26 & 35). 
These findings were in agreement with previous studies that revealed the dependence of 
endothelial muscarinic receptors on NO pathway for vasodilation (Buxton et al., 1993; 
Lopacinska & Strosznajder, 2005). Moreover, TRPV4 binds to a docking lipid raft, caveolae 
that is found in the ECs plasma membrane (Everaerts et al., 2010). Such lipid rich complexes 
might link TRPV4 to eNOS, so the TRPV4-facilitated Ca2+ influx will encourage NO release 
(Köhler et al., 2006). 
TRPM8 showed NO-independent vasodilation, which is similar to a previous in vivo study on 
Sprague-Dawley rats demonstrated NO-independence of TRPM8-induced vasodilation in 
cutaneous arteries. However, this study indicated that TRPM8 is able to induce vasodilation 
as well as vasoconstriction, depending on the previous vasomotor tone as it related such 
effects to VSMCs only (C. D. Johnson et al., 2009). 
To sum up the NO-dependent study, L-NAME abolished carbachol-induced vasodilation and 
partially inhibited TRPV4-induced vasodilation, revealing that NO is not the only 
vasodilation contributor in aorta (Figure 27). Whereas, TRPM8 might exert its vasodilatory 
function independent of NO (Figure 28). 
EDHF provides a secondary vasodilation system to NO pathway (Garland et al., 1995; 
McCulloch, Bottrill, Randall, & Hiley, 1997). Furthermore, elevated [Ca2+]i as consequence 
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of TRPV4 activation, activates Kca channels, SKca and IKca that yield endothelium 
hyperpolarisation which propagates through gap junctions into VSMCs and thereby causes 
vasodilation (Edwards, Félétou, & Weston, 2010).  
Further studies were conducted to examine the involvement of BKca in muscarinic, TRPV4 
and TRPM8-induced vasodilatory pathways. Incubating the aortic rings with iberiotoxin 
(1nM) showed significant suppression to carbachol-induced vasodilation (Figure 29). A 
previous study revealed that iberiotoxin (100nM) significantly reduces carbachol-induced 
vasodilation in rat isolated renal arteries (Jiang, Li, & Rand, 2000). 
TRPV4-induced vasodilation required 10-fold higher concentration of iberiotoxin (10nM) to 
show significant inhibition of TRPV4-mediated vasodilation (Figure 30a), this is in 
agreement with numerous studies that have demonstrated significant suppression of TRPV4-
induced vasodilation through iberiotoxin (100nM) in mice mesenteric arteries and renal 
collecting duct cells (Earley et al., 2009; Jin et al., 2012). These findings suggest what was 
concluded by  Earley et al. (2005), that TRPV4 forms a signalling complex with BKca to 
generate VSM hyperpolarisation and vasodilation. Moreover, TRPV4 mediates Ca2+ influx 
through cooperative gating in the MEPs that activates Kca channels to yield VSM 
hyperpolarisation and hence causes vasodilation (Bagher & Garland, 2014). 
Additionally, TRPM8-induced vasodilation was significantly compromised when BKca was 
blocked with iberiotoxin (1nM) (Figure 31). A small number of cardiovascular researches 
have been conducted on icilin-activated TRPM8 and iberiotoxin, while most of the studies on 
TRPM8 were conducted on macrophages cell lines. A study conducted on macrophage cell 
line raw 264.7 have found that iberiotoxin (200nM) does not have any effect on icilin-
stimulated cation current (S. N. Wu, Wu, & Tsai, 2011). Another cardiovascular studies have 
concluded  lysophosphatidylinositol as an extracellular mediator and an intracellular 
messenger affecting a number of ion channels including BKCa and TRPM8 (D. A. 
Andersson et al., 2007; Bondarenko et al., 2011a; Bondarenko et al., 2011b). Accordingly, 
BKca might form a signalling complex with TRPM8 through lysophosphatidylinositol, and 
therefore, inhibiting BKca with iberiotoxin (1nM, IC50= 500pM) might interfere with the 
signalling complex and hence block the TRPM8-induced hyperpolarisation and vasodilation. 
In addition to NO, these findings suggest that BKca is another major component of the 
vasodilation cascade in aorta. Moreover, BKca is a common vasodilatory component between 
muscarinic, TRPV4 and TRPM8 pathways. 
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Further experiments were conducted to examine the endothelium dependence of these three 
main pathways, muscarinic, TRPV4 and TRPM8, as previous studies demonstrated that 
endothelium expresses at least 20 TRP channels (Earley et al., 2010; H. Y. Kwan et al., 2007; 
Watanabe et al., 2008). 
As shown in Figure 32, muscarinic-induced vasodilation was significantly suppressed when 
endothelium was denuded. Such suppression was reproduced by NOS inhibition via L-
NAME (Figure 30), revealing that L-NAME (100μM) incubation for 30 minutes could be a 
possible simple model to of endothelium removal for muscarinic studies. Moreover, the 
removal of endothelium showed significant reduction in TRPV4-induced vasodilation, with 
Emax= 58.7 ± 9.5% vs intact endothelium Emax= 89.3 ± 4.0% (Figure 33). A previous study 
showed TRPV4 channels were expressed in MEPs in cremaster and mesenteric arteries 
(Bagher et al., 2012). TRPV4 expression in MEPs was suggested to activate VSM’s Kca, 
hence induce hyperpolarisation and vasodilation (Bagher & Garland, 2014). Therefore, 
TRPV4 might induce vasodilation in endothelium-dependent and endothelium-independent 
manners. 
TRPM8-mediated vasodilation was significantly influenced by endothelium removal without 
showing significant effect at any specific concentration of icilin-induced vasodilation (N=3, 
ns p ≥ 0.05, EC50= 5.3 ± 3.2μM and maximum vasodilation 67.4±9.67% vs intact 
endothelium icilin-induced vasodilation EC50= 1.3 ± 0.7μM and maximum vasodilation 
82.1±1.3%) (Figure 34). These findings suggest that TRPV4 and TRPM8 are not exclusively 
expressed in the endothelium, but also in the VSMCs. The expression of TRP channels in 
vasculature was studied through molecular assays such as Western blotting, RT-PCR and 
immunohistochemistry which recognised approximately 21 TRP channels in VSMCs 
(TRPC1-7, TRPM1-8, TRPV1-TRPV4, and TRPP1 and TRPP2) (H. Y. Kwan et al., 2007; 
Watanabe et al., 2008). The co-expression of TRPM8 and TRPV4 channels in the aortic 
vasculature was concluded as novel Ca2+ entry pathways that might control the systemic 
circulation (X. R. Yang et al., 2006). 
To sum up, inhibiting NOS showed significant inhibition of muscarinic and TRPV4 
vasodilatory pathways but not TRPM8, while blocking BKca with iberiotoxin showed 
significant reduction in all muscarinic, TRPV4 and TRPM8-induced vasodilation. Muscarinic 
receptors are known to stimulate PLC, an enzyme hydrolyses the membranous PIP2 into IP3 
and DAG from which IP3 is capable to activate TRPV4 and bind to ER’s IP3-R to induce 
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Ca2+ release from ER (Everaerts et al., 2010; Lawler et al., 2001; Murata et al., 2007). Such 
cellular Ca2+ storage depletion will trigger the extracellular Ca2+ influx through Ca2+ channels 
including CaM-activated TRPV4 channels (Haworth, Goknur, Hunter, Hegge, & Berkoff, 
1987; Lopacinska & Strosznajder, 2005; Ma, Cheng, Wong, et al., 2011). However, TRPM8 
is activated through TRP-domain bound PIP2, therefore when endothelial muscarinic and 
TRPV4 pathways are activated, TRPM8 might be inhibited as its cytoplasmic activator, PIP2 
level is reduced through upon PLC activation (B. Liu & Qin, 2005; Rohács et al., 2005). 
In conclusion, endothelial muscarinic, TRPV4 and TRPM8 pathways might be integrated in 
BKca-mediated vasodilation. However, inhibiting TRPM8 or TRPV4, if not both, is shown to 
interfere with muscarinic-induced vasodilation. NO is an essential part in muscarinic and 
TRPV4-vasodilatory pathways but not TRPM8-induced vasodilation. Muscarinic-induced 
vasodilation showed complete endothelium dependence, while the TRPV4-induced 
vasodilation is partially endothelium-dependent. Therefore, the endothelial muscarinic and 
TRPV4 pathways might be linked mainly through eNOS and BKca. Additionally, endothelial 
TRPM8 acts mainly as a hyperpolarisation inducer as it showed BKca and slightly 
endothelium dependent but NO-independent. This conclusion will be the base of the 
hypothesis to study the diabetic endothelial function in STZ diabetic-rats model. In the next 
chapter, endothelial function through carbachol, TRPV4 and TRPM8-induced vasodilation 
will be investigated with through main focus on TRPV4.  
 
 
 
 
 
 
 
 
 
 
1. Ch1: General introduction: 
2. Ch2: General methodology: 
3. Ch3: vascular physiology: 
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4. Chapter 4: The effect of STZ-induced diabetes on muscarinic, TRPV4 and 
TRPM8 responses on rat aortic and mesenteric arteries 
4.1. Introduction 
In the previous chapter, muscarinic, TRPV4 and TRPM8 pathways showed to play essential 
roles in mediating aortic rings vasodilation. Such vasodilation was through NO pathway in 
addition to BKca. Endothelial dysfunction is a common diabetes complication that renders 
the diabetic patients vulnerable to limbs fungal infections, nephropathy, and retinopathy (F. 
M. Ashcroft & Rorsman, 2012; A. Dhar et al., 2010). 
Endothelial dysfunction is a common diabetes complication in which endothelium-dependent 
vasodilation becomes impaired (Kolluru et al., 2012). The principal determinant of  
endothelial dysfunction is decreased NO bioavailability, with increased ET-1 biosynthesis as 
a close second (Bakker et al., 2009). The primary factors govern the bioavailability of 
endothelial NO: the generation of NO from eNOS and the elimination of active NO (van den 
Oever et al., 2010). Numerous studies have revealed different pathways of accelerated NO 
elimination. Under physiological circumstances, NO is produced from the dimeric eNOS that 
utilises L-arginine and molecular oxygen parallel to NADPH, FMN, FAD and BH4 as co-
substrates (M. I. Lin et al., 2003). BH4 downregulation contributes to eNOS uncoupling (Alp 
et al., 2003). Superoxide anions quench NO to produce ONOO- that compromise NO 
bioavailability and oxidise BH4 to BH2, as well as suppress GCH expression and thereby 
reduce BH4 expression (Alp et al., 2003; Milstien & Katusic, 1999). Elevated BH2 reduces 
NO production in addition to aggravating eNOS uncoupling due to BH4 reduction (Alp et al., 
2003; Milstien & Katusic, 1999). Arginase upregulation or hyperactivity, if not both, 
compromises L-arginine availability to induce eNOS uncoupling that culminates with ROS 
production and suppressed NO generation (Kashyap et al., 2008; Kim et al., 2009). 
Endothelial dysfunction might also be attributed to the impairment of the eNOS signalling 
cascade, such as PI3K/Akt/eNOS culminates with reduced NO production (Kolluru et al., 
2012; Liang et al., 2009; Tabit et al., 2010). 
 Another NO pathway component is the TRPV4 channel, which is highly expressed in the 
endothelium. H. Y. Kwan et al. (2007) hypothesised that a dysfunction in TRPV4 might 
contribute to endothelial dysfunction. Moreover, Köhler et al. (2006) provided the first 
evidence of TRPV4 dysfunction involvement in endothelial dysfunction. A recent study 
demonstrated TRPV4 downregulation in STZ-rats’ mesenteric endothelium (Ma et al., 2013). 
Moreover, TRPV4 downregulation was concluded to be involved in diabetic endothelial 
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dysfunction and retinopathy (Monaghan et al., 2015). These studies provide a very robust 
foundation that correlates TRPV4 alteration with endothelium dysfunction in diabetes. 
MGO inhibits eNOS phosphorylation and induces endothelial dysfunction (I. Dhar, Dhar, 
Wu, & Desai, 2012), and MGO generation is increased in diabetes as a consequence of 
accelerated glycolysis, lipolysis and proteins metabolism (Shamsaldeen et al., 2016). 
In response to these studies and findings, and as mentioned in section 1.7, the main objectives 
of this chapter were to investigate possible serum markers alteration in STZ-induced diabetes 
such as MGO and ox-LDL through ELISA. Moreover, since Hogikyan, Galecki, Halter, and 
Supiano (1999) showed that NA infusion induces exaggerated vasoconstriction in T2DM 
patients, therefore, NA-induced vasoconstriction was studied in both STZ-diabetic and non-
diabetic aortic rings. Moreover, investigating STZ-induced diabetes endothelial dysfunction 
through muscarinic and TRPV4 agonists in both aortic and mesenteric arteries. Finally, 
another TRP channel, TRPM8 will be investigated in parallel with muscarinic, TRPV4 and 
sodium nitroprusside (SNP)-induced vasodilation. 
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4.2. Materials and methods 
4.2.1. ELISA studies 
 MGO determination in naïve and STZ-diabetic rats’ serum samples 
Serum samples were analysed through sandwich ELISA according to the manufacturer’s 
instructions. Briefly, a sterile 96-well plate was coated with MGO conjugate (100µl of 
50ng/ml) which was prepared by the supplier through reacting BSA with MGO, followed by 
extensive dialysis and column purification. Samples (50µl) were incubated at 25°C for 10 
minutes prior to the addition of primary monoclonal mouse anti-MGO antibody (50µl). 
Afterward, the samples were incubated at room temperature on an orbital shaker for 1 hour. 
All samples were washed with washing buffer before the addition of secondary horseradish 
peroxidase labelled goat anti-mouse antibody (100µl) for 1 hour on orbital shaker. The 
loaded wells were washed three times and then incubated with TMB substrate solution 
(100µl) for 5 minutes. The reaction was stopped using sulphuric acid stop solution (100µl) 
and absorbance measured at 450nm. MGO standard curve was used to estimate the samples 
MGO concentrations (Figure 36). Eight different standard solutions of MGO conjugated 
bovine serum albumin (MGO-BSA) were prepared (0, 0.2, 0.39, 0.78, 1.56, 3.13, 6.26. 12.5 
and 25μg/ml) were read at 450nm wavelength. X-axis represents the concentration in 
logarithmic scale (0.2, 0.39, 0.78, 1.56, 3.13, 6.25, 12.5 and 25). R2 value showed 
approximately 97% strong correlation between absorbance and increased ox-LDL. The curve 
was used to estimate the sample (log) concentration (x-axis). 
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Figure 36. Methylglyoxal standard curve. The blue dotted line showed trend line robust fit. 
 Oxidised LDL (ox-LDL) determination in serum 
All samples were analysed through sandwich ELISA according to the manufacturer’s 
instructions. Briefly, a sterile coated 96-well plate was loaded with serum samples (100μl). 
Thereafter, the plate was covered and incubated in 37°C for 2 hours. Afterward, the samples 
were aspirated and the wells were added with primary biotin-conjugated monoclonal mouse 
antibody specific to Ox-LDL (100µl) (detection reagent A) and the plate was incubated in 
37°C for 1 hour. Detection reagent A was aspirated and wells were washed for 3 times with 
washing buffer (350µl) (provided by the supplier). The wells were then loaded with 
secondary polyclonal avidin-conjugated horseradish peroxidase labelled rabbit anti-mouse 
antibody (100µl) (detection reagent B), and incubated at 37°C for 30 minutes. Detection 
reagent B was aspirated and wells were washed for 5 times with washing buffer (350µl). The 
wells were then added with TMB substrate solution (100µl) and incubated at 37°C for 25 
y = 1.2751x-0.664
R² = 0.9694
-0.1
0.4
0.9
1.4
1.9
2.4
2.9
3.4
0.1 1 10 100
A
b
so
rb
an
ce
 a
t 
4
5
0
n
m
log MGO-BSA concentration (µg/ml)
Methylglyoxal standard curve
94 
 
minutes. The reaction was stopped using sulphuric acid stop solution (100µl) and the 
absorbance was measured at 450nm. Ox-LDL standard curve was used to estimate the 
samples ox-LDL concentrations (Figure 37). Eight different standard solutions of oxidised-
LDL (0, 31.25, 62.5, 125, 250, 500, 1000 and 2000pg/ml) were read at 450nm wavelength. 
R2 value showed approximately 98% correlation between absorbance and increased ox-LDL. 
The curve was used to estimate the sample concentration (x-axis). 
Figure 37. Oxidised LDL (ox-LDL) standard curve. The blue dotted line showed trend line robust fit. 
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4.2.2. Total serum proteins measurement 
The same serum samples were used for serum protein determination through BCA assay to 
investigate whether diabetes is associated with hypoproteinaemia. BCA standard curve was 
constructed and used for serum samples total proteins determination. Seven different standard 
solutions of bovine serum albumin (BSA) in deionised distilled water (0, 20, 40, 60, 100, 
200, 300 and 400µg/100µl) were read at 620nm wavelength. R-square showed approximately 
100% correlation between absorbance and concentration. The linear equation was applied to 
estimate the sample concentration (x) (Figure 38). 
Figure 38. Bicinchoninic acid (BCA) assay standard curve for serum samples analysis. The blue dotted line 
showed trend line robust fit. Bovine serum albumin= BSA 
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4.2.3. Naïve, control and STZ rats comparison 
 
 Vascular studies 
Vascular functions were evaluated in diabetic, control and naïve rats. Aortic rings from 
control rats’ injected with citrate buffer (control), or STZ diabetic rats were studied for 1-5 
weeks post injection and compared with naïve rats. Aortic rings (2-3mm) were isolated and 
left to equilibrate for approximately 60-90 minutes in Bennett isolated tissue vessel organ 
bath of 95% O2 / 5% CO2 Krebs solution pH 7.4 at 37°C ± 1°C as described in section 2.3.1. 
All aortic rings were initially contracted with NA CRC to determine the NA EC80. The NA 
EC80 was applied to pre-contract the aortic rings before being treated with either carbachol 
(CC) CRC (30nM- 300µM), TRPV4 agonists (RN1747 or 4-αPDD) CRC (3nM–30µM and 
3pM-3µM, respectively), TRPM8 agonist (icilin) CRC (3nM-3mM), or the direct vasodilator, 
SNP CRC (1nM-1mM). 
The vasodilation experiments started with pre-contracting the aortic rings and the mesenteric 
arteries (section 2.3.2.) with NA EC80 until the reading trace reached the plateau. Afterward, 
the vasodilator was added starting from the minimum concentration, and waiting for any 
response’s plateau before adding the higher concentration, until reaching the maximum CRC 
concentration. The extent of vasodilation was measured through iWORKS (version 1.817). 
Each value of the CRC was estimated in regard to the baseline value, the value of the trace 
before adding the NA EC80, which is approximately 1g (Figure 39). The extent of 
vasoconstriction and vasodilation was measured as described in 2.3.2. 
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Figure 39. Carbachol-induced vasodilation representative traces. Non-diabetic aortic rings showed vasodilation 
(upper trace: red). STZ-diabetic aortic rings showed impaired vasodilation (lower trace: turquoise). After 
noradrenaline EC80-induced vasoconstriction, aortic ring was treated with a series of carbachol concentrations to 
induce vasodilation. Once a plateau was reached, another higher concentration of carbachol (RN-174, 4-αPDD 
or icilin) was added until reaching the maximum vasodilation.  
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4.3. Results 
 
4.3.1. STZ model characteristics 
 
 Blood glucose was significantly elevated in STZ-diabetic rats: 
Approximately 95% of the STZ-injected rats developed diabetes as indicated by elevated 
blood glucose ˃ 16mmol/L. Blood glucose was significantly elevated in STZ-injected rats 
when measured at the day of sacrifice (N=28, *** p ˂ 0.001, 31 ± 1.1mmo/L vs pre-injection 
6.6 ± 0.13mmol/L). STZ-injected rats showed significant blood glucose increment from the 
1st week to the 5th week post injections [1st week: N=9, 31.7 ± 2mmol/L vs 6.5 ± 0.3mmol/L, 
2nd week: N=5, 28.0 ± 1.3mmol/L vs 6.3 ± 0.17mmol/L, 3rd week: N=6, 33.1 ± 2.7mmol/L vs 
6.5 ± 0.25, 4th week: N=4, 30.3 ± 3.1mmol/L vs 6.6 ± 0.3 & 5th week: N=4, 36.4 ± 
2.6mmol/L vs 7.2 ± 0.2mmol/L]. 
The mean blood glucose for naïve (non-injected) and control (injected with citrate buffer) rats 
did not show significant difference (p ≥ 0.05 naïve N=14: day of sacrifice 6.8 ± 1.4mmol/L 
vs pre-injection 6.8 ± 0.14mmol/L, control N=4: day of sacrifice 7.7 ± 0.34mmol/L vs pre-
injection 6.15 ± 1.9mmol/L) (Figure 40). 
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Figure 40. Naïve and STZ-diabetic rats blood glucose concentrations. Blood glucose was significantly increased 
in STZ rats among the 5 weeks course of study. Compared with respective pre-injection blood glucose levels 
versus respective pre-injection analysed through two-way ANOVA post hoc Bonferroni test. Significance is 
represented as *** p ˂ 0.001. Data presented as mean blood glucose ± SEM (Naïve, N=14, control, N=4, STZ- 
diabetic week 1, N= 9, STZ- diabetic week 2, N= 5, STZ- diabetic week 3, N= 6, STZ- diabetic week 4, N= 4 and 
STZ- diabetic week 5, N= 4). 
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Moreover, body weight did not increase during the study as seen with naive rats. Naïve rats 
across the 5 weeks showed significant weight gain (N=14, *** p ˂ 0.001, day of sacrifice 445 
± 20.7g vs when starting the study 336.8 ± 8.6g) while control rats across the 5 weeks did not 
show significant body weight increment (N=4, p ≥ 0.05, 420 ± 6.4g vs pre-injection 450 ± 
12.1g,). STZ-injected rats did not show significant weight gain. The 1st week showed 
insignificant weight loss while from the 2nd week – 5th week body weight was not 
significantly increased (1st week: N=9, p ≥ 0.05, 355.6 ± 10.0g vs 381.2 ± 11.0g, 2nd week: 
N=5, p ≥ 0.05, 405.0 ± 6.8g vs 387.2 ± 20.0g, 3rd week: N=6, p ≥ 0.05, 372.7 ± 9.9g vs 357.2 
± 13.7g, 4th week: N=4, p ≥ 0.05, 369.7 ± 10.8g vs 359.3 ± 13.3g, & 5th week: N=4, p ≥ 0.05, 
385.8 ± 21.1g vs 339.5 ± 4.1g) (Figure 41). 
Figure 41. Naïve and STZ-diabetic rats body weights. Body weight was not significantly changed in STZ rats 
compared to naive and control on the day of sacrifice. Analysed through two-way ANOVA with Bonferroni post 
hoc test p ˂ 0.001 *** versus respective pre-injection. Data presented as mean body weight ± SEM (Naïve, 
N=14, control, N=4, STZ- diabetic week 1, N= 9, STZ- diabetic week 2, N= 5, STZ- diabetic week 3, N= 6, 
STZ- diabetic week 4, N= 4 and STZ- diabetic week 5, N= 4). 
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Additionally, diabetic rat’s aorta showed reduced adipose tissue as a consequence of diabetic-
lipolysis which was associated with cloudy plasma from the 1st week of diabetes-induction 
(Figure 42). 
Figure 42. Diabetic lipolysis was shown evidently in diabetic rats in different compartments. Normal rats 
samples (upper row) of clear plasma, thick connective tissue surrounding the aorta and mesentery, whereas 
turbid and cloudy serum which was accompanied with thinned connective tissue surrounding the aorta and 
mesentery revealing lipolysis (lower three pictures).  
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 MGO and ox-LDL were significantly elevated in STZ-diabetic rats’ 
serum: 
Serum samples from naïve, control and STZ-diabetic rats were isolated as described in 
section 2.3.4 for ELISA studies. MGO and ox-LDL were both investigated in serum samples. 
MGO is a glycolytic metabolite that was attributed to endothelial dysfunction and diabetic 
complications such as neuropathy and nephropathy (M. Davies et al., 2006; A. Dhar et al., 
2010). According to these studies, serum MGO was measured through ELISA. As shown in 
Figure 43, MGO was significantly increased in STZ-diabetic rats’ serum (STZ week 1, N=4, 
* p ˂ 0.05, 124.0 ± 16.5μM, STZ week 2, N=5, * p ˂ 0.05, 121.4 ± 11.2μM, STZ week 3, 
N=4, *** p ˂ 0.001, 201.2 ± 44.4μM, STZ week 4, N= 4, p ≥ 0.05, 97.0 ± 26.4μM and STZ 
week 5, N= 4, * p ˂ 0.05,142.2±3.5μM vs naïve, N=5, 27.5 ± 9.2μM) (Figure 43a). Pooled 
STZ weeks showed significant MGO increase (STZ, N=21, *** p ˂ 0.001, 136.4 ± 12.2μM 
vs naïve, N=5, 27.5 ± 9.2μM) (Figure 43b). 
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Figure 43. Serum methylglyoxal concentration. STZ-diabetic rats’ serum showed significant increase in 
methylglyoxal across the studied timeframe (week 1- week 5) analysed through one-way ANOVA, post-hoc 
Tukey test (a). Pooled STZ weeks analysed through unpaired Student’s t-test (b). Significance is represented as 
* p ˂ 0.05 and *** p ˂ 0.001 compared with naïve serum MGO. Data shown as mean serum methylglyoxal 
concentration ± SEM (Naïve, N=5, STZ- diabetic week 1, N= 4, STZ- diabetic week 2, N= 5, STZ- diabetic 
week 3, N= 4, STZ- diabetic week 4, N= 4 and STZ- diabetic week 5, N= 4). 
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Previous studies correlated elevated serum ox-LDL with diabetic complications, neuropathy, 
nephropathy and vascular dysfunction (Tsuzura et al., 2004). Serum samples were isolated 
from naïve, STZ-diabetic rat at week 2 and randomised pooled samples from STZ-diabetic 
rats’ serum week 1-5 without week 2. Serum ox-LDL was estimated which showed 
significant increase in STZ-diabetic rats’ serum. STZ-diabetic rats’ serum showed significant 
increase in ox-LDL (STZ weeks 1-5, N= 8, * p ˂ 0.05, 1407 ± 178.1pg/ml, STZ week 2, N= 
4, * p ˂ 0.05, 1486 ± 78.1pg/ml vs naïve serum, N=5, 732.6 ± 160.6pg/ml) (Figure 44). 
Figure 44. Serum ox-LDL concentration. Analysed through one-way ANOVA, post-hoc Tukey test. 
Significance is represented as * p ˂ 0.05 against naïve serum ox-LDL. Data shown as mean serum ox-LDL 
concentration ± SEM (Naïve, N=5, STZ- diabetic week 1-5, N= 8 and STZ- diabetic week 2, N= 4). 
 STZ-diabetic rats’ serum showed significant hypoproteinaemia 
The same serum samples were used for serum protein determination through BCA assay to 
investigate whether diabetes is associated with hypoproteinaemia. Significant reduction in 
total serum proteins was shown in STZ-diabetic rats’ serum (*** p ˂ 0.001). STZ-diabetic 
week 1 did not show significant difference (N=4, p ≥ 0.05, serum proteins= 8.8 ± 1.03g/dl), 
STZ-diabetic week 2 showed significant difference (N=5, * p ˂ 0.05, serum proteins= 8.7 ± 
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0.6g/dl), STZ-diabetic week 3 showed significant difference (N=4, ** p ˂ 0.01, serum 
proteins= 7.7 ± 0.9g/dl), STZ-diabetic week 4 showed significant difference (N=4, *** p ˂ 
0.001, serum proteins= 5.7±0.3g/dl), STZ-diabetic week 5 showed significant difference 
(N=2, ** p ˂ 0.01, serum proteins= 6.4±0.8g/dl) when compared with naïve serum proteins 
(N=5, serum proteins= 12.0 ± 0.8g/dl) (Figure 45a). Pooled STZ-diabetic samples showed 
significant difference (N=19, *** p ˂ 0.001, serum proteins= 7.6 ± 0.4g/dl vs naïve, N=5, 
serum proteins= 12.0 ± 0.8g/dl) (Figure 45b). 
 
Figure 45. Total serum proteins. Diabetic total serum protein in STZ-diabetic rats from week 1-week 5 analysed 
through one-way ANOVA post hoc Tukey test (a). Pooled STZ-diabetic samples analysed through unpaired 
Student’s t-test. Significant is represented as * p ˂ 0.05, ** p ˂ 0.01 and *** p ˂ 0.001 when compared with 
naïve serum samples. Data shown as mean serum proteins concentration ± SEM (Naïve, N=5, STZ- diabetic 
week 1, N= 4, STZ- diabetic week 2, N= 5, STZ- diabetic week 3, N= 4, STZ- diabetic week 4, N= 4 and STZ- 
diabetic week 5, N= 2). 
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4.4. Vascular characteristics of naïve, control and STZ-diabetic rats 
A 5 weeks experiment was conducted to investigate vascular alterations throughout the STZ-
induced diabetes induction timeframe. STZ-induced diabetes rats were compared to control 
(injected with citrate buffer only) and non-injected naïve rats. 
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4.4.1. STZ-diabetic rats’ aortic rings showed similar noradrenaline EC80 
to naïve aortic rings with significantly higher response 
As shown in Figure 14 in chapter 3, the NA EC80 was be 300nM in naïve aortic rings. 
Therefore, STZ-diabetic aortic rings were studied to investigate any significant difference in 
EC80. STZ-diabetic aortic rings vasoconstriction showed significant difference (** p ˂ 0.01) 
when compared to naïve aortic rings (N=2, Emax= 0.55 ± 0.07g vs naïve, N=9, Emax= 0.41 
± 0.03%). However, STZ-diabetic aortic rings did not show significant difference in EC80 (p 
≥ 0.05) when normalised to maximum contraction and compared to naïve aortic rings (N=2, 
EC50= 121.2 ± 87.8nM, EC80= 794 ± 575.2nM and Emax= 100.0 ± 15.4% vs naïve, N=9, 
EC50= 112.0 ± 69.1, EC80= 630 ± 388.5nM and Emax= 100.0 ± 8.8%) (Figure 46). Therefore, 
the NA EC80 determined in chapter 3 was also applicable for STZ-diabetic aortic rings, 
300nM noradrenaline. 
Figure 46. Noradrenaline (NA) concentration response curve in STZ and naïve aortic rings. STZ aortic rings 
showed significant difference in vasoconstriction force (g) (a). STZ aortic rings did not show significant 
difference in EC80 (ns p ≥ 0.05) (b) Data analysed through two-way ANOVA post hoc Bonferroni test. 
Significance is represented as * p ˂ 0.05 and ** p ˂ 0.01. Data shown as mean contraction % ± SEM (Naïve, 
N=9 and STZ-induced diabetes, N= 2). 
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When NA (300nM) was applied to the freshly isolated aortic rings, STZ-diabetic aortic rings 
showed significantly higher contraction force compared to naïve aortic rings showed 
significantly higher contraction (N=21, *** p ˂ 0.001, vasoconstriction= 0.402 ± 0.02g vs 
naïve, N=12, vasoconstriction= 0.29 ± 0.02g) (Figure 47). 
Figure 47. Aortic rings contraction to noradrenaline (NA) EC80 (300nM). Significance is represented as *** p ˂ 
0.001 when compared against naïve aortic rings. Analysed through unpaired two-tailed Student’s t-test. Data 
shown as tension force (g) ± SEM (Naïve, N=12, STZ-diabetic rats, N=26). 
 
Moreover, mesenteric arteries resemble the peripheral vasculature where peripheral arterial 
resistance is found and contributes to hypertension and diabetic vascular complications. For 
this reason the effects of STZ treatment were also examined in this resistance artery. 
Vasoconstriction in mesenteric STZ rat’s mesenteric arteries showed significant difference (* 
p ˂ 0.05) when compared to naïve mesenteric arteries, however, there was not any significant 
difference at any applied noradrenaline concentration when analysing the data through 
Bonferroni post-hoc test (N=6, p ≥ 0.05, Emax= 17.6 ± 2.5g vs naïve, N=4, Emax= 22.4 ± 
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1.8g). When normalised to maximum vasoconstriction, STZ-diabetic mesenteric arteries did 
not show significant different when compared to naïve mesenteric arteries (N=6, p ≥ 0.05, 
EC50= 3.5 ± 2.5μM, N=6, EC80= 6.31 ± 4.5μM and Emax= 100.0 ± 14.4% vs naïve, N=4, 
EC50= 2.1 ± 1.4μM, N=6, EC80= 6.3 ± 4.3μM and Emax= 100.0 ± 8.1%)  (Figure 48) and 
therefore, the EC80 was also applicable for STZ-diabetic aortic rings, 10μM noradrenaline. 
Figure 48. Noradrenaline (NA) concentration response curve in STZ and naïve mesenteric arteries. STZ 
mesenteric arteries did not show significant difference in vasoconstriction force (g) (a). STZ-diabetic rats’ 
mesenteric arteries did not show significant difference in vasoconstriction force in EC80 when analysed through 
two-way ANOVA post hoc Bonferroni test (b). Data shown as mean contraction ± SEM (Naïve, N=4 and STZ-
diabetic rats, N=6). 
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4.4.2. Carbachol-induced vasodilation was significantly compromised in 
STZ-diabetic aortic and mesenteric arteries 
Since carbachol-induced vasodilation was endothelium-dependent (Figure 32), accordingly, 
pre-contracted rats’ aortic rings were treated with carbachol CRC, to investigate the viability 
of endothelium in STZ-diabetic models. STZ rats showed significant (*** p ˂ 0.001) 
alteration in vascular response in contrast to naïve rats as shown in Figure 49 with the 
maximum alteration was shown in the 2nd week as maximum vasodilation reduced by 
approximately 75%. 
As shown in Figure 49, control and STZ-diabetic EC50 values did not show significant 
difference throughout the course study when compared to naïve EC50 (p ≥ 0.05). The main 
significant difference was in the maximum vasodilation (Emax %). Early significant vascular 
dysfunction was shown in the 1st week (red) (N= 4, *** p ˂ 0.05, EC50= 0.95 ± 0.7µM & 
Emax= -55.3% ± 3.4%). The 2nd STZ-induced diabetes week (pink) showed the most retarded 
vascular dysfunction (N= 6, *** p ˂ 0.001, EC50= 0.6 ± 0.2µM & Emax= -29.6 ± 9.3%). The 
3rd week (green) showed significant endothelial dysfunction (N= 5, *** p ˂ 0.001, EC50= 1.3 
± 0.5µM & Emax= -58.6 ± 12.4%). However, endothelial dysfunction was significant in 
week 4 (blue) (N= 7, *** p ˂ 0.001, EC50= 0.6 ± 0.15µM & Emax= -35.1 ± 11.0%) and 5th 
week (grey) (N= 5, *** p ˂ 0.001, EC50= 1.02 ± 0.4µM & Emax= -52.3 ± 18.4%) when 
compared to carbachol-induced vasodilation in naïve aortic rings (N= 7, EC50=0.6 ± 0.3µM 
& Emax= 89.4 ± 4.4%). Control rats showed significant difference when compared to 
carbachol-induced vasodilation through two way ANOVA (* p ˂ 0.05) without showing any 
significant difference through Bonferroni post-hoc test in naïve aortic rings (N= 5, ns p ≥ 
0.05, EC50= 0.6 ± 0.4µM & Emax= -77.2 ± 2.5% vs EC50=0.6 ± 0.3µM & Emax= -89.4 ± 
4.4%) (Figure 49).  
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Figure 49. Concentration response curves of carbachol normalised to NA EC80 contraction in STZ-diabetic rats 
aorta (1st week – 5th week) compared to naïve (a). Maximum response induced by carbachol when normalised to 
NA-induced contraction (b). Analysed through two-way ANOVA post hoc Bonferroni test. All compared against naïve 
rats’ aorta. Data presented as mean ± SEM (Naïve, N= 7, control, N= 5, STZ-induced diabetes week 1, N=4, STZ-
induced diabetes week 2, N=6, STZ-induced diabetes week 3, N=5, STZ-induced diabetes week 4, N=7 and STZ-
induced diabetes week 5, N=4). Significance is represented as * p ˂ 0.05, ** p ˂ 0.01 and *** p ˂ 0.001. 
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Carbachol-induced vasodilation experiments were also performed on secondary mesenteric 
arteries in order to assess the level of dysfunction in these small resistance arteries. There was 
a significant reduction in carbachol-induced vasodilation due to the induction of diabetes 
when week 2 STZ-diabetic mesenteric arteries were compared to naïve mesenteric arteries 
(*** p ˂ 0.001). However, Bonferroni’s post-hoc test did not show significant difference at 
any concentration (Figure 50). STZ treatment showed to significantly affect the overall 
response compared to naïve (N=5, ns p ≥ 0.05, EC50= 157.7 ± 80.9nM and Emax= -63.5 ± 
9.9% vs naïve N=4 EC50= 90.9nM ± 62.8 and Emax= -91.2 ± 4.6). 
Figure 50. Mesenteric artery response to carbachol concentration response curve of normalised to NA EC80 
contraction in STZ rats’ mesenteric artery. Analysed through two-way ANOVA with Bonferroni’s post-hoc 
analysis did not show significance among the applied carbachol concentrations. Data presented as mean ± SEM 
(Naïve, N= 4 and STZ-diabetic week 2, N=5). 
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4.4.3. MGO significantly impaired the carbachol-induced vasodilation in 
naïve aortic rings 
A previous study conducted by A. Dhar et al. (2010) showed that MGO induces vascular 
dysfunction. As shown in Figure 43, MGO was significantly elevated in diabetic serum. 
Moreover, figure 49 showed significant impairment of carbachol-induced vasodilation in 
diabetic aortic rings. Therefore, MGO might contribute to diabetic endothelial dysfunction. 
To test this hypothesis, naïve aortic rings were exposed to MGO (100µM) ex vivo. This 
cannot be done over a period of two weeks as in the in vivo experiment, however normal 
function of aortic rings was retained over 12 hours ex vivo. Accordingly, aortic rings were 
kept for 12 hours as time control (control 12 hours), figure 51 shows the vasodilation to 
carbachol of control aorta rings after 12 hours compared to 1 hour after sacrifice (time 
control). Carbachol-induced full vasodilation was maintained across the 12 hours and the 
aortic rings became more sensitive to carbachol. The time factor showed significant influence 
on aortic rings response to carbachol (*** p ˂ 0.001). Aortic rings control 12 hours showed 
increased sensitivity to carbachol with significant EC50 reduction when compared to aortic 
rings time 0 (N= 4, *** p ˂ 0.001, EC50= 23.05 ± 13.3nM & Emax= -96.3±2.3% vs time 
control time, N= 6, EC50= 664.8 ± 449.5nM & Emax= -88.1 ± 3.6%) (Figure 51). 
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Figure 51. Carbachol concentration response curves normalised to NA EC80 contraction in fresh rat aortic rings 
(time control time) (green) compared to 12 hour time control aortic rings in the organ bath (control 12 hours) 
(black). Analysed through two-way ANOVA post hoc Bonferroni test. Significance is represented as ** p ˂ 
0.01 when compared with time control. Data is presented as mean ± SEM (Control 12 hours, N=4 and time 
control, N=6). 
Afterwards, MGO effect on endothelial function was investigated through incubating the 
aortic rings with MGO (100μM) for 12 hours. Moreover, L-arginine (100μM) was added to 
MGO (100μM) based on a previous study which concluded that L-arginine acts as MGO 
scavenger (I. Dhar et al., 2012). MGO (100μM) incubated aortic rings showed significant 
reduction in carbachol-induced vasodilation. Aortic rings incubated with MGO (100μM) for 
12 hours showed significant endothelial dysfunction when compared with time 12 hours 
control aortic rings (N= 4, *** p ˂ 0.001, EC50= 233.4 ± 125.3nM and Emax= -49.1 ± 5.0% 
vs control 12 hours: N= 4, EC50= 23.05 ± 13.3nM and Emax= -96.3 ± 2.3%). L-arginine 
showed significant influence on MGO-induced impaired vasodilation [N= 4, $$$ p ˂ 0.001, 
EC50= 33.6 ± 15.0nM & Emax= -84.6 ± 3.3% vs MGO (100μM), N= 4, EC50= 233.4 ± 
125.3nM and Emax= -49.1 ± 5.0%). However, aortic rings incubated with MGO (100μM) 
and L-arginine (100μM) did not show significant difference when compared to control 12 
hours (Figure 52). 
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Figure 52. Carbachol concentration response curves normalised to NA EC80 contraction in fresh rat aortic rings 
(control 12 hours) compared to aortic rings incubated with MGO for 12 hours in the organ bath. Analysed 
through two-way ANOVA post hoc Bonferroni test. Significance is represented as * p ˂ 0.05 and ** p ˂ 0.01 
and *** p ˂ 0.001 when compared to control 12 hours and $ p ˂ 0.05 and $$$ p ˂ 0.05 when compared to MGO 
(100μM) + L-arginine (100μM), and ns p ≥ 0.01 when MGO (100μM) and L-arginine (100μM) compared to 
control 12 hours. Data is presented as mean ± SEM (Control 12 hours, N=4, MGO (100μm), N=4 and MGO 
(100μm) + L-arginine (100μM) (N=4). 
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4.4.4. TRPV4-induced vasodilation was significantly impaired in STZ-
diabetic aortic and mesenteric arteries 
As the endothelial response to carbachol was compromised in STZ-diabetic aortic rings 
(Figure 49), together with the previous findings that revealed the TRPV4 involvement in 
endothelium-dependent vasodilation (Figure 33). Experiments were performed to investigate 
if TRPV4 mediated vasodilation were altered in STZ-diabetic aortic rings. Pre-contracted 
aortic rings were treated with the TRPV4 agonist RN-1747, to examine the TRPV4-induced 
vasodilation. STZ vascular responses were significantly altered (*** p ˂ 0.001) with the most 
compromised vascular function in the 2nd week post STZ-injection as TRPV4-induced 
vasodilation was reduced by approximately 60%, while control rats aorta did not show any 
significant difference to naïve (Figure 53). Control and STZ-diabetic EC50 values did not 
show significant difference throughout the course study when compared to naïve EC50 (p ≥ 
0.05). Diabetes contributed to a significant alteration to the RN-1747 CRC (*** p ˂ 0.001). 
TRPV4-induced vasodilation was reduced among the STZ weeks except the 3rd week (N= 5, 
ns p ≥ 0.05, EC50= 122.4 ± 48.7nM & Emax= -68.0 ± 11.2%) which showed similar pattern 
to naïve (N=7, EC50= 63.3 ± 33.2nM & Emax= -62.4 ± 8.7%) and control aortic rings (N=5, 
EC50= 36.5 ± 14.5nM & Emax= -56.2 ± 8.6%). RN-1747-induced vasodilation was 
significantly impaired in the 1st week STZ-diabetic aortic rings (N=4, *** p ˂ 0.001, EC50= 
35.0 ± 10.1nM & Emax= -19.0 ± 3.0%), 2nd week (N= 6, *** p ˂ 0.001, EC50= 431.7 ± 
86.1nM & Emax= -21.4 ± 7.7%), the 4th week diabetes showed significant vascular 
dysfunction (N= 6, *** p ˂ 0.05, EC50= 47.6 ± 11.4nM & Emax= -33.0 ± 6.8%) and the 5th 
week (N= 4, ** p ˂ 0.01, EC50= 63.1 ± 5.4nM & Emax= -19.4 ± 9.3%) (Figure 53). 
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Figure 53. TRPV4-induced vasodilation normalised to maximum NA-induced contraction in naïve and STZ-
diabetic aortic rings (a). Maximum response induced by RN-1747 when normalised to NA-induced contraction 
(b). Analysed through two-way ANOVA post hoc Bonferroni test. Significance is represented as ns p ≥ 0.05, p * 
˂ 0.05, ** ˂ 0.01 and *** p ˂ 0.001 versus naïve aortic rings. Data presented as mean ± SEM (Naïve, N= 5, 
control, N= 5, STZ-induced diabetes week 1, N=4, STZ-induced diabetes week 2, N=6, STZ-induced diabetes 
week 3, N=6, STZ-induced diabetes week 4, N=6 and STZ-induced diabetes week 5, N=4). 
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Another TRPV4 agonist, 4-αPDD was examined to confirm the observation with RN-1747. 
As shown in Figure 54, diabetes contributed to a significant alteration to the 4-αPDD CRC 
(*** p ˂ 0.001). Diabetic aortic rings showed significant impairment in 4-αPDD –induced 
vasodilation (N=4, EC50= 526.2 ± 317.1nM and Emax= 56.0 ± 5.5% vs naïve EC50= 92.9 ± 
54.7nM and Emax= 81.1 ± 2.1%) (Figure 54). However, STZ-diabetic EC50 values did not 
show significant difference when compared to naïve EC50 (p ≥ 0.05). 
Figure 54. 4-αPDD reduced vasodilation in STZ-diabetic aortic rings. Analysed through two-way ANOVA with 
Bonferroni post-hoc test. Significance is represented as * p ˂ 0.05 and ** p ˂ 0.01 when compared with naïve 
aortic rings. Data shown as percentage ± SEM (Naïve, N= 5 n= 11 and STZ-diabetic week 2, N=4 n= 8). 
 
 
 
119 
 
Mesenteric arteries’ response toward RN-1747 was recorded to compare STZ-diabetic with 
naïve rats’ mesenteric arteries. As shown in Figure 55, STZ-diabetic EC50 values did not 
show significant difference when compared to naïve EC50 (p ≥ 0.05), however, diabetes 
contributed to a significant alteration to the RN-1747 CRC (* p ˂ 0.05). STZ-diabetic rats’ 
mesenteric arteries showed significant compromise in RN-1747-induced vasodilation in week 
2 STZ-diabetic mesenteric arteries compared to naïve mesenteric arteries. Diabetic 
mesenteric arteries showed significant vascular dysfunction N=5, EC50= 0.3 ± 0.11μM and 
Emax= -41.5 ± 5.7% vs naïve EC50= 2.3 ± 1.02μM and Emax= -79.1 ± 6.1% (Figure 55). 
Figure 55. TRPV4-induced vasodilation in naïve and STZ-diabetic mesenteric arteries. RN-1747-induced 
vasodilation was significantly reduced in STZ-diabetic mesenteric arteries. Analysed through two-way ANOVA 
post hoc Bonferroni test. Significance is represented as * p ˂ 0.05 when compared with naïve mesenteric 
arteries. Data shown as percentage ± SEM (Naïve, N= 4 and STZ-diabetic week 2, N=5). 
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4.4.5. TRPM8-induced vasodilation was not significantly influenced in 
STZ-diabetic aortic arteries 
Previous findings in chapter 3 showed that TRPM8-induced vasodilation was not 
significantly compromised when endothelium was removed (Figure 34). Additionally, 
significant alteration in carbachol and TRPV4-mediated vasodilation was shown in 
endothelium denuded aortic ring (Figure 32 & 41). Moreover, both carbachol and TRPV4-
induced vasodilation was impaired in STZ-diabetic aortic rings (Figure 49-58 & 61-63). 
Therefore, pre-contracted aortic rings were relaxed with TRPM8 agonist, icilin CRC to 
investigate whether TRPM8 is impaired in the STZ-diabetic endothelium. As shown in 
Figure 56, TRPM8 was not affected in STZ-diabetic aortic rings (p ≥ 0.05). Icilin-induced 
vasodilation showed overlapping concentration response curve with naïve aortic rings (N=5, 
p ≥ 0.05, EC50= 0.82 ± 0.53μM and Emax= -76.3 ± 5.3% vs naive EC50= 2.7 ± 1.7μM and 
Emax= -78.3 ± 2.2%) (Figure 56). 
Figure 56. TRPM8 mediated vasodilation in naïve and STZ-diabetic aortic rings. Analysed through two-way 
ANOVA post hoc Bonferroni test compared with naïve aortic rings. Data shown as percentage ± SEM (Naïve, 
N= 4 and STZ-diabetic week 2, N=5). 
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4.4.6. SNP-induced vasodilation did not show significant difference 
between STZ-diabetic and naïve aortic rings 
To investigate whether the diabetic vascular dysfunction is mainly attributed to endothelium 
or both endothelium and VSM, SNP, a direct vasodilator was applied to pre-contracted aortic 
rings. This vasodilator acts independently from the endothelium and hence activates the 
VSM’s sGC (Boese, Busse, Miilsch, & Kerth, 1996). As illustrated in Figure 57, diabetic 
aortas showed a similar SNP-induced vasodilation pattern as naive aorta. SNP-induced 
vasodilation showed overlapping concentration response curve with naïve aortic rings (N=4, 
ns p ≥ 0.05, EC50= 5.2 ± 3.6nM Emax= 113.4 ± 7.2% vs naive N=6, EC50= 1.9 ± 1.2nM and 
Emax= 103.2 ± 2.8%) (Figure 57). 
Figure 57. SNP-induced vasodilation in naïve and STZ-diabetic aortic rings. Analysed through two-way 
ANOVA post hoc Bonferroni test compared with naïve aortic rings. Data shown as percentage ± SEM (Naïve, 
N= 6 and STZ-diabetic week 2, N=4). 
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4.5. Discussion 
In this chapter, STZ-induced diabetes model was used in these experiments and characterised 
through a number of parameters. Blood glucose concentration was the main diabetes marker 
as rats were considered diabetics when their blood glucose readings exceeded 16mmol/L. 
STZ induced hyperglycaemia with fourfold blood glucose increase in 95% of the STZ-
injected rats (Figure 40). These findings were similar to what was reported in a previous 
study (Bagri, Ali, Aeri, Bhowmik, & Sultana, 2009). 
ELISA studies were conducted to correlate hyperglycaemia and diabetes vascular dysfunction 
with selected circulating markers, MGO and ox-LDL. MGO showed significant increase in 
STZ-diabetic rats’ serum samples (Figure 43). The fourfold increase in serum MGO (Figure 
43b) was accompanied with fourfold increase in blood glucose concentration (Figure 40). 
Therefore, chronic hyperglycaemia, where blood glucose concentration exceeds 7mmol/L 
might contribute as the major endogenous MGO source (Kalapos, 2013). The glycolytic-
derived MGO is mainly attributed to triose phosphates, glyceraldehyde 3-phosphate and 
glycerone phosphate pathway through non-enzymatic or enzymatic reactions, if not both 
(Philips & Thornalley, 1993). Additionally, since lipolysis and proteins metabolism are 
accelerated in diabetes, MGO generation is increased through lipid peroxidation and SSAO, 
respectively (Boomsma et al., 1999; Mahendran et al., 2013; Mitch et al., 1999; Shamsaldeen 
et al., 2016). MGO is involved in common diabetes complications such as endothelial 
dysfunction, insulin resistance, and neuropathic pain (A. Dhar et al., 2010; A. Dhar, Dhar, 
Jiang, Desai, & Wu, 2011; Eberhardt et al., 2012). 
Serum ox-LDL showed significant increase in STZ-diabetic rats’ serum (Figure 44). Ox-LDL 
molecule is recognised by CD36 endothelial scavenger receptor that facilitates the uptake and 
the endocytosis of ox-LDL (Y. Zeng, Tao, Chung, Heuser, & Lublin, 2003). Additionally, 
ox-LDL is a cholesterol acceptor that competes with caveolae to deplete the caveolae from 
cholesterol and hence causes caveolae disruption (Blair, Shaul, Yuhanna, Conrad, & Smart, 
1999). Caveolae disruption inhibits eNOS attachment to CAV-1 which contributes to 
endothelial dysfunction (Blair et al., 1999). Moreover, previous studies revealed the 
correlation between elevated serum ox-LDL and diabetic complications, neuropathy, 
nephropathy and vascular dysfunction (Tsuzura et al., 2004). Daily consumption of tomato 
juice (500ml/day for 4 weeks) improves the serum antioxidant, lycopene concentration by 3–
fold. Such improvement is associated with decrease in LDL susceptibility to oxidation and 
decreased CRP aiming for reducing the risk of diabetes associated myocardial infarction 
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(Upritchard, Sutherland, & Mann, 2000). Moreover, HMG-CoA reductase inhibitors, statins 
(simvastatin and lovastatin) protects eNOS activity from ox-LDL-induced downregulation 
(Laufs, Fata, Plutzky, & Liao, 1998). High density lipoprotein (HDL) binds mainly on 
scavenger receptor class B isoform I (SR-BI) where it delivers the circulating cholesterol to 
the caveolae and hence maintains the caveolae integrity and enhances eNOS activity 
(Malerød, Juvet, & Berg, 2002; Thomas & Smart, 2008; Yuhanna et al., 2001).  
STZ-induced hyperglycaemia was associated with significant hypoproteinaemia (Figure 45). 
Serum total protein measurement showed significant time-dependent reduction in STZ-
diabetic rats (Figure 45a). Such hypoproteinaemia reveals the progression of diabetes as the 
1st week STZ-diabetic rats’ serum did not show significant serum hypoproteinaemia, while 
significant hypoproteinaemia was observed afterwards, (2nd week – 5th week). A previous 
study showed proteinuria as a common diabetes complication that is associated with plasma 
hypoproteinaemia (Bhonsle et al., 2012). Hypoproteinemia is mainly attributed to 
nephropathy and such finding was reported in previous study which was associated with 
significant eightfold increase in urine protein (Niwa et al., 1997). However, Niwa et al. 
(1997) did not show significant hypoproteinaemia although the STZ-induced diabetes was 3 
months duration revealing the robust diabetes model demonstrated in this study. 
Thereafter, NA-induced vasoconstriction was investigated. Both naïve and STZ-diabetic 
aortic rings showed similar EC80 of NA, 300nM (Figure 46), which went in agreement with 
Verbeuren et al. (1986) findings. However, STZ-diabetic rats’ aortic rings treated with NA 
(300nM) showed significant higher vasoconstriction compared to naïve aortic rings (Figure 
47). Such finding can be attributed to impaired endothelium hyperpolarisation which causes 
higher arterial response to exogenous vasoconstrictor than the naïve aortic rings (Fukao, 
Hattori, Kanno, Sakuma, & Kitabatake, 1997). Moreover, TRP channels-mediated striking 
influx of Ca2+ that might lead to vasoconstriction through agonist-induced membrane 
depolarisation-activated TRP channels as for instance in α1-adrenergic receptor-stimulated 
TRPC6 that is commonly found in rat’s aorta and cerebral arteries (Inoue et al., 2009). 
Additionally, previous studies revealed that ox-LDL induces the expression of endothelin-1, a 
potent vasoconstrictor which might exacerbate the vascular complications in diabetes (Galley 
& Webster, 2004). Therefore, in addition to being implicated in endothelial dysfunction, 
elevated serum ox-LDL (Figure 44) might be related to the significant increase in STZ-
vasoconstriction shown in Figure 47. Naïve and STZ-diabetic rats’ mesenteric arteries 
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showed similar NA EC80 at 10µM, which matched the concentration applied by Lewis, 
Surprenant, and Evans (1998) on the second order rats’ mesenteric arteries (Figure 48). 
Afterward, STZ rats were studied as diabetic models to examine the vascular function over a 
5 week period. Aortic rings were examined through applying vasodilators; carbachol or 
TRPV4 agonist (RN1747 or 4-αPDD) after being pre-contracted with NA (300nM). STZ-
diabetic rats showed significant vascular dysfunction which was started from the first couple 
of days post-injection and continued for the whole 5 weeks experiment timeframe. The most 
significant vascular dysfunction was shown in the 2nd week in STZ-induced diabetes model 
as shown in Figures 49 and 50. Therefore, the 2nd week (8th - 14th day) post-STZ injection 
was applied as a representative time-point for diabetic vascular dysfunction. Muscarinic-
induced vasodilation was significantly impaired in aortic rings and mesenteric arteries 
(Figures 49 & 50). These findings match with a previous study’s conclusion that vascular 
function of STZ-diabetic rats is attributed to impaired muscarinic-induced endothelium-
dependent vasodilation (Fukao et al., 1997). 
Carbachol-induced vasodilation was endothelium dependent (Figure 32). Therefore, STZ-
impaired muscarinic-induced vasodilation might be regarded as endothelial dysfunction. As a 
consequence of diabetes, endothelial dysfunction is a common complication where 
endothelium-dependent vasodilation is impaired that contributed to peripheral artery disease, 
foot ischemia, ulceration and even amputation (A. Dhar et al., 2010; Ruiter et al., 2012). 
To examine whether elevated MGO is implicated in inducing diabetic endothelial 
dysfunction, naïve aortic rings were incubated with MGO (100µM) for 12 hours. Carbachol-
induced vasodilation was significantly impaired (Figure 52). To ensure that the effect was not 
due to tissue failure, control rings were experimented in parallel which did not show 
endothelial alteration (Figure 51). Such finding is supported by previous study which found 
that MGO inhibits the phosphorylation of serine-1177 of eNOS and hence reduces 
endothelial NO release (A. Dhar et al., 2010). This finding is supported by STZ-diabetic 
endothelial dysfunction (Figure 49 & 58) which was correlated with the significant increase 
in serum MGO (Figure 43). Therefore, MGO might play a major role in diabetic endothelial 
dysfunction (Brownlee, 2001). L-arginine (100μM) restored the endothelial function in the 
presence of MGO (100μM) (Figure 52). Such finding is attributed to the ability of L-arginine 
to scavenge MGO (I. Dhar et al., 2012). However, further studies such as high performance 
liquid chromatography (HPLC) are required to prove the ability of L-arginine to scavenge 
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MGO. Moreover, incubating aortic rings with L-arginine (100μM) only, as L-arginine control 
should be investigated in parallel to the conditions applied in Figure 52, since L-arginine 
could potentiate eNOS activity to enhance NO generation (Böger, 2004) 
The deterioration in endothelium-dependent vasodilation characterised by impaired 
muscarinic-induced vasodilation (Figure 49 & 58) was in parallel with impaired TRPV4-
induced vasodilation in both aortic and mesenteric arteries (Figures 53 - 55). Therefore, 
muscarinic and TRPV4 impaired vasodilation reveals possible mechanistic collaboration of 
the muscarinic receptors and TRPV4 channels. Additionally, TRPV4 blocking was shown to 
significantly influence muscarinic-induced vasodilation (Figures 22 & 23). Muscarinic and 
TRPV4 cascades might be integrated through GPCR-activated PLC that hydrolyses the 
membranous PIP2 into DAG and IP3, IP3 binds to its corresponding smooth ER’s IP3-R to 
facilitate Ca2+ release from cellular stores (Clapham, 2003; Ying, Aaron, & Sanders, 2014). 
Moreover, TRPV4 is activated through the muscarinic downstream cascade element, DAG-
activated PKC binding (Rohacs & Nilius, 2007). Additionally, TRPV4 mice KO study have 
revealed its essential role in muscarinic-mediated endothelium-dependent vasodilation 
through novel mechanism that involves Ca2+ influx through endothelium derived factor, 11, 
12 EET-activated TRPV4 which enhances Ca2+ entry that activates and opens the BKCa to 
yield membrane hyperpolarisation and vasodilation (Earley et al., 2005; M. Freichel et al., 
2005).  
Among the channels of interest was TRPM8, which was elicited specifically for two main 
reasons: firstly, not like TRPV4 that mediates both BKca and NO-dependent vasodilation 
(Figure 27 & 39), TRPM8 showed to mediate vasodilation through BKca-dependent (Figure 
31) and NO-independent pathways (Figure 28). The second reason was for the commonly 
available and applicable agonist as it is activated by menthol or icilin (D. A. Andersson et al., 
2007). Pre-contracted diabetic aortic rings were relaxed through icilin CRC without any 
significant difference from non-diabetic aortic rings (Figure 56). This supports the previous 
findings (Figure 28 & 39) that TRPM8 is suggested to mediate vasodilation through different 
pathways to TRPV4 which was significantly compromised in diabetes. 
SNP study was conducted to investigate the viability of sGC (Boese et al., 1996). As 
illustrated in Figure 57, STZ-diabetic aortic rings showed similar SNP-induced vasodilation 
pattern as naive aortic rings revealing that sGC activity might not be significantly 
compromised in diabetic aortic rings. 
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To sum up, STZ-diabetic rats showed significant endothelial dysfunction through impaired 
carbachol-induced vasodilation. Such endothelial dysfunction was accompanied with 
compromised TRPV4-induced vasodilation. By contrast, TRPM8 vascular function was not 
significantly compromised in STZ-induced diabetes which might suggest that TRPM8 is acting 
through different pathways than TRPV4. ELISA studies showed significant increase in diabetic 
serum ox-LDL and MGO. Ox-LDL might explain the diabetic endothelial dysfunction and the 
exaggerated vasoconstriction. Elevated MGO serum concentration in STZ-diabetic rats’ serum 
might also explain the diabetic endothelial dysfunction as incubating naïve non-diabetic aortic 
rings with MGO (100µM) for 12 hours compromised endothelial function. To examine the 
mechanism of the compromised TRPV4-induced vasodilation and the involvement of MGO in 
endothelial TRPV4 dysfunction, the next chapter will include further MGO investigations. 
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5. Chapter 5: The effect of diabetes on TRPV4 function and expression in rat 
primary aortic ECs 
5.1. Introduction 
In the last chapter, muscarinic and TRPV4-induced vasodilation were significantly 
compromised in STZ-diabetic aortic and mesenteric arteries. However, TRPM8-induced 
vasodilation was not significantly influenced in STZ-diabetic aortic rings. 
Endothelial dysfunction is a common diabetes complication in which endothelium-dependent 
vasodilation becomes impaired (Kolluru et al., 2012). TRPV4 is highly expressed in the ECs 
and a major vascular tone controller (Köhler et al., 2006). H. Y. Kwan et al. (2007) 
hypothesised that a dysfunction in TRPV4 might contribute to endothelial dysfunction. 
Moreover, Köhler et al. (2006) provided the first evidence of TRPV4 dysfunction 
involvement in endothelial dysfunction when the flow-induced vasodilation was abolished by 
TRPV4 blockers, ruthenium red, and the PLA2 inhibitor, arachidonyl trifluoromethyl ketone 
in rat carotid arteries. A recent study demonstrated TRPV4 downregulation in STZ-rats’ 
mesenteric endothelium (Ma et al., 2013). Moreover, TRPV4 downregulation is involved in 
diabetic endothelial dysfunction and retinopathy (Monaghan et al., 2015). These studies 
provide a very robust foundation that correlates TRPV4 alteration with diabetes endothelium 
dysfunction. TRPV4 is coupled and functionally regulated by CAV-1 (Saliez et al., 2008). 
Additionally, CAV-1 is coupled with eNOS and both were downregulated in STZ-diabetic 
rats’ kidneys and bovine aortic ECs, and such downregulation was reversed through insulin 
treatment (Komers et al., 2006; H. Wang et al., 2009).  
As described in section 1.7., the main objectives of this chapter were to investigate whether 
TRPV4-induced [Ca2+]i elevation is influenced in diabetic ECs through fura-2 Ca
2+ imaging 
studies. Moreover, to investigate the contribution of diabetes on TRPV4 expression in ECs 
through LSCM studies, and whether other cellular proteins are influenced such as eNOS and 
CAV-1. Ex vivo insulin treatment of the ECs was conducted to examine the importance of 
insulin to maintain the endothelial function. Further investigations were conducted on the 
effect of MGO (100μM) on TRPV4 function through fura-2 Ca2+ imaging studies and LSCM. 
Moreover, TRPM8 fura-2 Ca2+ imaging studies were conducted to test the hypothesis that the 
vascular TRPM8 function is not influenced by diabetes. 
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5.2. Materials and methods 
5.2.1. Primary endothelial cells studies 
Primary aortic ECs were isolated and grown in t-25 collagen I-coated culture flasks as 
described in section 2.4. The primary aortic ECs showed morphological characteristics which 
became clearer under the LSCM when the ECs were tagged with Dil-Ac-LDL. After 
becoming fully confluent, the ECs were plated on poly-l-lysine coated glass coverslips. STZ-
diabetic ECs were treated with insulin (1 and 10μg/ml equivalent to 270mIU/ml and 
2.7mIU/ml) for 5 days. The expression level of TRPV4, CAV-1 and eNOS was studied 
through LSCM as described in section 2.7.1. Each ECs’ coverslip was initially tagged with 
Dil-Ac-LDL that is a selective marker for ECs in the vasculature. The Dil-Ac-LDL is taken-
up by the ECs that hydrolyse the acetyl bond to release the fluorescence LDL which is 
trapped intracellularly, endowing red fluorescence to the ECs. The Dil-Ac-LDL-tagged 
coverslips were then washed-out to remove any extracellular Dil-Ac-LDL. Afterward, the 
coverslips were incubated with the primary antibody to tag the protein of interest: TRPV4, 
CAV-1 or eNOS. Thereafter, the coverslips were washed-out of any unbound antibodies 
before being incubated with the secondary green fluorescence antibody that binds to the 
primary antibody. Thereafter, the unbound secondary antibodies were washed-out and the 
coverslips were added with mounting media containing the nucleus staining DAPI, which 
stains the nucleus in blue. The LSCM pictures were analysed through ImageJ. The nucleated, 
Dil-Ac-LDL tagged ECs were considered as ROI. Therefore, the expression of the protein of 
interest was measured only in the ROI. STZ-diabetic ECs were treated with insulin for 5 days 
to examine the effect of insulin treatment on TRPV4, CAV-1 and eNOS expression and 
distribution.  
In another experiment, the naïve control aortic ECs were treated with MGO (100µM) to 
examine the effect of MGO on TRPV4 expression and distribution. 
Fura-2 Ca2+ imaging studies were conducted to compare the STZ-diabetic and naïve primary 
aortic ECs response to 4-αPDD (1mM) and icilin (1mM) as described in section 2.6. 
Additionally, the effect of insulin on TRPV4 function was investigated in STZ-diabetic aortic 
ECs cells through fura-2 Ca2+ imaging. The naïve control aortic ECs were treated with MGO 
(100µM) to examine the effect of MGO on TRPV4 function. Additionally, L-arginine 
(100µM) was added to MGO (100µM) to examine the protective effect of L-arginine against 
MGO on TRPV4 function. 
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5.3. Results 
5.3.1. TRPV4 was significantly downregulated in STZ-diabetic ECs and 
restored through insulin treatment 
As previously shown in Figures 53-55, TRPV4-induced vasodilation was significantly 
impaired in diabetic aortic and mesenteric arteries. Moreover, TRPV4-induced vasodilation 
was significantly endothelium dependent (Figure 33). Therefore, naïve and STZ-diabetic ECs 
were visualised under the LSCM (figure 58). Additionally, STZ-diabetic ECs were treated 
with insulin (1 and 10μg/ml equivalent to 270mIU/ml and 2.7mIU/ml) for 5 days before 
being studied through LSCM. As shown in Figure 58, TRPV4 showed distribution around the 
nucleus and at the edge of plasma membrane in naïve aortic ECs (a2). STZ-diabetic ECs 
showed disrupted TRPV4 distribution with less green fluorescence emission (b2). Insulin 
treatment 270mIU/ml/day (c2) and 2.7IU/ml/day (d2) for 5 days restored TRPV4 distribution 
in STZ-ECs. Images were combined to matching endothelial marker (red), nucleus marker 
(blue) and TRPV4 florescence antibody (green) (a3, b3, c3 & d3). 
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Label AC-Dil-LDL TRPV4 antibody  AC-Dil-LDL + TRPV4 
antibody 
Naïve (or 
control) 
 
STZ-
diabetic 
ECs 
STZ-
diabetic 
ECs treated 
with insulin 
270mIU/ml 
STZ-
diabetic 
ECs treated 
with insulin 
2.7IU/ml 
Figure 58. TRPV4 expression in primary aortic endothelial cells under laser scanning confocal microscope. 
Endothelial cells were probed with DAPI to label the nucleus in blue and marked with acetylated LDL (Dil-Ac-
LDL) giving the cells the red colour (left: a1, b1, c1 & d1). Anti TRPV4 primary antibody probed with 
secondary green fluorescence antibody (middle: a2, b2, c2 & d2). Images were combined to match the selective 
ECs marker (red) with anti TRPV4 (green) and the nucleus marker (blue) (right: a3, b3 & c3 & d3) (200×) 
488nm laser. 
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The confocal microscopy images were quantitatively analysed through ImageJ software 
(version 1.46r) and statistically analysed through GraphPad prism (version 5.00). Total 
TRPV4 expression showed significant difference when insulin treated STZ-ECs were 
compared to untreated STZ-diabetic ECs (* p ˂ 0.05). As shown in Figure 59a, primary 
aortic ECs isolated from 3 different STZ-diabetic rats were treated with insulin (270mIU/ml 
& 2.7IU/ml). The three groups were compared through matched one way ANOVA analysis 
showing significant increase in TRPV4 expression when diabetic ECs were treated ex vivo 
with insulin (Insulin 270mIU/ml, N= 3, * p ˂ 0.05, average TRPV4 expression= 101.6 ± 
6.5% and insulin 2.7IU/ml, N= 3, average TRPV4 expression= 100.0 ± 10.9% vs STZ-
diabetic ECs N= 3, average TRPV4 expression= 68.4 ± 12.03%) (Figure 59a).  
When the whole data were pooled together and compared with naïve ECs, TRPV4 expression 
showed a significant increase through ex vivo insulin treatment (Figure 59b). Pooled data 
showed a significant reduction in STZ-diabetic ECs’ TRPV4 expression compared to naïve 
ECs’ TRPV4 (Naïve, N= 5, average TRPV4 expression= 100.0 ± 7.3% vs STZ-diabetic ECs 
N= 8, average TRPV4 expression= 58.9 ± 5.8%). Insulin treatment showed to significantly 
restore STZ-diabetic TRPV4 expression (270mIU/ml N= 3, * p ˂ 0.05, average TRPV4 
expression= 96.2 ± 6.2% and 2.7IU/ml N= 3, average TRPV4 expression= 94.7 ± 10.4% vs 
STZ N= 8, 58.9 ± 5.8%) (Figure 59b). 
Figure 59. Total TRPV4 expression in primary aortic endothelial cells. Matched data analysed through repeated measure one-
way ANOVA with Tukey post-hoc test (a). Pooled data analysed through one-way ANOVA with Tukey post-hoc test (b). 
Significance is represented as * p ˂ 0.05 and ** p ˂ 0.01 compared with TRPV4 expression in STZ endothelial cells. Data 
shown as average percentage ± SEM. 
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5.3.2. Caveolin-1 (CAV-1) was significantly downregulated in STZ-
diabetic ECs and restored through insulin treatment 
Caveolae are 50 to 100nm diameter lipid raft invaginations in the ECs membrane (X. Yao & 
Garland, 2005). Caveolae form approximately 95% of the ECs surface invaginations 
functioning as signalling platform that integrate the signalling molecules to facilitate their 
interactions (X. Yao & Garland, 2005). Among the signalling molecules docked in the 
caveolae is TRPV4 (Garland, Hiley, & Dora, 2010). CAV-1 is a major protein component of 
the endothelial caveolae. Previous studies showed CAV-1 is co-localised with TRPV4 (Saliez 
et al., 2008). Therefore, further studies were conducted on ECs to investigate whether CAV-1 
is affected by diabetes and restored through insulin treatment. 
As shown in Figure 60, CAV-1 showed distinct distribution around the nucleus and at the 
edge of plasma membrane in naïve aortic ECs (a2). STZ-diabetic ECs showed disrupted 
CAV-1 distribution with less green fluorescence emission (b2). Insulin treatment 
270mIU/ml/day (c2) and 2.7IU/ml/day (d2) for 5 days restored  CAV-1 distribution in STZ- 
diabetic ECs. Images were combined to matching endothelial marker (red), nucleus marker 
(blue) and CAV-1 florescence antibody (green) (a3, b3, c3 & d3). 
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Label AC-Dil-LDL CAV-1 antibody  AC-Dil-LDL + CAV-1 
antibody 
Naïve (or 
control) 
 
STZ-
diabetic 
ECs 
STZ-
diabetic 
ECs 
treated 
with 
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270mIU/
ml 
STZ-
diabetic 
ECs 
treated 
with 
insulin 
2.7IU/ml 
Figure 60. Caveolin-1 (CAV-1) expression in primary aortic endothelial cells under laser scanning confocal 
microscope. Endothelial cells were probed with DAPI to label the nucleus in blue and marked with acetylated 
LDL (Dil-Ac-LDL) giving the cells the red colour (left: a1, b1, c1 & d1). Anti caveolin-1 primary antibody 
probed with secondary green fluorescence antibody (middle: a2, b2, c2 & d2). Images were combined to match 
the selective ECs marker (red) with anti CAV-1 (green) and the nucleus marker (blue) (right: a3, b3 & c3 & d3) 
(200×) 488nm laser. 
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The confocal microscopy images were quantitatively analysed through ImageJ software 
(version 1.46r) and statistically analysed through Graph Pad prism (version 5.00). As shown 
in Figure 61a, primary aortic ECs isolated from 3 different STZ-diabetic rats were treated 
with insulin (270mIU/ml & 2.7IU/ml). The three groups were compared through matched one 
way ANOVA analysis showing significant increase in CAV-1 expression when STZ-diabetic 
ECs were treated ex vivo with insulin (Insulin 270mIU/ml, N= 3, * p ˂ 0.05, average CAV-1 
expression= 100.0 ± 3.0% and insulin 2.7IU/ml, N= 3, * p ˂ 0.05, average CAV-1 
expression= 100.0 ± 7.7% vs STZ-diabetic ECs, N= 3, average CAV-1 expression= 70.0 ± 
5.5%) (Figure 61a).  
When the whole data were pooled together and compared with naïve ECs, CAV-1 expression 
showed a significant increase following ex vivo insulin treatment (Figure 59b). Pooled data 
showed significant reduction in STZ-diabetic ECs’ CAV-1 expression compared to naïve 
ECs’ CAV-1 (Naïve, N= 5, average CAV-1 expression= 100.0 ± 3.0% vs STZ-diabetic ECs, 
N=4, average CAV-1 expression= 73.8 ± 4.3%). Insulin treatment significantly increased 
STZ-diabetic ECs’ CAV-1 expression at higher concentration (270mIU/ml N= 3, ns p ≥ 0.05, 
average CAV-1 expression= 99.3 ± 1.6% and 2.7IU/ml N= 3, * p ˂ 0.05, average CAV-1 
expression= 103.2 ± 8.0% vs STZ N= 4, 73.8 ± 4.3%). 
Figure 61. Total caveolin-1 (CAV-1) expression in primary aortic endothelial cells. Matched data analysed 
through repeated measure one-way ANOVA with Tukey post-hoc test (a). Pooled data analysed through one-
way ANOVA with Tukey post-hoc test (b). Significance is represented as * p ˂ 0.05 compared with CAV-1 
expression in STZ endothelial cells. Data shown as average percentage ± SEM. 
 
135 
 
5.3.3. eNOS was significantly downregulated in STZ-diabetic ECs and 
restored through insulin treatment 
Previous studies showed that eNOS and CAV-1 are co-localised in rat kidneys and cultured 
bovine aortic ECs (Komers et al., 2006; H. Wang et al., 2009). Additionally, being co-
localised with CAV-1 and affected by shear stress, eNOS was hypothesised to be co-localised 
with TRPV4 and CAV-1 and affected in diabetic rat aortic ECs. Therefore, 
immunocytochemistry studies were conducted to examine whether eNOS will show similar 
patterns as TRPV4 and CAV-1. eNOS was significantly downregulated in diabetic aortic ECs 
which was restored through insulin treatment (Figure 62 and 72). As illustrated in Figure 62, 
eNOS showed distinct distribution around the nucleus and at the edge of plasma membrane in 
naïve aortic ECs (a2). STZ-diabetic ECs showed disrupted eNOS distribution with less green 
fluorescence emission (b2). Insulin treatment 270mIU/ml/day (c2) and 2.7IU/ml/day (d2) for 
5 days restored eNOS distribution in STZ-diabetic ECs. Images were combined to matching 
endothelial marker (red), nucleus marker (blue) and eNOS florescence antibody (green) (a3, 
b3, c3 & d3). 
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Label AC-Dil-LDL eNOS antibody  AC-Dil-LDL + eNOS 
antibody 
Naïve (or 
control) 
 
STZ-
diabetic 
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ml 
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2.7IU/ml 
Figure 62. Endothelial nitric oxide synthase (eNOS) expression in primary aortic endothelial cells under laser 
scanning confocal microscope. Endothelial cells were probed with DAPI to label the nucleus in blue and marked 
with acetylated LDL (Dil-Ac-LDL) giving the cells the red colour (left: a1, b1, c1 & d1). Anti eNOS primary 
antibody probed with green secondary fluorescence antibody (middle: a2, b2 & c2 & d2). Images were 
combined to match the selective ECs marker (red) with anti eNOS (green) and the nucleus marker (blue) (right: 
a3, b3 & c3 & d3) (200×) 488nm laser. 
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The confocal microscopy images were quantitatively analysed through ImageJ software 
(version 1.46r) and statistically analysed through Graph Pad prism (version 5.00). As shown 
in Figure 63a, primary aortic ECs isolated from 3 different STZ-diabetic ECs were treated 
with insulin (270mIU/ml & 2.7IU/ml). The three groups were compared through matched one 
way ANOVA analysis showing significant improvement in eNOS expression when STZ-
diabetic ECs were treated ex vivo with insulin (Figure 63a). Matched data showed 
significantly enhanced eNOS expression in STZ-ECs treated with insulin (Insulin 
270mIU/ml, N= 3, * p ˂ 0.05, average eNOS expression= 98.5 ± 4.8% and insulin 2.7IU/ml, 
N= 3, average eNOS expression= 100.0 ± 5.5% vs STZ-diabetic ECs, N=3, average eNOS 
expression= 59.6±5.13%) (Figure 63a).  
Pooled data showed significant reduction in STZ-diabetic ECs’ eNOS expression compared to 
naïve ECs’ eNOS (Naïve, N= 5 average eNOS expression= 100.0 ± 4.3% vs STZ N=6, 62.1 ± 
5.8%). Insulin treatment showed to significantly restore STZ-diabetic ECs’ eNOS reduction 
(270mIU/ml N=3, average eNOS expression= 120.7 ± 5.8% and 2.7IU/ml N= 3, *** p ˂  0.001, 
average eNOS expression= 122.6 ± 6.7% vs STZ N= 6, 62.1 ± 5.8%) (Figure 63b). 
Figure 63. Total eNOS expression in primary aortic endothelial cells. Matched data analysed through repeated measure one-
way ANOVA with Tukey post-hoc test (a). Pooled data analysed through one-way ANOVA with Tukey post-hoc test (b). 
Significance is represented as * p ˂ 0.05 and *** p ˂ 0.01 compared with eNOS expression in STZ endothelial cells. Data 
shown as average percentage ± SEM. 
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These findings suggest that TRPV4, CAV-1, and eNOS are all downregulated in STZ-
diabetic rat aortic ECs and restored through insulin treatment. Therefore, further fura-2 Ca2+ 
imaging functional study was conducted to investigate whether TRPV4 downregulation 
influences the changes in [Ca2+]i following TRPV4 stimulation. 
5.4. TRPV4-induced intracellular calcium concentration was significantly 
reduced in STZ-diabetic ECs and restored through insulin treatment 
As shown in Figure 64, baseline fura-2 ratio was not significantly different across naïve ECs, 
STZ-diabetic ECs (untreated) and STZ-diabetic ECs treated with insulin (270mIU/ml/day for 
5 days).  
Figure 64. Baseline fura-2 ratio before 4-αPDD treatment. All studied groups were compared through Tukey’s 
one-way ANOVA, and no significant difference was shown. Non-significance is represented as ns p ≥ 0.05 
when the groups were compared with each other. Data shown as average fura-2 ratio ± SEM.   
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However, TRPV4-induced [Ca2+]i showed a significant decrease in STZ-diabetic ECs 
compared to naïve ECs (* p ˂ 0.05). In STZ-diabetic ECs treated with insulin 
270mIU/ml/day for 5 days, the amplitude of the intracellular Ca2+ in response to TRPV4 
activation was significantly restored. Naïve ECs (N=4, 1.0 ± 0.2 fura-2 ratio change) and 
STZ-diabetic ECs treated with insulin 270mIU/ml/day for 5 days (N=4, 1.1 ± 0.1 fura-2 ratio 
change) showed significant difference (* p ˂ 0.05) compared to STZ-diabetic ECs (N=4, 0.5 
± 0.13 fura-2 ratio change) (Figure 65). 
 
Figure 65 TRPV4 induced peak fura-2 ratio change through 4-αpdd (1mM) treatment. Analysed through one-
way ANOVA with Tukey post-hoc test. Significance is represented as * p ˂ 0.05 when compared to STZ ECs 
fura-2 ratio changes. Data shown as average fura-2 ratio ± SEM. 
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In addition to showing a reduced amplitude, the time course of the [Ca2+]i rise in the ECs 
isolated from STZ-diabetic rats was significantly delayed compared to naïve ECs. Naïve 
aortic ECs showed a significant difference in the required time to reach the fura-2 peak 
compared to STZ-diabetic ECs (Naïve, N= 4, * p ˂ 0.05, peak time= 81.3 ± 13.5 seconds vs 
STZ-diabetic ECs, N= 4, peak time= 202 ± 23.5 seconds). STZ-diabetic ECs treated with 
insulin 270mIU/ml/day for 5 days did not show a significant difference when compared to 
untreated STZ-diabetic ECs (STZ-diabetic ECs treated with insulin 270mIU/ml/day, N= 4, p 
≥ 0.05, peak time= 154.5 ± 40.2 seconds vs STZ-diabetic ECs, N= 4, peak time= 202 ± 23.5 
seconds) as shown in Figure 66. 
 
Figure 66 Time to reach peak 4-αPDD induced fura-2 ratio change. Analysed through one-way ANOVA with Tukey post-
hoc test. Significance is represented as * p ˂ 0.05 when compared to STZ ECs peak time. Data shown as mean ± SEM. 
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5.4.1. MGO significantly compromised the TRPV4-induced intracellular 
calcium concentration in naïve ECs, which was restored through L-
arginine treatment 
MGO was significantly elevated in diabetic serum (Figure 43), and MGO (100µM) inhibited 
endothelial-mediated vasodilation in whole naïve aortic rings (Figure 52). Additionally, 
TRPV4-mediated [Ca2+]i was significantly reduced in STZ-diabetic ECs (Figure 65). 
Accordingly, fura-2 Ca2+ imaging studies were conducted to examine whether TRPV4 
function is compromised through MGO treatment, and if L-arginine co-treatment can restore 
MGO-induced TRPV4 dysfunction. After plating the ECs on poly-L-lysine coated glass 
coverslips, they were treated with MGO (100μM) or MGO (100μM) and L-arginine (100μM) 
once daily until becoming confluent. As shown in Figure 67, MGO (100µM) showed 
significant reduction in TRPV4-induced [Ca2+]i elevation, whereas L-arginine (100µM) 
showed significant reversal of MGO-induced TRPV4 dysfunction (* p ˂ 0.05). Naïve ECs 
treated with MGO 100μM/day for 5 days (N=4, 0.54 ± 0.08 fura-2 ratio) showed significant 
difference in fura-2 ratio change (* p ˂ 0.05) compared to untreated naïve ECs (N=4, 0.995 ± 
0.16 fura-2 ratio) and naïve ECs treated with MGO 100μM and L-arginine100μM/day for 5 
days (N=4, 0.89 ± 0.08 fura-2 ratio) (Figure 67a). Such MGO-reduced fura-2 ratio change 
was significantly similar to what was shown in STZ-diabetic ECs (N=4, 0.5 ± 0.13 fura-2 
ratio) (Figure 67b). 
Moreover, naïve ECs treated with MGO 100μM/day for 5 days (N=4, 1.1 ± 0.2 fura-2 ratio) 
did not show significant difference (p ≥ 0.05) in the fura-2 ratio baseline when compared to 
naïve ECs (N=4, 0.84 ± 0.13 fura-2 ratio) and naïve ECs treated with MGO 100μM and L-
arginine100μM/day for 5 days (N= 4, 0.84 ± 0.3 fura-2 ratio) (Figure 68a). Similarly, naïve 
ECs cells treated with MGO 100μM/day for 5 days (N= 4, 1.1 ± 0.2 fura-2 ratio) did not 
show a significant difference (p ≥ 0.05) in the fura-2 ratio baseline when compared to STZ 
ECs (N= 4, 1.1 ± 0.1 fura-2 ratio) (Figure 68b). 
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Figure 67 TRPV4 induced intracellular Ca2+ elevation in the presence of MGO. MGO reduced the 4-αPDD-
induced fura-2 ratio change (a). Analysed through repeated measure one-way ANOVA with Tukey post-hoc 
test. Significance is represented as * p ˂ 0.05 compared to untreated naïve endothelial cells. Naïve endothelial 
cells treated with MGO compared to STZ ECs (b). Analysed through unpaired two-tailed Student’s t-test Non-
significance is represented as ns p ≥ 0.05. Data shown as average fura-2 ratio ± SEM. 
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Figure 68 Baseline fura-2 ratio before 4-αPDD treatment. Naïve ECs compared with naïve ECs treated with 
MGO 100μM/day for 5 days and naïve endothelial cells treated with MGO 100μM and L-arginine100μM/day 
for 5 days. Analysed through repeated measure one-way ANOVA with Tukey post-hoc test. Non-significance is 
represented as ns p ≥ 0.05 when the groups were compared with each other. (a). Naïve ECs treated with MGO 
100μM/day for 5 days compared with STZ ECs analysed through un-paired two-tailed Student’s t-test (b). Non-
significance is represented as ns p ≥ 0.05. Data shown as average fura-2 ratio ± SEM.  
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5.4.2. MGO significantly compromised the TRPV4 expression in naïve 
ECs 
As shown in Figures 58 and 59, TRPV4 was downregulated in STZ-diabetic primary aortic 
ECs. Additionally, since MGO was significantly elevated in STZ-diabetic rats’ serum (Figure 
43), therefore, control naïve primary aortic ECs were treated with MGO (100μM/day) for 5 
days and visualised under LSCM as described in section 2.7.1. As shown in Figure 69, 
TRPV4 expression was disrupted in control naïve ECs treated with MGO, showing similar 
distribution as STZ-diabetic aortic ECs. 
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Label AC-Dil-LDL eNOS antibody  AC-Dil-LDL + eNOS 
antibody 
Naïve (or 
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Figure 69. MGO effect on TRPV4 expression in primary aortic endothelial cells under laser scanning confocal 
microscope. Endothelial cells were probed with DAPI to label the nucleus in blue and marked with acetylate 
LDL (Dil-Ac-LDL) giving the cells the red colour (left: a1, b1 & c1). Anti TRPV4 primary antibody probed 
with secondary fluorescence antibody. TRPV4 showed unique distribution around the nucleus and at the edge of 
plasma membrane in naïve aortic endothelial cells (a2). STZ-diabetic endothelial cells showed disrupted TRPV4 
distribution with less fluorescence light emission (b2). Naïve endothelial cells treated with MGO (100μm/day) 
showed disrupted TRPV4 distribution with less fluorescence light emission. Images were combined to matching 
endothelial marker (red), nucleus marker (blue) and TRPV4 florescence antibody (green) (right: a3, b3 & c3) 
(200×) 488nm laser. 
146 
 
The LSCM images were quantitatively analysed through ImageJ software (version 1.46r) and 
statistically analysed through Graph Pad prism (version 5.00). As shown in Figure 70a, paired 
data showed significant TRPV4 downregulation in MGO-treated naïve ECs (N=4, ** p ˂ 
0.01, average total TRPV4 expression= 54.1 ± 6.6% vs naïve, N= 4, 100.0 ± 9.4%) 
Moreover, when the findings were pooled with STZ-diabetic ECs, control naïve ECs treated 
with MGO (100µM) for 5 days showed similar fura-2 ratio (ns p ≥ 0.05). Naïve ECs treated 
with MGO (100μm/day for 5 days) showed similar TRPV4 expression to STZ-diabetic ECs, 
and showed significant difference in TRPV4 expression compared to naïve ECs (Naïve 
treated with MGO, N=4, ** p ˂ 0.01, average TRPV4 expression= 53.6 ± 6.6% and STZ-
diabetic ECs, N=8, average TRPV4 expression= 58.9±5.8% vs naïve, N=5 average TRPV4 
expression= 100.0 ± 7.3%) (Figure 70b).  
Figure 70 MGO treatment of primary aortic ECs cultures reduces total TRPV4 expression. Paired data analysed 
through paired two-tailed Student’s t-test. Significance is represented as ** p ˂ 0.01 (a). Naïve ECs treated with 
MGO (100μm/day for 5 days) showed significant difference in TRPV4 expression compared to untreated naïve 
ECs when analysed through one-way ANOVA with Tukey post-hoc test (b). Significance is represented as ** p 
˂ 0.01 when compared with untreated naïve endothelial cells. Data shown as average percentage ± SEM. 
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5.4.3. TRPM8-induced intracellular calcium elevation was not 
significantly affected in STZ-diabetic ECs 
Previous findings showed that TRPM8-induced vasodilation was not significantly changed in 
STZ-diabetic aortic rings (Figure 56). Accordingly, fura-2 Ca2+ imaging functional study was 
conducted to investigate the TRPM8-increased [Ca2+]i in both naïve and STZ-diabetic ECs. 
Baseline readings were recorded for a minute before adding icilin (1mM) in HBS buffer. As 
shown in Figure 72, baseline ratios were not significantly different (STZ N=3, p ≥ 0.05, 1.3 ± 
0.2 fura-2 ratio vs naïve, N=3, 0.9 ± 0.1 fura-2 ratio). 
 
Figure 71 Baseline fura-2 ratio before icilin treatment. Analysed through unpaired two-tailed Student’s t-test. Non-
significance is represented as ns p ≥ 0.05. Data shown as average fura-2 ratio ± SEM.   
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Fura-2 ratio change was recorded for further 9 minutes were recorded for measuring [Ca2+]i 
through icilin treatment. Icilin-induced [Ca2+]i did not show significant difference between 
STZ-diabetic aortic ECs and naïve ECs (N=3, p ≥ 0.05, 1.2 ± 0.4 fura-2 ratio vs naïve, N=3, 
1.80 ± 0.4 fura-2 ratio) (Figure 72). 
 
Figure 72 TRPM8 induced peak fura-2 ratio change through icilin (1mM) treatment. Analysed through unpaired 
two-tailed Student’s t-test. Non-significance is represented as ns p ≥ 0.05. Data shown as average fura-2 ratio ± 
SEM. 
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Additionally, the time required for fura-2 ratio to reach the peak did not show a significant 
difference. As shown in Figure 73, STZ-diabetic ECs did not show a significant difference in 
the required time to reach fura-2 peak compared to naïve ECs (N=3, p ≥ 0.05, peak time= 190 
± 5.8 seconds vs Naïve, N=3, peak time= 152 ± 65.4 seconds). 
 
Figure 73 Peak time for icilin induced fura-2 ratio. Analysed through unpaired Student’s t-test. Non-significance is 
represented as ns p ≥ 0.05. Data shown as mean peak time ± SEM. 
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5.5. Discussion 
As an extension to the compromised TRPV4-induced vasodilation in STZ-diabetic rats’ 
aortic and mesenteric arteries shown in Figures 53-55, immunocytochemistry studies were 
conducted on primary aortic ECs in this chapter, to examine the molecular mechanism of 
TRPV4 dysfunction. The ECs were tagged with the selective marker (Dil-Ac-LDL), however, 
other antibodies are also applicable such as anti CD34 (Fina et al., 1990). Since other 
antibodies were used to target the expression of TRPV4, CAV-1 and eNOS, therefore, Dil-
Ac-LDL labelling was applied to prevent any possible cross reaction between these 
antibodies with the selective ECs antibody marker. As shown in Figure 58 and 68, TRPV4 
expression in primary aortic ECs was significantly reduced by approximately 50% in STZ-
diabetic ECs. Moreover, TRPV4 channels distribution around the nucleus and the plasma 
membrane edges was disrupted in STZ-diabetic ECs (Figure 58). These findings may explain 
the TRPV4 endothelial dysfunction in diabetes that might be attributed to TRPV4 
downregulation. Primary ECs TRPV4 downregulation match the findings of recent study by 
Monaghan et al. (2015) that showed TRPV4 downregulation in diabetic retinal microvascular 
ECs.  
Furthermore, CAV-1 was investigated in parallel with TRPV4 in the primary ECs. Caveolae 
form highly organised microdomains in the ECs plasma membrane through providing 
docking sites for numerous signalling molecules such as TRPV4, GPCR and IKca (Frank, 
Woodman, Park, & Lisanti, 2003; Garland et al., 2010). CAV-1 is a principal protein and 
marker found in the endothelial caveolae (Frank et al., 2003). Previous studies showed that 
CAV-1 is an essential component in modulating TRPV4-induced vasodilation through 
modulating TRPV4 membrane localisation (Saliez et al., 2008). Moreover, a recent study 
showed that TRPV4 is co-localised with CAV-1 and SKca in human ECs (Fritz et al., 2015). 
Therefore, CAV-1 investigation was conducted for two main purposes: to confirm the 
TRPV4-CAV-1 co-localisation in naïve ECs, and accordingly, whether CAV-1 expression is 
affected through diabetes. 
As shown in Figure 60 and 61, CAV-1 was significantly compromised by approximately 30% 
in STZ-diabetic aortic ECs. This finding match the previous study on diabetic kidneys that 
revealed CAV-1 significant reduction when compared to non-diabetic kidneys (Komers et al., 
2006). CAV-1 is an essential ECs component in mediating TRPV4-induced EDHF and hence 
causes vasodilation (Saliez et al., 2008). This was supported through CAV-1 gene deletion in 
mice mesenteric arteries which resulted in abolished EDHF-induced vasodilation (Saliez et 
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al., 2008). Additionally, diabetic kidneys showed significant reduction in CAV-1 when 
compared to non-diabetic kidneys (Komers et al., 2006). 
A previous study concluded that CAV-1 reduction is accompanied with eNOS 
downregulation (Komers et al., 2006). CAV-1 is co-localised with eNOS in bovine aortic 
endothelial cells (H. Wang et al., 2009). Accordingly, further investigations were conducted 
on eNOS in parallel with TRPV4 and CAV-1 using the same ECs batch, which showed 
similar distribution of eNOS, TRPV4, and CAV-1 in naïve primary aortic ECs (Figures 58a3, 
60a3 and 62a3) revealing the possible co-localisation of these three essential elements in 
endothelial cells plasma membrane. Moreover, eNOS showed significant downregulation in 
STZ-diabetic ECs (Figure 62 & 72). This is supported by H. Wang et al. (2009)’s findings 
that eNOS and CAV-1 are co-localised in bovine aortic ECs, and Saliez et al. (2008)’s 
conclusion of CAV-1 and TRPV4 co-localisation. Diabetic-induced eNOS and CAV-1 
downregulation might be attributed to inhibited phosphatidylinositol 3-kinase/Akt (PI3K/Akt) 
pathway since PI3K inhibitor, wortmannin was shown to inhibit the eNOS and CAV-1 
translocation to the plasma membrane (H. Wang et al., 2009). However, further studies such 
as co-immunoprecipitation are required to confirm the co-localisation of TRPV4, CAV-1 and 
eNOS in endothelial cells. 
Further studies were applied to investigate the beneficial effect of insulin on endothelial 
TRPV4, CAV-1 and eNOS. The applied insulin concentrations were similar to what was 
applied by previous studies (Cuevas, Yang, Upadhyay, Armando, & Jose, 2014; Vaidya, 
Goyal, & Cheema, 2012). As shown in Figure 58c&d and 59, primary STZ-diabetic ECs 
treated with insulin for 5 days showed significant improvement in TRPV4 expression, 
distribution and function. Such TRPV4 restored expression and distribution was in parallel 
with CAV-1 (Figure 60c&d) and eNOS restored expression and distribution (Figure 62c&d). 
As explained by H. Wang et al. (2009), insulin induces the PI3K/Akt pathway to stimulate 
eNOS and CAV-1 translocation toward the plasma membrane. Insulin induces eNOS 
palmitoylation. eNOS and CAV-1 palmitoylation is governed through Golgi’s palmitoyl acyl 
transferase, an enzyme that catalyses eNOS and CAV-1 acetylation and further translocation 
toward the plasma membrane (Hernando et al., 2006). Additionally, eNOS palmitoylation 
increases the CAV-1 coupling by 10-fold, a process that is required to optimise eNOS 
activity (Shaul et al., 1996).  
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The molecular mechanism of TRPV4 downregulation in diabetes is not fully understood. 
TRPV4 N-linked mannose glycosylation in the ER is followed by complex TRPV4 protein 
glycosylation in Golgi apparatus, both are vital post-translational modification steps for the 
channel maturation, membrane translocation and function (Lei et al., 2013). Deleting 857-838 
residues of the TRPV4 c-terminus renders the channels immature and trapped in the ER that  
culminates in TRPV4 downregulation (Lei et al., 2013). Therefore, as shown in Figures 
58b2&c2, TRPV4 was downregulated and seems to be trapped in a region that is overlapped 
with the nucleus which might be the endoplasmic reticulum. Additionally, TRPV4 
downregulation might be exacerbated through CAV-1 disruption and downregulation as 
numerous studies showed that TRPV4 co-localisation with CAV-1 is essential for TRPV4 
function to induce EDHF and vasodilation (Saliez et al., 2008; Serban, Nilius, & Vanhoutte, 
2010). These researches have suggested the importance of CAV-1 and TRPV4 co-localisation 
to maintain the TRPV4 Ca2+ required for EDHF and NO generation (Saliez et al., 2008; 
Serban et al., 2010). Moreover, the TRPV4-CAV-1-eNOS co-localisation might provide a 
cooperative functional complex (Köhler et al., 2006; Saliez et al., 2008; H. Wang et al., 
2009). ECs constitutively secrete NO which is generated from eNOS that oxidises L-arginine 
to L-citrulline (Cines et al., 1998). eNOS can be stimulated through shear stress (Lüscher & 
Barton, 1997). Moreover, increased blood shear stress activates the membrane bound PLA-2 
which generates arachidonic acid (AA) from membrane cholesterol followed by series 
reactions that yield epoxyeicosatrienoic acid (EET) generation which is a direct TRPV4 
activator (Inoue et al., 2009). These findings reveal the pivotal role of TRPV4 in regulating 
vascular tone and function through sustained endothelium Ca2+ entry that induces NO and PG 
activation and release (Watanabe et al., 2008). Additionally, TRPV4 was shown to regulate 
blood pressure (BP) in endothelium-dependent manner through enhancing calcium-influx and 
thereby generating NO and EDHF (Inoue et al., 2009; Serban et al., 2010). 
TRPV4-elevated [Ca2+]i was significantly compromised when naïve ECs were treated with 
MGO (100µM/day for 5 days) (Figure 67). Such reduction in TRPV4-mediated [Ca2+]i 
elevation was similar to the [Ca2+]i reduction shown in STZ-diabetic ECs and significantly 
less than naïve control ECs (Figure 67). Moreover, LSCM pictures showed similar TRPV4 
distribution and downregulation in STZ-diabetic ECs and naïve ECs treated with MGO 
(100µM/day for 5 days) compared to naïve control ECs’ TRPV4 (Figures 69 & 70). 
Additionally, since MGO was significantly elevated in STZ-diabetic rats’ serum (Figure 43). 
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Therefore, MGO-induced TRPV4 downregulation and dysfunction in naïve ECs might 
explain the STZ-diabetic TRPV4 downregulation in ECs.  
As previously stated, TRPV4 N-linked mannose glycosylation in the ER and protein 
glycosylation in Golgi apparatus are vital post-translational modification steps for the channel 
maturation, membrane translocation and function (Lei et al., 2013). Immature channels are 
trapped in the ER that culminates in TRPV4 downregulation (Lei et al., 2013). Therefore, as 
shown in Figure 69, TRPV4 was downregulated and seems to be trapped in a region that is 
overlapped with the nucleus which might be the ER. In eukaryotic cells, the ER provides 3 
main cellular functions: firstly, proteins folding before being transferred to the Golgi 
apparatus, secondly, ER provide a cellular Ca2+ storage, and lastly, it is a site for the synthesis 
of phospholipids, sterols and unsaturated fatty acids (FA) (Schröder, 2008). A perturbation in 
any of these functions contributes to ER stress and hence affects the overall ER performance 
(Schröder, 2008). Misfolded proteins accumulation in the ER lumen is a distinct hallmark of 
perturbation of any of the mentioned ER physiological functions (Schröder, 2008). Unlike the 
cytosolic reducing environment, the ER lumen is an oxidising environment with a high ratio 
of the reduced to oxidised glutathione (GSH:GSSG) (1-3:1), whereas the GSSG:GSH is 
approximately 50:1 in the cytoplasm (Malhotra & Kaufman, 2007). Being the primary Ca2+ 
storing organelle in the cell, enables the ER to use the Ca2+ stored in the ER lumen for both 
protein-folding reactions and protein chaperone functions (Malhotra & Kaufman, 2007). 
Moreover, N-linked glycosylation is a post-translational modification process performed in 
the ER (Malhotra & Kaufman, 2007). N-linked glycosylation is coupled with protein folding 
and chaperone interactions to ensure that only the properly folded proteins are released from 
the ER compartment (Malhotra & Kaufman, 2007). ER Ca2+ depletion induces protein 
misfolding (Lodish, Kong, & Wikstrom, 1992) and inhibits the ER-Golgi trafficking (Lodish 
& Kong, 1990). Ca2+ depletion from ER stores induces the accumulation of unfolded proteins 
through inhibiting endoplasmic reticulum-associated degradation (ERAD) due to decreased 
endoplasmic reticulum-a(1,2)mannosidase activity (Schröder, 2008). MGO induces ER Ca2+ 
release that contributes to the initial and the sustained [Ca2+]i elevation (Jan, Chen, Wang, & 
Kuo, 2005). Therefore, chronic MGO elevation, as shown in STZ-induced diabetes (Figure 
43) might lead to ER Ca2+ stores perturbation that culminates in protein misfolding and ER 
stress and hence causes significant decrease in TRPV4 expression through MGO-treatment 
(Figures 69 & 70). 
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Misfolded proteins form hydrophobic patches that inhibit other proteins, especially the 
proteins that act through interacting with other proteins such as transcription factors 
(Schröder, 2008). To counteract the misfolded proteins complications, the ER monitors the 
protein misfolding through UPR’s numerous transmembrane proteins such as protein kinase 
receptor (PKR)-like eukaryotic initiation factor 2 kinase (PERK) (Schröder, 2008). Activated 
PERK phosphorylates the eukaryotic initiation factor2α (eIF2α), a transcription factor which 
is inhibited by phosphorylation and accordingly, inhibiting new protein translation and hence 
reduces the ER stress (Marciniak & Ron, 2006). Phosphorylated eIF2α activates a 
downstream orchestrated cascade including the transcription factor ATF4 that induces the 
expression of other transcription factors such as GADD34 which relieves translational 
attenuation and ERO1α which promotes oxidative protein folding (Marciniak & Ron, 2006). 
Antioxidants buffer the increased ROS produced by ERO1α to maintain the redox status of 
ER (Marciniak & Ron, 2006). Since MGO induces ER Ca2+ release that contributes to the 
initial and the sustained intracellular Ca2+ elevation (Jan et al., 2005). Additionally, chronic 
MGO elevation might lead to ER Ca2+ stores perturbation that culminates in ER stress (Jan et 
al., 2005). Accordingly, when primary aortic ECs were incubated with MGO (100μM), 
TRPV4-induecd rise in [Ca2+]i was significantly reduced (Figure 67) which was in parallel 
with the significant TRPV4 downregulation (Figure 69 & 79). By contrast, when L-arginine 
(100μM) was added to the primary aortic ECs in the presence of MGO (100μM), TRPV4-
induecd rise in [Ca2+]i was significantly restore (Figure 67). This might be attributed to 2 
main factors: L-arginine ability to scavenge MGO (I. Dhar et al., 2012), in addition to the 
ability of L-arginine to facilitate the maintenance of ER redox status (Marciniak & Ron, 
2006) and hence relieves ER stress induced by MGO-induced OS which was shown in Figure 
69 and 79, and therefore, TRPV4 function might be restored when ECs were incubated with 
L-arginine in the presence of MGO (Figure 67). To the best of our knowledge, this is the first 
study that investigates the MGO-compromised TRPV4 function in ECs. 
Since pre-contracted diabetic aortic rings were relaxed through icilin CRC without any 
significant difference from non-diabetic aortic rings (Figure 56). Moreover, fura-2 Ca2+ 
imaging studies did not show significant difference in TRPM8-mediated Ca2+ influx in 
primary ECs isolated from either naïve control or STZ-rats’ ECs (Figure 72). This supports 
the previous findings (Figure 28 & 39) that TRPM8 might mediate vasodilation through 
different pathways to TRPV4 which was significantly compromised in diabetes. 
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To sum up, TRPV4 was significantly downregulated in STZ-diabetic ECs. Such 
downregulation was accompanied with TRPV4 dysfunction characterised by compromised 
TRPV4-induced vasodilation and reduced TRPV4-mediated [Ca2+]i elevation. STZ-diabetic 
ECs treated with insulin ex vivo showed restored TRPV4 function and expression. 
Additionally, CAV-1 and eNOS were both downregulated in parallel with TRPV4. STZ-
diabetic ECs treated with insulin ex vivo showed restored CAV-1 and eNOS expression, 
revealing that TRPV4-CAV-1-eNOS might form an endothelial functional complex. Since 
the main objective was to examine the effect on insulin treatment on STZ-diabetic primary 
aortic ECs, therefore insulin was only applied to the STZ-diabetic primary aortic ECs. 
However, a control of naïve primary aortic ECs treated with insulin would show whether 
insulin would provide beneficial effect to naïve primary aortic ECs. 
MGO was elevated in STZ-diabetic rats’ serum to approximately 100µM. Incubating non-
diabetic ECs with MGO (100µM/day for 5 days) compromised TRPV4 expression and 
function similar to what was shown in STZ-diabetic ECs. L-arginine showed vascular 
protection properties as a possible MGO scavenger through restoring ECs’ TRPV4 function. 
Chronic MGO elevation as shown in STZ-induced diabetes might contribute to ER stress and 
hence causes protein misfolding. Not like TRPV4, TRPM8 function was not significantly 
affected in STZ-diabetic ECs. However, another group of naïve primary aortic ECs treated 
with L-arginine only would provide an idea of whether L-arginine treatment could induce 
TRPV4 expression.  
In conclusions, insulin is might be involved in regulating vascular function and endothelial 
protein expression such as TRPV4, CAV-1 and eNOS. MGO might be a pivotal therapeutic 
target to manage diabetes complications. L-arginine was shown to act as a scavenger for 
MGO and hence it might play a major therapeutic strategy for MGO-related diabetic 
complications such as endothelial dysfunction (Bierhaus et al., 2012; A. Dhar et al., 2010). 
Therefore, the next chapter will cover further vascular studies conducted on primary aortic 
smooth muscle cells (ASMCs) as a component of tunica media and the effect of MGO on 
ASMCs. 
1. Ch1 
2. Ch2 
3. Ch3 
4. Ch4 
5. Ch5 
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6. Chapter 6: The effect of diabetes on nitric oxide production and TRPV4 
expression in primary rat ASMCs 
6.1. Introduction 
According to the last two chapters, both TRPV4-induced vasodilation and [Ca2+]i elevation in 
primary aortic ECs were significantly compromised in STZ-induced diabetes. Such 
significant TRPV4 dysfunction was accompanied with significant eNOS downregulation. 
Moreover, TRPV4-induced vasodilation was endothelium-dependent and independent, as the 
endothelium removal did not completely abolish the TRPV4-induced vasodilation. TRPV4 
expression in MEPs was suggested to induce VSM hyperpolarisation through Kca activation 
and hence inducing vasodilation (Bagher & Garland, 2014). Moreover, the VSM’s calcium-
independent NOS isoform, iNOS releases NO that was shown to reduce the NA-induced 
vasoconstriction by activating Kca channels (Hall et al., 1996). Moreover, other studies 
showed that iNOS expression through LPS infusion reduces the NA-induced vasoconstriction 
through cGMP pathway (Gray et al., 1991; C.-C. Wu, Szabo, Chen, Thiemermann, & Vane, 
1994). The blood vessels’ hyporeactivity to NA was L-arginine-dependent, thus when 
extracellular L-arginine increases, the vascular reactivity to NA decreases (Schott, Gray, & 
Stoclet, 1993). Accordingly, the aim of this chapter is to investigate the influence of diabetes 
on iNOS and TRPV4 expression in primary ASMCs. iNOS was induced through incubating 
ASMCs with LPS and interferon gamma (IFN-γ) to induce inflammation and NO release 
(Arnal et al., 1999; Uemura et al., 2002).  
The main objectives of these experiments were to investigate whether iNOS-generated NO 
from primary ASMCs was influenced by STZ-induced diabetes, through SDS-PAGE 
Western blotting and the Griess assay to measure iNOS expression and function, respectively. 
Moreover, further investigations were conducted on the effect of MGO (100μM) on iNOS 
expression and NO release, and to investigate if L-arginine was able to counteract the MGO 
effect. Moreover, TRPV4 expression was studied through SDS-PAGE Western blotting. 
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6.2. Materials and methods 
6.2.1. Primary aortic smooth muscle cells studies 
As described in section 2.5, primary aortic smooth muscle cells (ASMCs) were isolated to 
investigate iNOS and TRPV4 expression. iNOS was stimulated to release NO through 
incubating a 100% confluent naïve (or STZ-diabetic) primary ASMCs with IFN-γ (100IU/ml) 
and LPS (100μg/ml) for 24 hours. To study the effect of MGO on iNOS expression and NO 
release, naïve ASMCs were treated with MGO representing the pathological and 
physiological concentration (100 and 10µM, respectively) as well as without MGO (positive 
control) in addition to untreated cells (negative control), and ASMCs treated with IFN-γ 
(100IU/ml) and LPS (100μg/ml) with MGO (100µM) and L-arginine (100µM) for 24 hours. 
After being treated, the ASMCs cultures were incubated at 37°C CO2 5% for 24 hours. Total 
nitrite (NO2) was estimated through the Griess assay. The Griess assay was conducted for 
measuring NO indirectly through total NO2 released from ASMCs. A total NO2 standard 
curve was used to estimate the samples total NO2 (Figure 74). The reaction based on 
oxidising NO into NO2 from 100µl sample from the well which was then added with 100µl 
Griess mixed reagents A and B (1:1 Griess reagents ratio), Sulfanilamide and N-1-
naphthylethylenediamine, respectively. The reaction generates a pink azo dye and its 
intensity is proportional to the NO2 concentration. The total NO2 was estimated through an 
automated spectrophotometer at 540nm (Coneski & Schoenfisch, 2012). Afterward, the 
ASMCs cultures were lysed for BCA to estimate the required volume of the cell lysate to 
load 20μg total proteins for western blotting as described in section 2.8. 
Total TRPV4 expression in ASMCs was studied through growing the ASMCs primarily from 
the aortic rings in a six well plate. After 3-5 days, the wells become confluent and the cells 
were lysed and the cells lysate samples were studied through SDS-PAGE Western blotting for 
TRPV4 expression level as described in section 2.8.1. 
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Figure 74. Griess assay standard curve. Seven different standard solutions of sodium nitrite in complete culture 
media (0, 10, 20, 30, 40, 50 and 100nmol/ml) were read at 540nm wavelength. The linear equation was applied 
to estimate the sample concentration (x). The blue dotted line showed trend line robust fit. 
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6.3. Results 
6.3.1. Total NO2 release was significantly elevated after incubating 
ASMCs with IFN-γ and LPS for 24 hours 
A time course study was conducted to estimate the suitable required time for iNOS induction. 
Incubation time points were 1, 3, 6 and 24 hours. iNOS induction was evaluated through total 
NO2 measurement. As shown in Figure 75, incubating ASMCs with IFN-γ (100IU/ml) and 
LPS (100μg/ml) for 24 hours was the most suitable time point to induce iNOS. Incubating 
ASMCs with IFN-γ (100IU/ml) and LPS (100μg/ml) for 24 hours was shown to significantly 
induce NO release which was measured through total NO2 (N=3, total NO2= 3.0 ± 
1.0nmol/ml) when compared to negative control and the other groups of shorter time points 
(1-6 hours) or ASMCs treated with LPS only. LPS only groups were treated with LPS 
(100μg/ml) in cell culture complete media. The negative control was incubated with cell 
culture complete media only for 24 hours. 
 
Figure 75. Time course study of total nitrite (NO2) production from ASMCs. Analysed through one-way 
ANOVA with Tukey post-hoc test. ASMCs treated with IFN-γ (100IU/ml) and LPS (100μg/ml) compared with 
LPS only groups were treated with LPS (100μg/ml) and untreated ASMCs (negative control). Significance is 
represented as *** P ˂ 0.001 compared with IFN-γ (100IU/ml) and LPS (100μg/ml) (positive control). Data 
shown as average total nitrite ± SEM (Every group, N= 3). 
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According to the previous time course finding (Figure 75), NO release and iNOS expression 
from primary ASMCs isolated from naïve STZ-diabetic rats were compared. iNOS was 
detected through SDS-PAGE western blotting (Figure 76 & 86a). STZ-diabetic ASMCs were 
incubated with IFN-γ and LPS (positive STZ) for 24 hours and showed a significant 
reduction in iNOS expression when compared to naïve ASMCs’ (Figure 77b). The Griess 
assay showed significant suppression of total NO2 release when STZ-diabetic ASMC were 
incubated with IFN-γ and LPS for 24 hours compared to naïve ASMCs (Figure 77c). 
 
Figure 76. SDS-PAGE Western blotting for iNOS expression in STZ-diabetic and naïve ASMCs. iNOS was 
detected in positive control (IFN-γ and LPS) lanes but not in negative control (untreated). Positive control (IFN-
γ and LPS) lanes were loaded with cell lysate that corresponds to 20μg. iNOS band was matched to 
approximately 135kDa through using the 140kDa band shown in protein ladder. β-actin protein was detected at 
approximately 43kDa just above the 40kDa band shown in protein ladder.  
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When the Western blot gels were analysed through densitometric analysis as describe in 
section 2.7, iNOS expression in STZ-diabetic rats’ ASMCs was significantly suppressed (N= 
5, * p ˂ 0.05, average iNOS expression= 56.1 ± 13.4% vs naïve ASMCs’ average iNOS 
expression= 100 ± 4.4%) (Figure 77b). Additionally, total NO2 released from STZ-diabetic 
rats’ ASMCs was significantly reduced (N= 6, * p ˂ 0.05, total NO2= 37.02 ± 13.8% vs naïve 
ASMCs’ total NO2= 100 ± 18.0%) (Figure 77c). 
Figure 77. iNOS expression and total nitrite (NO2) released from STZ-diabetic and naïve ASMCs. Western 
blotting of rats’ aortic smooth muscle cells’ (ASMCs) inducible nitric oxide synthase (iNOS) (a). iNOS 
expression in STZ-diabetic and naïve ASMCs (b). Total NO2 released from STZ-diabetic rats’ and naïve 
ASMCs (c). Data is presented as mean ± SEM. Significance is represented as * p ˂ 0.05 versus naive analyses 
by unpaired two-tailed Student’s t-test. 
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6.3.2. MGO studies on ASMCs 
 MGO significantly increased the NA-induced vasoconstriction 
A previous report showed that the VSM’s calcium-independent NOS isoform, iNOS releases 
NO that was shown to reduce the NA-induced vasoconstriction through activating Kca 
channels (Hall et al., 1996). Moreover, other studies showed that iNOS expression through 
LPS infusion reduces the NA-induced vasoconstriction through cGMP pathway (Gray et al., 
1991; C.-C. Wu et al., 1994). The blood vessels’ hyporeactivity was enhanced through L-
arginine incubation (Schott et al., 1993). 
Since, MGO was elevated in STZ serum (Figure 43), and a previous study revealed that 
MGO inhibits the calcium-dependent NOS form, eNOS phosphorylation and activation (A. 
Dhar et al., 2010). Moreover, as iNOS and eNOS are NOS isoforms which are expressed 
predominantly in VSMCs and ECs, respectively. Therefore, it was hypothesised that freshly 
isolated STZ-rat aortic rings may show higher vasoconstriction than naïve aortic rings when 
treated with NA EC80 (300nM), due to the effect of MGO to reduce NO production from 
iNOS (Hall et al., 1996; C.-C. Wu et al., 1994). 
Aortic rings were treated with NA (300nM) and showed time-dependent increased 
vasoconstriction. NA-induced vasoconstriction was significantly elevated in the 3rd week 
STZ-diabetic rats (N= 5, * p ˂ 0.05, vasoconstriction= 0.32 ± 0.03g), the 4th week STZ-
diabetic rats (N= 7, ***P˂0.001, vasoconstriction= 0.36 ± 0.04g) and the 5th week STZ-
diabetic rats (N= 4, **P˂0.01, vasoconstriction= 0.44 ± 0.01g) compared with control naïve 
rats (N= 12, vasoconstriction= 0.29 ± 0.02g). However, NA-induced vasoconstriction did not 
show significant difference (ns p ≥ 0.05) in the first 2 weeks after STZ-induced diabetes 
induction (1st week STZ-rats, N= 4, ns p ≥ 0.05, , vasoconstriction= 0.31 ± 0.01g, 2nd week 
STZ rats ns p ≥ 0.05, N= 6, , vasoconstriction= 0.316 ± 0.02g vs control naive aortic rings, 
N= 12, , vasoconstriction= 0.29 ± 0.02g) (Figure 79a).  
To investigate the iNOS contribution from smooth muscle cells in counteracting 
vasoconstriction, aortic rings were denuded from endothelium and incubated for 30 minutes 
with L-NAME (100μM) before being treated with NA (300nM). To ensure that the 
endothelium removal was effective in the denuded tissue we tested this by measuring the 
carbachol induced vasodilation of NA induced tension in control and denuded tissue (Figure 
91). As expected the carbachol induced vasodilation was almost completely abolished in the 
denuded rings consistent with endothelium removal. Endothelium denuding showed 
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significant reduction in carbachol-induced vasodilation (N=5, *** p ˂ 0.001, Emax= -
16.6±4.8% vs intact endothelium carbachol induced-vasodilation Emax= -68.4±2.3%)  
(Figure 91). However, the EC50 was not significantly influenced (N=5, p ≥ 0.05, EC50= 3.8 
± 0.6μM and vs intact endothelium carbachol induced-vasodilation EC50= 1.8 ± 1.1μM) 
(Figure 78). 
Figure 78. Carbachol cumulative concentration response curve when endothelium was denuded. Analysed 
through two-way ANOVA with Bonferroni post-hoc test. Significance is shown as *** p ˂ 0.001 versus 
carbachol-induced vasodilation in intact endothelium aortic rings (N= 5). 
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Endothelial denuded rats’ aortic rings incubated with L-NAME (100μM) were compared to 
untreated endothelial denuded aortic rings and intact aortic rings contraction. Denuded naïve 
aortic rings incubated with L-NAME showed significantly higher vasoconstriction compared 
to untreated denuded control aortic rings (** p ˂ 0.01). Endothelium denuded control aortic 
rings did not show a significant difference when compared to intact aortic rings 
vasoconstriction (ns P ≥ 0.05) (denuded control rings incubated with L-NAME, N= 4, ** p ˂ 
0.01, vasoconstriction= 0.47 ± 0.05g vs denuded aortic rings N= 7, vasoconstriction= 0.30 ± 
0.02g and *** p ˂ 0.001 vs intact aortic rings, N= 12, vasoconstriction= 0.29 ± 0.02g) 
(Figure 79b). 
Figure 79. Fresh rats’ aortic rings contractility with NA EC80 (300nM). STZ-diabetic aortic rings 
constricted through NA (300nM) compared with naïve aortic rings constriction (a). Denuded control aortic 
rings incubated with L-NAME compared to untreated denuded aortic rings and intact aortic rings (b). 
Analysed through one-way ANOVA and Tukey post-hoc test. Significance is represented as * p ˂ 0.05, ** 
p ˂ 0.01 and *** p ˂ 0.001. Data is presented as mean ± SEM. 
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 MGO significantly suppressed iNOS expression and total NO2 release in 
ASMCs 
STZ-rat primary ASMCs showed significant reduction in NO2 release and iNOS expression 
following IFN-γ and LPS induction (Figure 77). Additionally, MGO was significantly 
increased in STZ-diabetic rats’ serum (Figure 43). Therefore, the effect of MGO on NO2 
release and iNOS expression in naïve rat primary ASMCs was investigated. When ASMCs 
were incubated with IFN-γ, LPS and MGO (100µM) for 24 hours it showed significant iNOS 
suppression (***p ˂ 0.001) but not with MGO (10µM) (ns p ≥ 0.05) compared to ASMCs 
incubated with IFN-γ and LPS only. Incubating ASMCs with LPS and IFN-γ for 24 hours in 
addition to MGO 100µM for 2 hours causes non-significant reduction to iNOS expression (ns 
p ≥ 0.05). When ASMCs were incubated with IFN-γ, LPS and MGO (100µM) for 24 hours 
showed significant iNOS suppression (N= 9, *** p ˂ 0.001, average iNOS expression= 35.3 
± 3.7% vs positive control, N= 9, average iNOS expression= 100 ± 7.6%) but not with MGO 
(10µM) (N= 6, ns p ≥ 0.05, 113.4±6.3%). Incubating ASMCs with IFN-γ and LPS for 24 
hours with MGO (100µM) added for 2 hours causes non-significant reduction to iNOS 
expression (N= 5, ns p ≥ 0.05, average iNOS expression= 73.4±14.5% vs positive control, 
N= 5, average iNOS expression= 100 ± 7.6%). When ASMCs were incubated with media 
only it showed significant iNOS suppression (N= 9, *** p ˂0.001, average iNOS expression= 
16.3 ± 3.0% vs positive control, N= 9, average iNOS expression= 100 ± 7.6%) (Figure 81b). 
We next performed Griess assay to see if the changes in iNOS expression resulted in changes 
in total NO2 release. The Griess assay showed significant suppression of NO2 release when 
ASMC were incubated with IFN-γ and LPS with MGO 100µM for 24 hours (*** p ˂ 0.001) 
but not with MGO (10µM) (ns p ≥ 0.05). Incubating ASMC with LPS and IFN-γ for 24 hours 
with MGO (100µM) added for 2 hours did not cause significant reduction to NO2 release (ns 
p ≥ 0.05). The Griess assay showed significant suppression of total NO2 release when ASMC 
were incubated with IFN-γ and LPS with MGO (100µM) for 24 hours (N= 9 *** p ˂ 0.001, 
total NO2= 2.8 ± 15.1% vs positive control, N=9, total NO2= 100 ± 17.8%) but not with 
MGO 10µM (N= 6, ns p ≥ 0.05, total NO2= 84.2 ± 16.2% vs positive control, N=9, total 
NO2= 100 ± 17.8%). Incubating ASMC with LPS and IFN-γ for 24 hours with MGO 100µM 
added for 2 hours causes non-significant reduction to total NO2 release (N=5, ns p ≥ 0.05, 
total NO2= 62.3 ± 24.4% vs positive control, N=9, total NO2= 100 ± 17.8%) (Figure 81c). 
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Figure 80. SDS-PAGE western blotting for iNOS expression in naïve ASMCs treated with MGO. Each lane 
was loaded with cells lysate that corresponds to 20μg. iNOS band was matched to approximately 135kDa 
through using the 140kDa band shown in protein ladder. β-actin protein was detected at approximately 43kDa 
just above the 40kDa band shown in protein ladder. The 1st lane was loaded with lysate of untreated ASMCs, 
the 2nd lane positive control of ASMCs incubated with IFN-γ (100IU/ml) and LPS (100μg/ml) for 24 hours. 
The 3rd lane of ASMCs incubated with IFN-γ (100IU/ml), LPS (100μg/ml) and MGO (100μM) for 24 hours. 
The 4th lane of ASMCs incubated with IFN-γ (100IU/ml), LPS (100μg/ml) and MGO (100μM) for 2 hours. The 
5th lane of ASMCs incubated with IFN-γ (100IU/ml), LPS (100μg/ml) and MGO (10μM) for 24 hours. 
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Figure 81. iNOS expression and NO2 production in the presence of MGO physiological (10µM) and pathological 
(100µM) concentrations. SDS-PAGE western blotting showing iNOS bands expression (a). iNOS expression from 
ASMCs incubated with IFN-γ, LPS and MGO 10µM for 24 hours and 100µM for 24 hours and 2 hours compared 
with positive and negative controls ASMCs (b). Total NO2 released from ASMCs incubated with IFN-γ, LPS and 
MGO 10µM for 24 hours and 100µM for 24 hours and 2 hours compared with positive and negative controls 
ASMCs (c). Data is presented as mean ± SEM. Significance is represented as *** p ˂ 0.001 when compared with 
positive control by one-way ANOVA with Tukey post-hoc test. 
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 L-arginine restores MGO-suppressed iNOS inhibition 
As shown in Figure 52, L-arginine (100μM) restored the endothelial function which was 
impaired through MGO (100μM). Moreover, L-arginine (100μM) restored the TRPV4 function 
which was suppressed through MGO (100μM) (Figure 68). Therefore, further confirmatory 
study was conducted to investigate the ability of L-arginine to restore the MGO-suppressed 
iNOS expression. L-arginine (100μM) was added to the ASMCs in addition to IFN-γ 
(100IU/ml), LPS (100μg/ml) and MGO (100μM) and the effect of L-arginine was analysed 
against untreated negative control, positive control (ASMCs treated with IFN-γ and LPS only) 
and positive control added with MGO (100μM) only. L-arginine was applied (100μM) at a 
concentration that is within the range of normal plasma L-arginine concentration (60-140μM) 
(Schwedhelm et al., 2008). 
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Figure 82. SDS-PAGE western blotting for iNOS expression in naïve ASMCs treated with MGO and L-arginine. 
Each lane was loaded with cells lysate that corresponds to 20μg. iNOS band was matched to approximately 
135kDa through using the 140kDa band shown in protein ladder (the first lane on left). β-actin protein was detected 
at approximately 43kDa just above the 40kDa band shown in protein ladder. The 1st lane was loaded with lysate 
of ASMCs incubated with IFN-γ (100IU/ml), LPS (100μg/ml), MGO (100μM) and L-arginine (100μM) for 24 
hours. The 2nd lane was loaded with ASMCs incubated with IFN-γ (100IU/ml), LPS (100μg/ml) and MGO 
(100μM) for 24 hours. The 3rd lane was loaded with ASMCs lysate of positive control of ASMCs incubated with 
IFN-γ (100IU/ml) and LPS (100μg/ml) for 24 hours. The 4th lane was loaded with lysate of untreated ASMCs 
(a). For the second membrane, the 1st lane was loaded with lysate of ASMCs lysate of positive control of ASMCs 
incubated with IFN-γ (100IU/ml) and LPS (100μg/ml) for 24 hours. The 2nd lane was loaded with untreated 
ASMCs lysate. The 3rd lane was loaded with cell lysate of ASMCs treated with IFN-γ (100IU/ml), LPS 
(100μg/ml) and metformin (10μM) whereas the 4th lane was loaded with ASMCs treated with metformin (10μM) 
only. The 5th lane was loaded with cell lysate of ASMCs treated with IFN-γ (100IU/ml), LPS (100μg/ml) and L-
arginine (100μM) whereas the 6th lane was loaded with ASMCs treated with L-arginine (100μM) only (b). 
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iNOS expression and total NO2 production were measured to evaluate the effect of L-arginine 
on MGO. ASMCs incubated with IFN-γ, LPS and MGO (100µM) for 24 hours showed 
significant iNOS suppression compared with L-arginine (100µM) co-treatment (N=4, *** p ˂ 
0.001, average iNOS expression= 33.9 ± 7.4% vs IFN-γ and LPS with MGO and L-arginine, 
average iNOS expression= 86.1 ± 7.7%). ASMCs treated with IFN-γ and LPS with MGO 
(100µM) and L-arginine (100µM), and ASMCs treated with IFN-γ, LPS and L-arginine 
(100µM) did not show significant difference in iNOS expression when compared with 
positive control ASMCs treated with IFN-γ and LPS only (N=4, ns p ≥ 0.05, average iNOS 
expression= 86.1 ± 7.7%, ASMCs treated with IFN-γ, LPS and L-arginine , N=3, ns p ≥ 0.05, 
average iNOS expression= 124.4 ± 6.7% vs positive control, average iNOS expression= 
100.0 ± 3.5%). ASMCs treated with IFN-γ and LPS with MGO (100µM) and L-arginine 
(100µM) showed significantly iNOS downregulation compared with ASMCs treated with 
IFN-γ, LPS and L-arginine (100µM) (N=4, * p ˂ 0.05, average iNOS expression= 86.1 ± 
7.7% vs ASMCs treated with IFN-γ, LPS and L-arginine, N=3, average iNOS expression= 
124.4 ± 6.7%) (Figure 83b). 
Griess assay data showed significant reversal of total  NO2 release when ASMCs were 
incubated with L-arginine (100µM), IFN-γ, LPS with MGO (100µM) for 24 hours (IFN-γ 
and LPS with MGO, N=4, ** p ˂ 0.01, total NO2= 4.75±4.75% vs IFN-γ and LPS with MGO 
and L-arginine, total NO2= 125.7 ± 34.4%). ASMCs treated with IFN-γ and LPS with MGO 
(100µM) and L-arginine (100µM), and ASMCs treated with IFN-γ, LPS and L-arginine 
(100µM) did not show significant difference in total NO2 production when compared with 
positive control ASMCs treated with IFN-γ and LPS only (N=4, ns p ≥ 0.05, total NO2= 
125.7 ± 34.4%, ASMCs treated with IFN-γ, LPS and L-arginine, N=3, ns p ≥ 0.05, total 
NO2= 146.0±7.6% vs positive control, total NO2= 100.0 ± 26.5%). Co-incubating ASMCs 
with IFN-γ, LPS, MGO (100µM) and L-arginine (100µM) did not show significant difference 
in total NO2 released compared with ASMCs treated with IFN-γ, LPS and L-arginine (N=4, 
ns p ≥ 0.05, total NO2= 125.7±34.4% vs ASMCs treated with IFN-γ, LPS and LA, N=3, ns p 
≥ 0.05, total NO2= 146.0 ± 7.6%). L-arginine incubation did not induce iNOS expression (N= 
3, average iNOS expression= 21.1 ± 9.7% and total NO2= 12.6 ± 6.3%) (Figure 83c). 
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Figure 83. L-arginine effect on MGO in naïve ASMCs cultures. iNOS expression and NO2 production induced 
by IFN-γ and LPS with L-arginine (LA) with/without MGO. SDS-PAGE western blotting showing iNOS bands 
expression (9a). iNOS expression from ASMCs incubated with IFN-γ, LPS and L-arginine (100μM) in the absence 
and presence of MGO (100µM) for 24 compared with negative and positive control ASMCs, and with L-arginine 
incubated ASMCs only (b). Griess assay of total NO2 released from ASMCs incubated with IFN-γ, LPS and L-
arginine (100μM) in the absence and presence of MGO 100µM for 24 compared with negative and positive control 
ASMCs, and L-arginine incubated ASMCs only (c). Data is presented as mean ± SEM. Significance is represented 
as *** p ˂ 0.001 when compared with positive control (IFN-γ and LPS) or IFN-γ + LPS + MGO (100µM) treated 
ASMCs by one-way ANOVA with Tukey post-hoc test. 
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 MGO suppressed iNOS expression through inhibiting Akt 
phosphorylation 
Previous studies found that protein kinase B (Akt) phosphorylation is essential for IFN-γ/LPS-
induced iNOS expression in VSMCs (Hattori et al., 2003). Moreover, the phosphorylation of 
MAPK p38 is involved in insulin-induced iNOS expression in VSMCs (Begum & Ragolia, 
2000). According to these studies, to decipher the mechanism through which iNOS expression 
was inhibited by MGO, levels of phospho-Akt (Ser473) and phospho-p38 (Thr180/Tyr182) 
were investigated to see whether they were affected by MGO (100µM) incubation. When 
ASMCs were incubated with IFN-γ, LPS and MGO (100µM) for 24 hours it showed a 
significant reduction in p-Akt (** p ˂ 0.01) compared to the level of p-Akt induced by IFN-γ 
and LPS (N=3, ** p ˂ 0.01, average p-Akt expression= 31.7±12.0% vs positive control, N=3, 
average p-Akt expression= 100±18.5%). When ASMCs were treated with IFN-γ and LPS, it 
showed significant increase in p-Akt (N=3, * p ˂  0.05, average p-Akt expression= 100 ± 18.5% 
vs negative untreated ASMCs, N=3, average p-Akt expression= 46.1 ± 13.2%) (Figure 84b). 
Figure 84. The effect of MGO (100µM) on IFN-γ and LPS-induced Akt phosphorylation (p-Akt). SDS-PAGE 
western blotting showing p-Akt expression bands (a). P-Akt expression from ASMCs incubated with IFN-γ, LPS 
and MGO (100µM) for 24 hours compared with positive and negative control ASMCs (b). Data is presented as 
mean ± SEM. Significance is represented as * p ˂ 0.05 and ** p ˂ 0.01 compared with positive control (IFN-γ + 
LPS) by repeated measures one-way ANOVA with Tukey post-hoc test. 
However, when ASMCs were incubated with IFN-γ, LPS and MGO (100µM) for 24 hours, 
p-p38 levels were not changed (N= 3, ns p ≥ 0.05, average p-p38 expression= 85.0 ± 28.3% 
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vs positive control, N= 3, average p-p38 expression= 100 ± 25.2%). When ASMCs were 
incubated with media only it did not show significant p-p38 suppression (N= 3, ns p ≥ 0.05, 
average p-p38 expression= 90.6 ± 33.7% vs positive control, N= 3, average p-p38 
expression= 100 ± 25.2%) (Figure 85b). 
Figure 85. The effect of MGO (100µM) on IFN-γ and LPS-induced p38 phosphorylation (p-p38). SDS-PAGE 
western blotting showing p-p38 expression bands (a). P-p38 expression from ASMCs incubated with IFN-γ, LPS 
and MGO (100µM) for 24 hours compared with positive and negative control ASMCs. Data is presented as mean 
± SEM. Non significance is represented as ns p ≥ 0.05 compared with positive control (IFN-γ + LPS) by repeated 
measures one-way ANOVA with Tukey post-hoc test. 
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6.3.3. TRPV4 was significantly downregulated in STZ-diabetic ASMCs 
ASMCs’ TRPV4 expression was studied since TRPV4 showed partial endothelium-
independent vasodilation (Figure 33) and aortic endothelial TRPV4 was significantly 
downregulated in STZ-diabetic rats (Figure 58 & 68). SDS-PAGE western blotting detected 
TRPV4 band at approximately 98kDa (Figure 86).  
Figure 86. SDS-PAGE western blotting for TRPV4 expression in naïve and STZ-diabetic ASMCs. Each lane 
was loaded with cells lysate that corresponds to 20μg. TRPV4 band was matched to approximately 98kDa 
through using the 100kDa band shown in protein ladder. β-actin protein was detected at approximately 43kDa 
just above the 40kDa band shown in protein ladder. The 1st membrane was loaded with naïve cells lysate 
(membrane 1). The second membrane (left) was loaded with STZ-diabetic primary ASMCs lysate and 1 naïve 
primary ASMCs lysate (membrane 2). 
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When the Western blot gels were analysed through densitometric analysis as describe in 
section 2.7, TRPV4 expression in STZ-diabetic rats’ ASMCs was significantly suppressed 
(N=5, ** p ˂ 0.01, average TRPV4 expression= 56.2 ± 5.4% vs naïve ASMCs’ average 
TRPV4 expression= 100 ± 8.8%) (Figure 87b). 
Figure 87. TRPV4 expression in naïve and STZ-diabetic ASMCs. Western blotting of rats’ aortic smooth 
muscle cells’ (ASMCs) TRPV4 (a). TRPV4 expression in streptozotocin (STZ)-diabetic rats’ ASMCs was 
significantly suppressed (b). Data is presented as mean ± SEM. Significance is represented as ** p ˂ 0.01 by 
unpaired two-tailed Student’s t-test. 
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6.4. Discussion 
In this chapter, the expression of both iNOS and TRPV4 in rat primary ASMCs was studied 
through SDS-PAGE Western blotting. Significant iNOS downregulation was shown in STZ-
rats’ ASMCs (Figure 77). According to this finding, and in addition to the previous findings 
of eNOS downregulation (Figures 62 & 63), it is suggested that both endothelium-dependent 
and endothelium-independent NOS function might be significantly compromised in diabetes. 
A previous study showed that iNOS-derived NO plays a preventive role against increased 
vasospastic responses that is associated with arteriosclerosis (Fukumoto et al., 1997). 
Moreover, NOS blockade through L-NAME (100μM) showed significant increase in 
vasoconstriction tension in rat middle cerebral artery (McNeish, Altayo, & Garland, 2010). 
Such exaggerated vasoconstriction was reproduced in endothelial denuded control aortic 
rings incubated with L-NAME (100μM) that functionally inhibits NOS from releasing NO 
(Figure 79b). Additionally, since endothelium and adventitia were removed, therefore iNOS 
was supposed as the predominant NOS isoform in the endothelium denuded aortic rings 
(Figure 79b). Therefore, applying the available non-selective NOS inhibitor, L-NAME to the 
adventitia-cleaned and endothelium-denuded aortic rings was suggested to block the 
predominant NOS isoform, iNOS (Schott et al., 1993). STZ-diabetic rats’ aortic rings showed 
significant increase in NA-induced vasoconstriction than vehicle control aortic rings (Figure 
79a). Western blotting data showed significant reduction in iNOS expression from STZ-
diabetic ASMCs stimulated with IFN-γ and LPS (Figure 77). These findings were supported 
by a previous study which revealed that endothelium denuding did not increase 
phenylephrine-induced vasoconstriction in rat small mesenteric arteries (Dora, Hinton, 
Walker, & Garland, 2000). Moreover, in endothelium intact rat mesenteric arteries, L-NAME 
(100μM) showed significant increase in phenylephrine-induced vasoconstriction (Dora et al., 
2000). Therefore, the significant increase in STZ-diabetic aortic rings NA-induced 
vasoconstriction might be attributed to suppressed NOS activity. 
Since MGO was significantly elevated in STZ-diabetic rats’ serum (Figure 43), it was applied 
in both physiological (10μM) and diabetic (100μM) concentrations on naïve non-diabetic 
primary ASMCs which were treated with IFN-γ and LPS. Diabetic levels of MGO (100μM) 
suppressed iNOS expression in naïve non-diabetic primary ASMCs which was accompanied 
with abolished total NO2 release (Figure 81). However, a physiological MGO concentration 
(10μM) did not suppress iNOS expression (Figure 81). Since iNOS is induced through 
bacterial inflammatory mediators such as LPS, therefore, MGO-suppressed iNOS might 
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explain the reason of diabetics being prone to infection with their immunity compromised. 
Moreover, in addition to MGO being an eNOS inhibitor, MGO impairs iNOS expression 
revealing that MGO impairs NO-mediated vasodilatory pathways. 
These findings correlate the elevated serum MGO (Figure 43) with iNOS suppression 
(Figures 77 & 81), and increased vasoconstriction (Figure 79) since previous study revealed 
that LPS-induced iNOS causes NO release, that causes hyporeactivity to vasoconstrictors 
such as phenylephrine (Hall et al., 1996). Numerous researchers have shown that MGO 
induces iNOS and NO production together with superoxide anions to form ONOO-, however, 
these studies were conducted on thoracic aortic smooth muscle cell line (A-10 cells) (Chang 
et al., 2005; Arti Dhar, Desai, Kazachmov, Yu, & Wu, 2008). By contrast, our study was 
conducted to primary ASMCs which would provide a robust evidence to the mechanism of 
MGO on iNOS which was proven through Akt and p38 studies. To the best of our knowledge 
this is the first study that shows MGO effect on primary ASMCs’ iNOS suppression, and 
such effect was proven through further studies on the upstream factors involved in iNOS 
expression such as Akt. 
Akt and p38 phosphorylation was investigated, since previous reports showed the essential 
role of these two second messengers in regulating iNOS expression (Begum & Ragolia, 2000; 
Hattori et al., 2003). As shown in Figure 84, Akt phosphorylation was significantly 
compromised in ASMCs incubated with IFN-γ (100IU/ml), LPS (100µg/ml) and MGO 
(100µM). However, p38 phosphorylation was not significantly influenced through MGO 
(100µM) co-incubation with IFN-γ (100IU/ml) and LPS (100µg/ml) (figure 85). These 
findings support the MGO mechanism of action through inhibiting iNOS. Akt is a protein 
kinase that is activated through PI3K activation. PI3K phosphorylates the membranous 
phosphoinositide lipids that provide docking sites for Akt. Akt binds to its phosphoinositide 
docking sites where it is phosphorylated at threonine 308 and serine 473 (Ser473) to further 
phosphorylate IκB (inhibitor nuclear factor of kappa light polypeptide gene enhancer in B-
cells inhibitor) and hence tags it for ubiquitination and degradation. Once IκB is degraded, 
nuclear factor κB (NF κB) becomes active and translocates into the nucleus to induce iNOS 
expression (Hattori et al., 2003). Therefore, as shown in Figure 84, inhibiting Akt 
phosphorylation (Ser 473) contributed to the MGO-downregulated iNOS (Figure 81). Such 
effect might contribute to the exagerated vasospastic responses shown in Figure 79, since 
iNOS-derived NO plays a preventive role against increased vasospastic responses (Fukumoto 
et al., 1997). Moreover, since Akt plays a major role in glucose metabolism  in addition to 
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being a cell survival factor (Franke, Kaplan, & Cantley, 1997), therefore, MGO elevation in 
diabetes might exacerbate the hyperglycaemia and might be attributed to accelerated aging 
(A. Dhar et al., 2011; Nicolay et al., 2006; Ramasamy et al., 2005). 
L-arginine restored the MGO-inhibitory effect on iNOS expression (Figure 83). This finding 
was supported by a previous study which found that L-arginine serves as MGO scavenger (I. 
Dhar et al., 2012). Therefore, further analytical studies such as HPLC are required to prove 
the ability of L-arginine to scavenge MGO. Moreover, MGO effect on inhibiting iNOS 
expression was completely abolished in the presence of L-arginine revealing that both 
compounds were not free when they were in the same media and suggesting their capability 
to bind each other as shown in a previous HPLC study (I. Dhar et al., 2012). L-arginine 
(100μM) was applied within the normal plasma concentration (60-140μM) (Schwedhelm et 
al., 2008), which is less than the concentration applied in I. Dhar et al. (2012) study where it 
was applied at 300μM concentration. The applied L-arginine concentration did not induce 
iNOS expression (Figure 83) which supports the hypothesis of L-arginine acting as MGO 
scavenger (I. Dhar et al., 2012). Therefore, the applied L-arginine concentration is 
physiologically applicable. These findings suggest the importance of L-arginine as a 
therapeutic option for diabetics as previous studies revealed that L-arginine supplementation 
(3x2g/day) showed significant improvement in antioxidants and NO release (Jabłecka et al., 
2012). Moreover, previous studies showed significant insulin sensitivity improvement in 
T2DM patients when they were given 8.3g/day L-arginine, such improvement was 
accompanied with improved glucose metabolism and antioxidants capacity (Lucotti et al., 
2006). Therefore, L-arginine may play an essential role as a supplement for diabetes patients, 
especially with MGO impairing insulin pharmacokinetic and pharmacodynamic parameters 
that culminates in insulin resistance, endothelium dysfunction as well as neuropathic pain 
which are all common complications in diabetes (A. Dhar et al., 2011; Eberhardt et al., 2012; 
S. Jia et al., 2006; Van Eupen et al., 2013). 
ASMCs’ TRPV4 expression was also studied since TRPV4 showed partial endothelium-
independent vasodilation (Figure 33) and aortic endothelial TRPV4 was downregulated in 
STZ-diabetic rats (Figures 58 & 59).  Accordingly, significant reduction in TRPV4 
expression was shown in primary ASMCs (Figure 87). A previous study conducted by Earley 
et al. (2005) revealed that TRPV4 forms a signalling complex with BKca to generate VSM 
hyperpolarisation and hence causes vasodilation. Moreover, Bagher and Garland (2014) 
revealed that TRPV4 mediates Ca2+ influx through cooperative gating in the MEPs that 
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activates Kca to exert VSM hyperpolarisation and vasodilation. These findings suggested that 
TRPV4 downregulation contributes to the impairment of both endothelium-dependent and 
endothelium-independent TRPV4-induced vasodilation. 
To sum up, MGO was elevated in STZ-diabetic rats’ serum to approximately 100µM. 
Incubating naïve non-diabetic ASMCs with MGO (100µM) for 24 hours inhibited Akt-
phosphorylation and hence suppressed iNOS expression which might be attributed to increased 
diabetic aortic rings vasoconstriction. These findings suggest that MGO induces iNOS 
downregulation in addition to increasing vasoconstriction which are all culminate in 
compromised circulation in diabetes. L-arginine restored MGO-downregulated iNOS, this 
effect might be attributed to the L-arginine ability to scavenge MGO. According to these 
conclusions, MGO might be a pivotal therapeutic target to manage diabetes complications. L-
arginine was shown to act as a scavenger for MGO and hence it might play a major therapeutic 
strategy for MGO-related diabetic complications such as vascular dysfunction (Bierhaus et al., 
2012; A. Dhar et al., 2010). Moreover, TRPV4 downregulation in STZ-diabetic ASMCs might 
exaggerate the diabetic vascular dysfunction. 
In the next chapter, the short-term effect of MGO will be discussed to investigate whether acute 
MGO treatment shows similar vascular effects to chronic MGO treatment. 
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7. Chapter 7: Acute effect of methylglyoxal on the vascular tone 
7.1. Introduction 
Chronic hyperglycaemia is the main DM complication where blood glucose concentration 
exceeds 7mmol/L (125mg/dl) (Sheader et al., 2001). Approximately 0.5% of glycolysis; 
glucose metabolism, elaborates electrophilic ROS such as MGO which is highly reactive with 
various cellular and interstitial molecules such as proteins and phospholipids to form stable 
adducts and AGE (Uchida, 2000). As shown in the previous two chapters, long-term 
incubation of non-diabetic aortic rings (for 12 hours) and primary ECs (for 5 days) and 
ASMCs (for 24 hours) with MGO (100μM) showed significant endothelial dysfunction, 
compromised TRPV4 function and NO2 release, respectively. Numerous authors have 
correlated MGO elevation to vascular dysfunction and end organ damage such as 
nephropathy and neuropathy in diabetes (Chang et al., 2005; Shamsaldeen et al., 2016). In 
this chapter, the aim was to investigate the acute effect of MGO (100μM) on vascular 
function. 
The main objectives of this chapter were to decipher the MGO targets in a whole aortic rings 
organ bath studies where aortic rings were incubated with a wide range of antagonists and 
blockers. Moreover, the second objective was to investigate the molecular mechanism of the 
acute effect of MGO on vasculature through FlexStation studies. 
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7.2. Materials and methods 
7.2.1. MGO vascular contractility persistence studies 
Contractility persistence was examined in separately different sets of naïve rats aortic rings 
through initial incubation with L-NAME (100µM) for 30 minutes or with TRPV4 antagonist: 
HC067047 (1µM) or RN-1734 (1µM), TRPM8 antagonist: AMTB (1µM), BKCa antagonist: 
iberiotoxin (1nM) for 30 minutes followed by the co-incubation of MGO (100nM) for 120 
minutes. The aortic rings were then contracted with NA (300nM). Similar experiments were 
conducted on endothelium denuded aortic rings with MGO (100μM) alone for 120 minutes or 
in the presence of TRPV4 antagonist: HC067047 (1µM) or TRPM8 antagonist: AMTB 
(1µM). Additionally, MGO vascular effect was examined against high potassium Krebs-
induced contraction. 
7.2.2. FlexStation experiments on TRPM8 expressing CHO cells 
FlexStation Ca2+ assay was conducted at King’s College London, Wolfson centre for age 
related diseases with an invaluable supervision from Professor Stuart Bevan. Chinese hamster 
ovary cells transfected with rat TRPM8 channel (r-TRPM8) were grown in MEM AQmedia 
containing 10% of FBS, 1% of streptomycin-penicillin and 200µg/ml of hygromycin. 
However, the un-transfected Chinese hamster ovary (CHO) cells were grown in MEM 
AQmedia containing 10% FBS and 1% streptomycin-penicillin. When the cells became 
confluent, they were seeded in a black-wall 96 well plate (Costar 3603: tissue-culture plates) 
and incubated for 24 hours (CO2 5%, 37°C). Thereafter, the cells were loaded with fura2-AM 
(2.5µM) and probenecid (1mM) in extracellular fluid (ECF) containing 130mM of NaCl, 
5mM of KCl, 10mM of glucose, 10mM of HEPES, 2mM of CaCl2, 1mM of MgCl2 with a pH 
of 7.4. The loaded cells were then incubated for 1 hour (CO2 5%, 37°C). Afterward, the cells 
were washed for once with ECF and loaded with 50µl ECF before being launched into the 
FlexStation. The CHO cells and r-TRPM8 cells were treated with icilin CRC (1nM-200nM) 
in the presence and absence of AMTB (5µM, 10µM and 50µM) to confirm the AMTB 
antagonistic efficiency on r-TRPM8 cells. Similarly, the r-TRPM8 cells and the un-
transfected CHO cells were incubated with MGO (100µM-10mM) whilst in the FlexStation 
(28°C) for 1 hour. Moreover, r-TRPM8 cells-blocked with AMTB (5µM and 10µM) were 
treated with MGO (100µM-10mM). Sucrose (50mM) in ECF was applied as osmotic control 
since Quallo et al. (2015) concluded TRPM8 as a peripheral osmosensor. Therefore, applying 
an osmotic control was used to exclude any osmotic effect of MGO on rTRPM8 cells. 
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7.3. Results 
7.3.1. Short-term effects of MGO on vascular tissue 
In chapter 4-6, it was shown that 12 hour exposure of MGO (100μM) mimicked some of the 
change in vascular function seen in the STZ-induced diabetes model, consistent with the idea 
that chronic MGO elevation in the STZ model might be responsible for some of these 
changes. However, previous studies demonstrated acute effects of MGO on isolated tissues, 
so it was of interest to look at shorter exposure times. A study conducted by A. Dhar et al. 
(2010) found that incubating rat aortic ECs with MGO (30μM) for 3 hours showed significant 
reduction in acetylcholine mediated vascular vasodilation and  in bradykinin-induced total 
NO2 release. Therefore, pathological concentration of MGO (100μM) was investigated 
through incubating aortic rings with different time points, 15 minutes, 30 minutes, 1 hour and 
2 hours followed by carbachol (100μM and 1mM). 
As shown in Figures 88 and 89, incubating the aortic ring with MGO (100μM) for 15-60 
minutes did not show significant difference compared to control aortic rings when carbachol 
was applied to induce vasodilation [N=6, ns p ≥ 0.05, untreated control carbachol (1mM)= -
73.1 ± 11.4%, N=4, MGO 15 minutes carbachol (1mM)= -53.3 ± 2.2%, N=3, MGO 30 
minutes carbachol (1mM)= -67.4 ± 3.2% and N=5, MGO 60 minutes carbachol (1mM)= -
75.1±10.6%) (Figure 88). 
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Figure 88. Representative trace of carbachol-induced vasodilation of pre-contracted rat’s aortic rings after being 
incubated with MGO 100μM for 30 minutes. Aortic rings were incubated with MGO FBC 100μM for 30 
minutes (right) which were pre-contracted with NA (300nM) followed by carbachol FBC 300μM, compared to 
non-MGO tissues. Both aortic rings showed full vasodilation, when recorded through iWORX LabScribe 
software. 
Figure 89. Aortic response to carbachol FBC 300μM and 1m3M normalised to noradrenaline (NA)-induced 
contraction through FBC 300nM. Control rat aortic rings were incubated with 100μM MGO at different time 
points (15, 30 and 60 minutes). Analysed through two-way ANOVA with Bonferroni post-hoc test. Data shown 
as percentage ± SEM [Control, N= 6, MGO (100μm) 15 minutes, N= 4, MGO (100μm) 30 minutes, N= 3 and 
MGO (100μm) 60 minutes, N= 5]. 
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However, when aortic rings were incubated for 2 hours with MGO (100µM), spontaneous 
loss of vascular tone occurred after contracting the aortic rings with NA (300nM) instead of 
the normal sustained tension observed with NA as shown in Figure 90.  
Figure 90. Representative trace of MGO-induced loss of contractility persistence (upper red) compared to 
control; non MGO. Aortic rings were incubated with MGO (100µM or 0 µM) for 2 hours before being 
contracted with NA 300nM to show loss of contractility persistence in MGO incubated aortic rings distinctively, 
when recorded through iWORX LabScribe.  
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7.3.2. MGO-induced loss of NA-induced contractility persistence 
The loss of contractility persistence induced by MGO (100µM) incubation for 2 hours was 
unexpected, given the inhibition of vasodilation observed with longer MGO exposure (Figure 
52). So, it was of interest to further explore the mechanism of this effect. L-NAME (100µM) 
and HC067047 (1µM), RN-1734 (1µM), AMTB (1µM), and high potassium Krebs solution 
were applied to examine their effect on the loss of contractility persistence induced by 120 
minutes MGO (1µM & 100µM). In another experiment, different rat aortic rings were 
mechanically stripped of endothelium (denuded) to examine the endothelium dependence of 
MGO. All conditions were compared to MGO-induced loss of contractility persistence and 
non MGO-treated tissues (control). All antagonists were applied at approximately 30 minutes 
before adding MGO. HC067047 but not RN-1734 abolished MGO-induced loss of 
contractility persistence. Similar to HC067047, TRPM8 antagonist, AMTB showed 
significant suppression to MGO-induced loss of contractility persistence. Moreover, L-
NAME, iberiotoxin and high potassium Krebs solution showed significant compromised 
MGO-induced loss of contractility persistence. 
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To ensure that the endothelium removal was effective in the denuded tissue we tested this by 
measuring the carbachol induced vasodilation of NA induced tension in control and denuded 
tissue (Figure 91). As expected, the carbachol induced vasodilation was almost completely 
abolished in the denuded rings consistent with endothelium removal. Endothelium denuding 
showed significant reduction in carbachol-induced vasodilation (N=5, *** p ˂ 0.001, Emax= 
16.6±4.8% vs intact endothelium carbachol induced-vasodilation Emax= 68.4±2.3%)  (Figure 
91). However, the EC50 was not significantly influenced (N=5, p ≥ 0.05, EC50= 3.8 ± 0.6μM 
and vs intact endothelium carbachol induced-vasodilation EC50= 1.8 ± 1.1μM) (Figure 91). 
Figure 91. Carbachol cumulative concentration response curve when endothelium was denuded. Analysed 
through two-way ANOVA with Bonferroni post-hoc test. Significance is shown as *** p ˂ 0.001 versus 
carbachol-induced vasodilation in intact endothelium aortic rings (N= 5). 
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 MGO induced significant loss of contractility persistence in intact aortic 
rings and in endothelium denuded aortic rings 
MGO (1µM and 100µM) incubation for 2 hours showed significant spontaneous loss of 
contractility persistence (MGO 100µM: N= 5, *** p ˂ 0.001, Emax: -90.4 ± 6.9%, tmax= 30 
minutes, denuded endothelium MGO 100µM: N= 5, Emax: -103.2 ± 5.4%, tmax= 30 
minutes, MGO 100µM: N= 6, Emax: -88.3 ± 7.1%, tmax= 30 minutes vs control, Emax: -
12.7 ± 11.1%, tmax= 30 minutes) (Figure 92). 
Figure 92. Methylglyoxal (MGO)-induced loss of vascular tone. MGO-induced significant loss of contractility 
persistence when aortic rings were incubated with MGO for 2 hours before being contracted with noradrenaline 
(300nM) even in the absence of endothelium analysed through Bonferroni’s two-way ANOVA. Significance is 
represented as * p ˂ 0.05, ** p ˂ 0.01 and *** p ˂ 0.001 when compared with untreated aortic rings (control). 
Data shown as percentage ± SEM (Control, N= 8, MGO 100μM 2 hours, N= 5, Denuded MGO 100μM 2 hours, 
N= 5 and MGO 1μM 2 hours, N= 6). 
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 MGO-induced loss of contractility persistence was significantly inhibited 
through incubating intact aortic rings with HC067047 
Aortic rings were incubated for 30 minutes with either of two different TRPV4 blockers, 
HC067047 and RN1734. Afterward, MGO (100µM) was added for another 2 hours before 
adding NA (300nM). HC067047 showed significant reduction in the MGO-induced loss of 
contractility persistence [HC067047 (1µM) + MGO (100µM), N=4, *** p ˂ 0.001, Emax= -
13.2 ± 16.6%, tmax= 30 minutes, vs MGO (100µM), N= 5, Emax= -90.4 ± 6.9%, tmax= 30 
minutes]. However, endothelium denuding significantly suppressed the effect of HC067047 
[HC067047 (1µM) + MGO (100µM), N=4, $$$ p ˂ 0.001, Emax: -13.2 ± 16.6%, tmax= 30 
minutes vs endothelium denuded HC067047 (1µM) + MGO 100µM, N=4, Emax: -88.5 ± 
12.3%, tmax= 30 minutes]. RN1734 showed significant inhibition to MGO-induced loss of 
contractility persistence [RN1734 (1µM) + MGO (100µM), N=5, && p ˂ 0.01, Emax= -69.0 
± 11.3%, tmax= 30 minutes vs MGO (100µM), N=5, Emax= -90.4 ± 6.9%, tmax= 30 
minutes] (Figure 93). The inconsistent effects of the two TRPV4 antagonists and the 
endothelium-dependent effect of HC067047 suggest that this might be acting as a functional 
antagonist by another mechanism. 
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Figure 93. Methylglyoxal (MGO)-induced loss of contractility persistence against TRPV4 blockers (HC067047 
and RN-1734). Intact and endothelium denuded aortic rings incubated with TRPV4 blocker and MGO were 
compared to intact and endothelium denuded aortic rings incubated with MGO only, all groups were compared 
to untreated aortic rings (control). Analysed through two-way ANOVA Bonferroni post-hoc test. Significance is 
represented as * P˂0.05, ** p ˂ 0.01 and *** p ˂ 0.001 vs aortic rings treated with MGO (100μM). Significance 
is represented as $$ p ˂ 0.01 and $$$ p ˂ 0.001 vs endothelium denuded aortic rings treated with MGO 
(100μM). Data shown as percentage ± SEM (Control, N= 8, MGO 100μM 2 hours, N= 5, Denuded MGO 
100μM 2 hours, N= 5, RN-1734 1μM+MGO 100μM, N= 5, HC067047 1μM+MGO 100μM, N= 4 and denuded 
HC067047 1μM+MGO 100μM, N= 4). 
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 MGO-induced loss of contractility persistence was significantly inhibited 
through incubating the intact and endothelium denuded aortic rings with 
AMTB 
We next looked at the contribution of TRPM8 channels to the MGO-induced loss of 
contractility persistence. Aortic rings were incubated with TRPM8 blocker, AMTB (1μM) for 
30 minutes. Afterward, the aortic ring was treated with MGO (100µM) for 2 hours, before 
adding NA (300nM). AMTB significantly reduced the MGO-induced loss of contractility 
persistence (*** p ˂ 0.001) in intact rings and even when the endothelium was removed 
(denuded) ($$$ p ˂ 0.001) as shown in Figure 94. This is consistent with the possibility that 
MGO is acting as a TRPM8 agonist in denuded rings. MGO-induced loss of contractility 
persistence was significantly blocked through AMTB (1µM) incubation [AMTB (1µM) + 
MGO (100µM), N= 4, *** p ˂ 0.001, Emax= -38.2 ± 7.6% and tmax= 30 minutes vs MGO 
(100µM), N= 5, Emax: -90.4 ± 6.9% and tmax= 30 minutes). Endothelium denuding showed 
significant effect of AMTB to abolish MGO-induced loss of contractility persistence 
(endothelium denuded AMTB (1µM) + MGO (100µM), N= 4, $$$ p ˂ 0.001, Emax= -23.8 ± 
8.7% and tmax= 30 minutes vs denuded MGO 100µM, N= 5, Emax: -103.2 ± 5.4%, tmax= 
30 minutes). AMTB effect on MGO-induced loss of contractility persistence was not 
significantly affected through endothelium denuding [AMTB (1µM) + MGO (100µM), N=4, 
p ≥ 0.05, Emax= 38.2 ± 7.6% and tmax= 30 minutes vs denuded AMTB (1µM) + MGO 
(100µM), N=4, Emax: 23.8 ± 8.7% and tmax= 30 minutes] (Figure 94). 
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Figure 94. Methylglyoxal (MGO)-induced loss of contractility persistence against TRPM8 blocker (AMTB). 
Intact and endothelium denuded aortic rings incubated with AMTB and MGO were compared to intact and 
endothelium denuded aortic rings incubated with MGO only, all groups were compared to untreated aortic rings 
(control). Analysed through two-way ANOVA with Bonferroni post-hoc test. Significance is represented as * p 
˂ 0.05 and *** p ˂ 0.001 vs intact aortic rings treated with MGO (100μM). Significance is represented as $ p ˂ 
0.05, $$ p ˂ 0.01 and $$$ p ˂ 0.001 vs endothelium denuded aortic rings treated with MGO (100μM). Data 
shown as percentage ± SEM (Control, N= 8, MGO 100μM 2 hours, N= 5, Denuded MGO 100μM 2 hours, N= 
5, AMTB 1μM+MGO 100μM, N= 4 and denuded AMTB 1μM+MGO 100μM 2 hours, N= 4). 
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 MGO-induced loss of contractility persistence was significantly inhibited 
through incubating the intact aortic rings with iberiotoxin, L-NAME or 
contracting the aortic rings with high potassium Krebs solution 
The involvement of intracellular signalling molecules in MGO-induced loss of contractility 
persistence was investigated next. Aortic rings were incubated with either NOS inhibitor (L-
NAME) or BKCa blocker (iberiotoxin) in addition to MGO (100µM) incubation before being 
contracted with NA (300nM). In addition to these experiments, high potassium Krebs 
solution was applied to aortic rings incubated with MGO (100µM) to abolish the effect of 
potassium channels. L-NAME significantly reduced MGO-induced loss of contractility 
persistence [L-NAME (100µM) + MGO (100µM), N=4, *** p ˂ 0.001, Emax= -37.1 ± 
18.3% and tmax= 30 minutes vs MGO (100µM), N=5, Emax= -90.4±6.9% and tmax= 30 
minutes). Iberiotoxin showed significant effect on MGO-induced loss of contractility 
persistence [iberiotoxin (1nM) + MGO (100µM), N=4, ££ P˂0.01, Emax= -55.8 ± 5.5% and 
tmax= 30 minutes vs MGO (100µM), N=5, Emax= -90.4 ± 6.9% and tmax= 30 minutes). 
High potassium Krebs (123mM)-induced contraction showed significant resistance toward 
MGO-induced loss of contractility persistence [high potassium Krebs solution (123mM) + 
MGO (100µM), N=4, $$$ p ˂ 0.001, Emax= -22.4 ± 10.5% and tmax= 30 minutes vs MGO 
(100µM), N=5, Emax: -90.4 ± 6.9% and tmax= 30 minutes) (Figure 95). 
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Figure 95. Methylglyoxal (MGO)-induced loss of contractility persistence against L-NAME, Iberiotoxin and 
high potassium Krebs solution. Analysed through two-way ANOVA with Bonferroni post-hoc test. Significance 
is represented as £ or $ or * p ˂ 0.05 and $$ p ˂ 0.01 when compared with intact aortic rings incubated with 
MGO (100μM). Data shown as percentage ± SEM (Control, N= 8 n= 8, MGO 100μM 2 hours, N= 5, L-NAME 
100μM+MGO 100μM, N= 4, iberiotoxin 1nM+MGO 100μM, N= 4 n= 5 and high potassium Krebs + MGO 
100μM, N= 4). 
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 Experiments visuals summary 
The conducted experiments are summarised in the following figure. 
 
Figure 96. Methylglyoxal (MGO)-induced loss of contractility persistence in rat aortic rings experiments 
summary.  
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7.3.3.  MGO and TRPM8 through FlexStation studies 
MGO-induced loss of contractility persistence was abolished through TRPM8 antagonism 
with AMTB (Figure 94). This is consistent with the hypothesis that MGO is acting as a 
TRPM8 agonist. To test this idea we investigated the action of MGO on rTRPM8 cells. 
A FlexStation Ca2+ assay was conducted to investigate whether MGO-induced [Ca2+]i 
through TRPM8 might explain the AMTB blocked MGO-induced loss of contractility 
persistence. R-TRPM8 cells showed significant increase in [Ca2+]i in response to icilin CRC 
(200nM-1nM) which was completely abolished by AMTB pre-incubation (5-50µM) for 30 
minutes. Moreover, untransfected CHO cells showed no response to icilin CRC (200nM-
1nM) (p ˂ 0.01) consistent with the effect of icilin being due to TRPM8 activation, as shown 
in Figure 97. Pre-incubating r-TRPM8 with AMTB (5-50µM) showed significant reduction 
in icilin-induced [Ca2+]i [AMTB (5µM), * p ˂ 0.05, Emax= 0.58 ± 0.0 fura-2 ratio change, 
AMTB (10µM), $ p ˂ 0.05, Emax= 0.3 ± 0.0 fura-2 ratio change and AMTB (50µM), # p ˂ 
0.05, Emax= 0.2 ± 0.0 fura-2 ratio change vs icilin control, N=3, Emax= 2.4 ± 0.6 fura-2 ratio 
change). Moreover, untransfected CHO cells showed no significant icilin-induced [Ca2+]i 
(N=1, && P˂0.01, Emax= 0.2 ± 0.0 fura-2 ratio change) (Figure 97). 
Figure 97. Icilin concentration response curve on r-TRPM8 and CHO cells. Pre-incubating r-TRPM8 with 
AMTB (5-50µM) before adding treating the cells with icilin CRC (1nM-200nM). Analysed through one-way 
ANOVA with Tuckey post-hoc test. Significance is represented as * or $ or # when p ˂ 0.05 and && when p ˂ 
0.01 when compared against icilin control.  Data is represented as fura-2 ratio. FWC: final well concentration. 
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 MGO induced intracellular calcium elevation in rTRPM8 cells 
Afterward, r-TRPM8 cells were incubated with MGO (100µM-10mM) and an osmotic 
control well of sucrose (50mM) for 1 hour. MGO concentrations of 2mM and above showed 
a significant increase in [Ca2+]i level in time and dose-dependent manner as shown in Figure 
98. MGO (10mM) showed significantly higher fura-2 ratio ([Ca2+]i elevation) (N=3, *** p ˂ 
0.001, Emax= 0.5 ± 0.2 fura-2 ratio change, vs the lower concentrations (5mM-100µM) and 
sucrose (50mM)]. MGO (5mM) showed significantly higher [Ca2+]i [N=3, && p ˂ 0.01, 
Emax= 0.4 ± 0.15 fura-2 ratio change vs MGO (2mM) Emax= 0.35 ± 0.13 fura-2 ratio 
change, and $$$ p ˂ 0.01 vs (1mM-100µM) and sucrose (50mM)]. MGO (2mM) showed 
significantly higher fura-2 ratio [N=3, £££ p ˂ 0.001, Emax= 0.35 ± 0.13 fura-2 ratio change 
vs the lower concentrations (1mM-100µM) and sucrose (50mM)]. MGO (1mM-100µM) did 
not show significant difference (p ≥ 0.05, N=3, Emax= 0.22 ± 0.07 fura-2 ratio change, 
Emax= 0.16 ± 0.05 fura-2 ratio change, Emax= 0.15 ± 0.05 fura-2 ratio change and Emax= 
0.16 ± 0.06 fura-2 ratio change, respectively) when compared to sucrose (50mM) osmotic 
control (N=3, p ≥ 0.05, Emax= 0.17 ± 0.05) (Figure 98). 
 
Figure 98. Methylglyoxal (MGO)-induced calcium influx in r-TRPM8 cells. R-TRPM8 cells incubated with 
MGO (1mM - 100µM) for 60 minutes compared to osmotic control of sucrose (50mM). Data analysed through 
one-way ANOVA with Tukey post-hoc test. Significance is represented as *** p ˂ 0.001 vs MGO (5mM - 
100μM) and sucrose (50mM). Significance is represented as && when p ˂ 0.01 vs MGO (2mM). Significance 
is represented as $$$ or £££ p ˂ 0.001 vs MGO (1mM -100μM) and sucrose (50mM). Data is represented as 
fura-2 ratio. 
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 MGO induced intracellular calcium elevation was significantly reduced in 
rTRPM8 cells and CHO cells pre-incubated with AMTB 
Since AMTB (5µM) abolished icilin-induced Ca2+ influx in r-TRPM8 cells (Figure 97) we 
next investigate whether AMTB (5µM) could block the MGO-elevated [Ca2+]i. Therefore, r-
TRPM8 cells were incubated with AMTB (5µM) and (10µM) for 30 minutes before adding 
MGO (10 - 2mM). Each MGO concentration that showed significant increase in Ca2+ influx 
in Figure 97 was compared in a separate figure 99-111). As shown in Figure 99, MGO 
(10mM)-elevated [Ca2+]i was significantly reduced when rTRPM8 were pre-incubated with 
AMTB (5μM & 10μM) [AMTB (5µM), N=1, *** p ˂ 0.001, t50= 18.4 minutes and Emax= 
0.35 ± 0.0 fura-2 ratio change, AMTB (10µM), N=1, $$$ p ˂ 0.001, t50= 16.7 minutes and 
Emax= 0.24 ± 0.0 fura-2 ratio change vs MGO (10mM) in r-TRPM8 without AMTB, N=3, 
t50= 3.7 minutes and Emax= 0.5±0.2 fura-2 ratio change) (Figure 99). 
 
Figure 99. Methylglyoxal (MGO, 10mM)-induced intracellular calcium elevation in r-TRPM8 cells with AMTB 
(5µM and 10µM). Analysed through one-way ANOVA with Tukey post-hoc test. Significance is represented as 
£ when p ˂ 0.05 and *** or $$$ when p ˂ 0.001 vs r-TRPM8 treated with MGO (10mM). Data is represented as 
fura-2 ratio. 
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However, when applying MGO (10mM) to untransfected CHO cells, [Ca2+]i was 
significantly influenced with AMTB (5μM) pre-incubation [CHO cells, N=1, *** p ˂ 0.001, 
t50= 16.7 minutes and Emax= 0.56 ± 0.0 fura-2 ratio change vs CHO cells with AMTB 
(5µM), N=1, t50= 30.7 minutes and Emax= 0.55 ± 0.0 fura-2 ratio change) (Figure 100). 
 
Figure 100. Methylglyoxal (MGO, 10mM)-increased intracellular calcium concentration with AMTB (5µM) in 
CHO cells. Analysed through paired two-tailed Student’s t-test. Significance is represented as *** when 
p˂0.001. Data is represented as fura-2 ratio. 
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MGO (5mM)-induced [Ca2+]i elevation was significantly reduced in r-TRPM8 cells pre-
incubated with AMTB (5μM & 10μM) [AMTB (5µM), N=1, *** p ˂ 0.001, t50=6.3 minutes 
and Emax= 0.2 ± 0.0 fura-2 ratio change and $$$ p ˂ 0.001, AMTB (10µM), N=1, t50= 4 
minutes and Emax= 0.23 ± 0.0 fura-2 ratio change vs MGO (5mM) in r-TRPM8 without 
AMTB, N=2, t50= 3.4 minutes and Emax= 0.4 ± 0.15 fura-2 ratio change) (Figure 101).  
 
Figure 101. Methylglyoxal (MGO, 5mM)-induced calcium influx in r-TRPM8 cells with AMTB (5µM and 
10µM). Analysed through one-way ANOVA with Tukey post-hoc test. Significance is represented as *** or $$$ 
when p ˂ 0.001 vs r-TRPM8 treated with MGO (5mM). Data is represented as fura-2 ratio. 
 
200 
 
However, when applying MGO (5mM) to untransfected CHO cells, [Ca2+]i was significantly 
influenced with AMTB (5μM) pre-incubation [CHO cells, N=1, *** p ˂ 0.001, t50= 7.1 
minutes and Emax= 0.29 ± 0.0 fura-2 ratio change vs CHO cells with AMTB 5µM, N=1, 
t50= 32.0 minutes and Emax= 0.23 ± 0.0 fura-2 ratio change) (Figure 102). 
 
Figure 102. Methylglyoxal (MGO, 5mM)-increased intracellular calcium concentration with AMTB (5µM) in 
CHO cells. Analysed through paired two-tailed Student’s t-test. Significance is represented as *** when p ˂ 
0.001. Data is represented as fura-2 ratio. 
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MGO (2mM)-elevated [Ca2+]i was significantly compromised in r-TRPM8 cells were pre-
incubated with AMTB (5μM & 10μM) [AMTB (5µM), N=1, *** p ˂ 0.001, t50= 9.0 minutes 
and Emax= 0.2 ± 0.0 fura-2 ratio change and AMTB (10µM), N=1, $$$ p ˂ 0.001, t50= 5.6 
minutes and Emax= 0.27 ± 0.0 fura-2 ratio change vs MGO 5mM in r-TRPM8 without 
AMTB, t50= 9.8 minutes and Emax= 0.35 ± 0.13 fura-2 ratio change] (Figure 103). 
 
Figure 103. Methylglyoxal (MGO, 2mM)-induced calcium influx in r-TRPM8 cells with AMTB (5µM and 
10µM). Analysed through Tukey’s one-way ANOVA. Significance is represented as *** or $$$ when p ˂ 0.001 
vs r-TRPM8 treated with MGO (2mM). Data is represented as fura-2 ratio. 
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However, when applying MGO (2mM) to untransfected CHO cells, [Ca2+]i was significantly 
influenced with AMTB (5μM) pre-incubation [CHO cells, N=1, *** p ˂ 0.001, t50= 4.9 
minutes and Emax= 0.17 ± 0.0 fura-2 ratio change vs CHO cells with AMTB (5µM), N=1, 
t50= 29.5 minutes and Emax= 0.15 ± 0.0 fura-2 ratio change] (Figure 104). 
 
Figure 104. Methylglyoxal (MGO, 2mM)-increased intracellular calcium concentration with AMTB (5µM) in 
CHO cells. Analysed through paired two-tailed Student’s t-test. Significance is represented as *** when p ˂  0.001. 
Data is represented as fura-2 ratio. 
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7.4. Discussion 
In this chapter, the short-term effect of MGO was studied as the naïve rats’ aortic rings were 
incubated with MGO (100µM) for 2 hours, 1 hour, 30 minutes and 15 minutes. However, 
NA-constricted aortic rings spontaneously relaxed when incubated with MGO (1µM or 
100µM) for 2 hours (Figure 90 & 100) but not for 1 hour or less (Figure 88 & 97). 
Aortic rings were pre-incubated with numerous blockers before being incubated with MGO 
(100µM) to decipher the mechanisms by which MGO induced vasodilation. TRPV4 
antagonist, HC067047 but not RN-1734 showed significant inhibition to MGO-induced loss 
of contractility persistence (Figure 93). This finding suggests that HC067047 may act 
differently to RN-1734 as Vincent and Duncton (2011) revealed that HC067047 inhibits 
TRPM8 and voltage-gated K+ channels (Kv1.1) at sub-micro molar concentrations while RN-
1734 is a more selective TRPV4 antagonist. Moreover, as RN-1734 showed partial inhibition 
to MGO-induced loss of contractility persistence, it also showed significant difference to 
HC067047 effect on MGO-induced loss of contractility persistence revealing and confirming 
possible differences in the mechanism of TRPV4-antagonism (Figure 93). However, 
HC067047 did not inhibit MGO-induced loss of contractility persistence when endothelium 
was removed (Figure 93). Since HC067047 was reported to block TRPM8 (Vincent & 
Duncton, 2011), therefore, blocking TRPM8 with AMTB was examined against MGO-
induced loss of contractility persistence. 
As shown in Figure 94, AMTB counteracted MGO-induced loss of contractility persistence 
significantly and this effect was not influenced by the endothelium removal. This finding 
supports the previous finding that TRPM8-induced vasodilation is partially endothelium-
independent (Figure 34). Moreover, as shown in Figure 31, BKCa blocking showed 
significant suppression to icilin-induced vasodilation. Therefore, iberiotoxin (1nM) was 
investigated against MGO-induced loss of contractility persistence. 
As shown in Figure 95, MGO-induced loss of contractility persistence was significantly 
compromised through BKCa blocking with iberiotoxin (1nM). Moreover, MGO-induced loss 
of contractility persistence was significantly abolished when aortic rings were constricted 
with high potassium Krebs solution rather than NA (300nM) (Figure 95). In addition to these 
findings, Dragoni, Guida, and McIntyre (2006) revealed that TRPM8 activity is critically 
controlled through two cysteine residues located at positions 929 and 940 in the pore forming 
region, which might be preferentially targeted by MGO (Benemei et al., 2013). Moreover, 
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Eberhardt et al. (2012) concluded that TRPA1 is a pivotal mediator in MGO-induced 
nociception together with approximately 20% sequence homology among all TRP channels, 
including TRPM8 (Clapham, 2003). Therefore, TRPM8 was hypothesised as a possible target 
for MGO in the vascular tissue. 
According to the stated hypothesis, r-TRPM8 cells were studied using FlexStation which 
showed significant [Ca2+]i elevation in a time and MGO dose-dependent manner (Figure 98). 
MGO-induced [Ca2+]i was significantly reduced by AMTB (5µM & 10µM) incubation 
(Figures 99, 101 & 103) revealing TRPM8 as a possible target for MGO. This finding was 
similar to Jan et al. (2005) who concluded that MGO higher than 0.5mM increases [Ca2+]i in 
Madin-Darby canine kidney (MDCK) renal tubular cells. Moreover, un-transfected CHO 
cells showed significant reduction in MGO-induced [Ca2+]i (Figures 100, 102 &104), 
however, the response was not abolished when compared to icilin-induced [Ca2+]i (Figure 
97). This might be attributed to the effect of MGO on intracellular Ca2+ stores as a previous 
study showed that MGO increases [Ca2+]i as a product of both ER Ca2+ release and 
extracellular Ca2+ influx (Jan et al., 2005). Another previous study revealed that MGO-
induced [Ca2+]i was significantly reduced but not abolished when MDCK cells were treated 
with Ca2+ free ECF containing MGO, suggesting that MGO induces ER Ca2+ release that 
contributes to the initial and the sustained [Ca2+]i elevation (Jan et al., 2005).  
By contrast, when CHO cells incubated with AMTB (5µM), MGO-induced [Ca2+]i was 
significantly reduced as shown in Figures 100, 109 and 111. A previous study found that 
TRPM8 agonist; menthol induces Ca2+ release from intracellular ER Ca2+ stores which was 
concomitant with SOCs activation in human prostate cancer epithelial cells (LNCaP) and 
CHO cells (Mahieu et al., 2007; Thebault et al., 2005). These studies revealed that TRPM8 
channels might contribute to Ca2+ release from ER cellular stores (Thebault et al., 2005). 
Therefore, in our studies, MGO might act on ER’s TRPM8 channels in CHO cells. However, 
CHO cells incubated with AMTB (5 - 10μM) did not abolish MGO-induced Ca2+ elevation. 
As concluded by (Mahieu et al., 2007) study on un-transfected HEK293 and CHO cells, 
higher doses of TRPM8 agonist; menthol (1mM) can induce Ca2+ release independent of 
TRPM8. According to these findings, MGO is suggested to enhance [Ca2+]i elevation partly 
through three main sources; (i) membrane TRPM8 channels, (ii) intracellular TRPM8-
dependent  ER Ca2+ stores and (iii) intracellular TRPM8-independent ER Ca2+ stores which 
require further investigations. 
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Moreover, the increase in ECs cytoplasmic Ca2+ from ER stores (< 300ms) is called ECs Ca2+ 
pulsars. ECs Ca2+ pulsars are released from ER at spatially ﬁxed sites proximal to MEPs 
(Bagher & Garland, 2014). Therefore, MGO might induce vasodilation through ECs Ca2+ 
pulsars that activate the MEPs’ Kca (Bagher & Garland, 2014). Such non-selective MGO 
targeting might explain the 20-fold difference shown between the whole aortic rings (100μM) 
and the rTRPM8 cells (2mM). Therefore, in addition of showing its pathological role when 
elevated in diabetic serum, MGO might act as a redox-based cell signalling regulator (Chang 
et al., 2005; X. Jia & Wu, 2007). 
To sum up, MGO was elevated in STZ-diabetic rats’ serum to approximately 100µM. 
Incubating naïve non-diabetic aortic rings with MGO (100μM) for 2 hours induced 
spontaneous vasodilation which was partly mediated through TRPM8 as well as intracellular 
Ca2+ stores. These findings suggest that acute MGO might play an important physiological 
role in regulating cellular Ca2+ homeostasis and ER function. However, chronic MGO 
elevation might contribute to ER stress and hence causes protein misfolding as shown in 
chapter 6. Collectively these findings suggest that MGO might be a pivotal therapeutic target 
to manage diabetes vascular complications. 
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8. Chapter 8: General Discussion 
Since the significant reduction in TRPV4-mediated vasodilation observed in aortic rings from 
STZ-induced diabetic rats in preliminary experiments, the aim of the present study was to 
investigate the effect of diabetes on the function of TRPV4 channels in the endothelium. The 
study examined primarily muscarinic, TRPV4, and TRPM8 function in the aortic 
endothelium of STZ-diabetic and control rats, with a conventional organ bath, myographic 
techniques, and a range of appropriate agonists and antagonists. Downstream functions of 
those pathways were investigated by using L-NAME and iberiotoxin, for example, and 
observations were extended to isolated primary aortic ECs and ASMCs using fura-2 Ca2+ 
imaging, LSCM, and SDS–PAGE Western blotting.  These techniques enabled the discovery 
of whether the signalling pathways of TRP channels are altered. The course of diabetes’s 
induction in relation to TRP channel function was studied in order to explain changes in the 
channels during the onset or development of the disease. The study also involved 
investigating circulating markers such as ox-LDL and MGO with ELISA, as well as the 
application of MGO to nondiabetic cells and tissues as a means to develop an in vitro diabetic 
model of endothelial and TRPV4 dysfunction. Ultimately, the study should expand 
understandings of endothelial dysfunction in diabetic patients and guide novel therapeutic 
strategies.  
8.1. STZ-induced diabetes characterised with elevated blood glucose, serum 
MGO, and ox-LDL 
The characterisation of the STZ model used in the studies highlighted numerous features 
consistent with human patients with diabetes. STZ-induced diabetes was characterised in 
terms of blood glucose elevation, and on that point, 95% of the STZ-injected rats were 
hyperglycaemic (blood glucose ˃ 16mmol/L) by day 7, a condition which continued for 5 
weeks (Figure 40), as consistent with other studies (Wei et al., 2003). By comparison, 
according to the most recent diagnostic criteria for diabetes, random plasma glucose should 
be ≥ 11.1mmol/L for a human patient with classic symptoms of hyperglycaemia (American 
Diabetes Association, 2016). This STZ-induced diabetes model thus provided an exceptional 
foundation for representing complications associated with diabetes and hyperglycaemia. An 
acute time point (i.e., Week 2) was used in most of the studies, since it showed the most 
significant endothelial dysfunction (Figure 49) and appeared to be less detrimental to animal 
health by the means of weight loss and neuropathic pain. 
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The fourfold increase in MGO levels in STZ-diabetic rats’ serum samples (Figure 43) was 
accompanied by a fourfold increase in blood glucose concentration (Figure 40). As such, 
chronic hyperglycaemia might serve as a primary source of endogenous MGO (Kalapos, 
2013; Shamsaldeen et al., 2016). A previous study revealed that MGO is four times greater in 
T2DM patients’ plasma and can reach approximately 500nmol/g haemoglobin and thereby 
contributes to eryptosis (Nicolay et al., 2006). The MGO ratio in the STZ-induced diabetes 
model could therefore represent a robust translational marker for diabetic patients, since both 
showed a fourfold increase in the concentration of MGO, which is involved in common 
diabetes complications such as endothelial dysfunction (Figure 52) and neuropathic pain (A. 
Dhar et al., 2010; A. Dhar et al., 2011; Eberhardt et al., 2012). 
Ox-LDL is increased by twofold in type 2 diabetic patients (L. Zhang, Guo, Zhang, Niu, & 
Wang, 2016), which corresponded with significant serum ox-LDL elevation observed in 
STZ-diabetic rats (Figure 44). The ox-LDL molecule is a cholesterol acceptor that binds to 
the CD36 endothelial scavenger receptor and competes with caveolae to deplete the caveolae 
from cholesterol, thereby causes caveolae disruption (Blair et al., 1999; Y. Zeng et al., 2003), 
which inhibits eNOS attachment to caveolin-1 (CAV-1) and prompts endothelial dysfunction, 
as detailed in Figures 60–63 (Blair et al., 1999). Previous studies have revealed a correlation 
between elevated serum ox-LDL and diabetic complications such as nephropathy and 
vascular dysfunction (Tsuzura et al., 2004). The consumption of tomato juice (500ml/day for 
4 weeks) improved the concentration of the serum antioxidant lycopene by threefold. Such 
improvement was associated with decreased LDL susceptibility to oxidation and decreased c-
reactive protein (CRP) that could reduce the risk of diabetes-associated myocardial infarction 
(Upritchard et al., 2000). Interestingly, as HMG-CoA reductase inhibitors, statins (i.e., 
simvastatin and lovastatin) protected eNOS activity from ox-LDL-induced downregulation 
(Laufs et al., 1998). 
Ox-LDL is clearly higher in diabetes, and hyperglycaemia might be a principal contributor to 
its increased susceptibility to glycation and oxidation. LDL glycation and oxidation occurs 
simultaneously, since free radicals are generated through glycation from glucose and 
Amadori products, which enhances LDL susceptibility to further oxidation (H. Yoshida & 
Kisugi, 2010). Lipolysis is also accelerated in diabetes, and such accelerated lipid catabolism 
includes increased lipid peroxidation (Shamsaldeen et al., 2016), which begins with the 
production of lipid hydroperoxide, which undergoes metal-induced alkoxyl radical generation 
that forms a variety of aldehydes, including MGO  (H. Yoshida & Kisugi, 2010).  
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Serum total protein measurements showed a significant time-dependent reduction in STZ-
diabetic rats (Figure 45a). As a previous study has shown, proteinuria is a common 
complication of diabetes associated with plasma hypoproteinaemia (Bhonsle et al., 2012), a 
condition that is primarily attributed to nephropathy and has been associated with a 
significant (eight-fold) increase in urine protein in at least one study (Niwa et al., 1997). 
More recent research has shown that MGO increases by approximately twofold in patients 
with type 2 diabetes and nephropathy, as well as by twofold in similar patients without 
nephropathy, when compared to nondiabetic ones (Lu et al., 2011). Such data revealed that 
MGO might be implicated in diabetes prognosis by developing both nephropathy and 
endothelial dysfunction. Another recent study revealed that ox-LDL is significantly elevated 
(i.e., by twofold) in diabetic nephropathy (L. Zhang et al., 2016) and furthermore associated 
with the overexpression of lectin-like ox-LDL receptor (LOX-1) and the inactivation of p38, 
which might contribute to diabetic nephropathy (L. Zhang et al., 2016). 
Altogether, chronic hyperglycaemia might increase MGO production, and by extension, 
hyperglycaemia and MGO elevation might contribute to LDL oxidation. As such, controlling 
blood glucose and reducing MGO production could limit ox-LDL formation, which could 
further provide an essential therapeutic strategy to limit the progression of complications in 
diabetes. 
8.2. Increased vasoconstriction as a vascular complication in diabetes 
STZ-diabetic aortic rings treated with NA (300nM) showed significantly higher 
vasoconstriction than naïve aortic rings (Figure 47). As a possible mechanism, the 
exaggerated TRP channels-mediated influx of Ca2+ might lead to vasoconstriction through 
agonist-induced membrane depolarisation-activated TRP channels—for instance, in α1-
adrenergic receptor-stimulated TRPC6 commonly found in rat aortas and cerebral arteries 
(Inoue et al., 2009). Earlier studies have revealed that ox-LDL induces the expression of 
endothelin-1, a potent vasoconstrictor that might exacerbate vascular complications in 
diabetes (Galley & Webster, 2004). Therefore, along with being implicated in endothelial 
dysfunction, elevated serum ox-LDL (Figure 44) might also be related to the significant 
increase in STZ-vasoconstriction shown in Figure 47. 
A previous study showed that NA infusion in type 2 diabetic patients’ intrabrachial artery 
showed more vasoconstriction than in nondiabetic individuals (Hogikyan et al., 1999). 
However, plasma NA was not significantly different between the groups. Such an increase in 
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vascular tone was attributed to increased adrenergic responsiveness as a result of increased 
systemic sympathetic nervous system activity (Hogikyan et al., 1999). 
MGO interacts with cellular proteins and nucleic acid and thereby accelerates AGE 
production and β-cell cytotoxicity (Sheader et al., 2001). AGE act as ligands for 
corresponding receptors, RAGE, which are upregulated in hyperglycaemia and normalised 
through GLO1 overexpression, which reveals the contribution of MGO in inducing RAGE 
expression (Schmidt et al., 1999; D. Yao & Brownlee, 2010). As other previous studies have 
showed, MGO induces RAGE expression and induces endothelial dysfunction (Sena et al., 
2012), as well as ONOO- formation by inducing superoxide anion formation and NO in 
VSMCs (Chang et al., 2005). Superoxide anions quench NO to produce ONOO- that 
compromise NO bioavailability and hence cause endothelial dysfunction and exaggerated 
vasoconstriction (Alp et al., 2003; Hall et al., 1996; Milstien & Katusic, 1999). Moreover, 
superoxide anions inhibit SERCA pumps in VSMCs, thereby increasing [Ca2+]i, impairing 
the vasodilation, and exaggerating vasoconstriction (Adachi et al., 2004; Cohen et al., 1999). 
Earlier research has demonstrated that iNOS-derived NO plays a preventive role against 
increased vasospastic responses associated with arteriosclerosis (Fukumoto et al., 1997). 
Moreover, NOS blockade through L-NAME (100μM) significantly increased 
vasoconstriction tension force in the middle cerebral arteries of rats (McNeish et al., 2010). 
Such increased vasoconstriction was reproduced in endothelial denuded control aortic rings 
incubated with L-NAME (100μM), which functionally inhibits NOS from releasing NO 
(Figure 79b). Additionally, 3–5-week-old STZ-rats’ aortic rings showed more significant 
increases in NA-induced vasoconstriction than vehicle control aortic rings (Figure 79a). 
Western blotting data moreover indicated significant reduction in iNOS expression from STZ 
ASMCs stimulated with IFN-γ and LPS (Figure 77). Therefore, the exaggerated NA-induced 
vasoconstriction in STZ-diabetic rats’ aortic rings might be attributed to suppressed NOS 
activity (Figure 79a&b). 
When non-diabetic ASMCs were treated with diabetic levels of MGO (100μM), iNOS 
expression was significantly suppressed which was accompanied with abolished NO release 
(Figure 81). Since iNOS is induced through bacterial inflammatory mediators such as LPS, 
MGO-suppressed iNOS might explain the reason of diabetics being prone to infection with 
their impaired immunity, and compromised circulation due to exaggerated vasoconstriction. 
Therefore, in addition to MGO inhibiting eNOS phosphorylation and hence impairing the 
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endothelium-dependent vasodilation, MGO impairs iNOS expression revealing that MGO 
might contribute to exaggerated vasoconstriction in diabetes.  
As shown in Figure 84, since Akt phosphorylation was significantly compromised in ASMCs 
incubated with IFN-γ (100IU/ml), LPS (100 µg/ml), and MGO (100 µM), inhibiting Akt 
phosphorylation (Ser 473) contributed to MGO-downregulated iNOS (Figure 81). Such an 
effect might contribute to the increase in vasospastic responses shown in Figure 79, since 
iNOS-derived NO plays a preventive role against increased vasospastic responses  
(Fukumoto et al., 1997). Moreover, since Akt is vital to glucose metabolism and cell survival 
(Franke et al., 1997), MGO elevation in diabetes might exacerbate hyperglycaemia and be 
attributed to accelerated aging (A. Dhar et al., 2011; Nicolay et al., 2006; Ramasamy et al., 
2005).  
L-arginine restored the MGO-inhibitory effect on iNOS expression (Figure 82), which takes 
support from a previous study that found that L-arginine serves as an MGO scavenger (I. 
Dhar et al., 2012). However, further studies, including those with HPLC, are required to 
prove the ability of L-arginine to scavenge MGO. As Schwedhelm et al. (2008) showed 
earlier, L-arginine (100μM) applied as such is within the normal plasma concentration (60–
140μM). Those findings thus suggest the importance of L-arginine as a therapeutic option for 
diabetics, particularly given earlier results that L-arginine supplementation (3 × 2g/day) 
significantly improved antioxidants and NO release (Jabłecka et al., 2012). Other previous 
research has observed significant improvement in insulin sensitivity in T2DM patients when 
given 8.3g/day  L-arginine a day, an outcome accompanied by improved glucose metabolism 
and antioxidant capacity (Lucotti et al., 2006). Such findings suggest the importance of MGO 
scavenging via L-arginine for diabetes patients, especially when MGO impairs insulin 
pharmacokinetic and pharmacodynamic parameters culminating in insulin resistance, 
endothelium dysfunction, and neuropathic pain, all of which are common complications in 
diabetes (A. Dhar et al., 2011; Eberhardt et al., 2012; S. Jia et al., 2006; Van Eupen et al., 
2013). Endothelial dysfunction (Figure 49) was moreover suggested to contribute to 
exaggerated vasoconstriction (Fukao et al., 1997). 
A primary acyclic unsaturated terpene alcohol found in essential oils of ginger and citrus 
fruits, geraniol was shown to counteract the exaggerated vasoconstriction induced by 
phenylephrine in diabetic rats, possibly by inhibiting VGCCs and receptors-operated calcium 
channels (El-Bassossy, Elberry, & Ghareib, 2016). In an earlier study, when quercetin 
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(50mg/day) was administered orally to STZ-adult male albino diabetic rats, it reduced the 
exaggerated phenylephrine-induced vasoconstriction, putatively due to the inhibitory effect of 
quercetin on proinflammatory mediators such as CRP (Mahmoud, Hassan, El Bassossy, & 
Fahmy, 2013). Therefore, geraniol and quercetin could provide essential therapeutic benefits 
to prevent vasoconstriction exaggerated by diabetes.  
8.3. Association of STZ-induced diabetes and endothelial dysfunction 
Muscarinic-induced vasodilation was significantly compromised in aortic rings and 
mesenteric arteries, as illustrated in Figures 49 and 50. Those findings correspond with a 
previous study’s conclusion that the vascular dysfunction of STZ-diabetic rats is attributed to 
impaired muscarinic-induced endothelium-dependent vasodilation (Fukao et al., 1997). STZ-
diabetic endothelial dysfunction, shown in Figures 49 and 58, correlated with the significant 
increase in serum MGO (Figure 43). Therefore, when nondiabetic aortic rings were incubated 
with MGO (100 µM) for 12 hours, carbachol-induced vasodilation was significantly impaired 
(Figure 52). That finding takes support from a previous study that found that MGO inhibits 
the phosphorylation of serine-1177 of eNOS and thereby reduces endothelial NO release (A. 
Dhar et al., 2010). Accordingly, MGO might play a major role in diabetic endothelial 
dysfunction (Brownlee, 2001). At the same time, L-arginine (100μM) restored endothelial 
function in the presence of MGO (100μM), as shown in Figure 52, and such improved 
endothelial function could be attributed L-arginine’s ability to scavenge MGO (I. Dhar et al., 
2012) and increase the L-arginine concentration required to improve the endothelial function. 
Indeed, a study with Sprague–Dawley rats showed a significant reduction in plasma L-
arginine in STZ-diabetic rats (65μM) compared to control rats (190μM), which was 
accompanied with endothelial dysfunction (Pieper & Dondlinger, 1997). 
As a consequence of diabetes, endothelial dysfunction is a common complication in which 
endothelium-dependent vasodilation is impaired and results in peripheral artery disease, foot 
ischemia, and ulceration and can even require amputation (A. Dhar et al., 2010; Ruiter et al., 
2012). Therefore, and as previously mentioned, L-arginine (3 × 2g/day or 8.3g/day) might 
allow significant benefits toward improving common diabetes complications such as 
endothelial dysfunction (Jabłecka et al., 2012; Lucotti et al., 2006). 
 
 
212 
 
8.4. Association of STZ-induced diabetes and TRPV4 
The deterioration in endothelium-dependent vasodilation characterised by impaired 
muscarinic-induced vasodilation (Figures 49 and 58) was in parallel with impaired TRPV4-
induced vasodilation in both STZ-diabetic aortic and mesenteric arteries (Figures 53–55). 
Therefore, the concomitant muscarinic and TRPV4 impaired vasodilation reveals a possible 
mechanistic collaboration of muscarinic receptors and TRPV4 channels (Figures 22 and 23). 
Muscarinic and TRPV4 cascades might be integrated through GPCR-activated PLC, which 
hydrolyses membranous PIP2 into DAG and IP3, the latter of which binds to its 
corresponding smooth ER receptors, IP3-R, to facilitate Ca2+ release from cellular stores, as 
observed in endothelial M3 receptors (Clapham, 2003; Ying et al., 2014). Moreover, TRPV4 
was activated by the muscarinic downstream cascade component of DAG-activated PKC 
binding (Rohacs & Nilius, 2007). TRPV4 mice KO studies have also revealed TRPV4’s 
essential role in muscarinic-mediated endothelium-dependent vasodilation by way of a novel 
mechanism that involves 11, 12 EET-activated TRPV4, which activates BKCa to induce 
membrane hyperpolarisation and vasodilation (Earley et al., 2005; M. Freichel et al., 2005).  
Fura-2 studies illustrated that nondiabetic aortic ECs treated with MGO (100 µM/day for 5 
days) significantly suppressed TRPV4-elevated [Ca2+]i (Figure 67). Such a reduction in 
TRPV4-mediated [Ca2+]i elevation was similar to the reduction in STZ-diabetic ECs and 
significantly less than in naïve control ECs (Figure 67). Moreover, LSCM images illustrated 
similar TRPV4 downregulation in STZ-diabetic ECs and naïve ECs treated with MGO (100 
µM/day for 5 days) compared to naïve control ECs’ TRPV4 (Figures 69 and 70). 
Accordingly, MGO-induced TRPV4 downregulation and dysfunction in naïve ECs might 
explain the STZ-diabetic TRPV4 downregulation in ECs. By extension, chronic MGO 
elevation might perturb ER Ca2+ stores and culminate in protein misfolding and ER stress 
and, in turn, significant decreases in TRPV4 expression with MGO-based treatment (Figures 
69 and 70). 
Antioxidants such as L-arginine buffer the increased ROS produced by ERO1α to maintain 
the redox status of ER (Marciniak & Ron, 2006). Therefore, L-arginine might not only act as 
a scavenger for MGO, but also facilitate the maintenance of ER redox status and hence 
relieve ER stress induced by MGO-induced OS (Figure 67). Therefore, TRPV4 function 
might be restored when ECs are incubated with L-arginine in the presence of MGO (Figure 
67). A previous study with 26 individuals showed that an L-arginine oral supplement (9g/day 
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for 6 months) improved endothelial function in the coronary artery, thereby suggesting L-
arginine as a potential therapeutic option for improved endothelial function (Lerman, Burnett, 
Higano, McKinley, & Holmes, 1998). 
TRPV4 expression in STZ-diabetic primary aortic ECs was reduced by approximately 50% 
(Figure 58 and 68), which might reveal TRPV4 endothelial dysfunction in diabetes 
attributable to TRPV4 downregulation. Primary aortic ECs’ TRPV4 downregulation matches 
the findings of a recent study by Monaghan et al. (2015) which reported TRPV4 
downregulation in diabetic retinal microvascular ECs. Previous studies have also showed that 
CAV-1 is an essential component in modulating TRPV4-induced vasodilation by modulating 
TRPV4 membrane localisation (Saliez et al., 2008). Indeed, a recent study showed that 
TRPV4 is co-localised with CAV-1 and SK3 in human ECs (Fritz et al., 2015). As shown in 
Figures 60 and 70, CAV-1 was significantly compromised by approximately 30% in STZ-
diabetic aortic ECs.  
HDL binds mainly on scavenger SR-BI, where it delivers circulating cholesterol to caveolae 
and thereby maintains caveolae integrity and enhances eNOS activity (Malerød et al., 2002; 
Thomas & Smart, 2008; Yuhanna et al., 2001). Reconstituted HDL infusion (80mg/kg IV for 
4 hours) improved HDL concentration by twofold and significantly improved the 
acetylcholine-induced vasodilation measure through the forearm blood flow in 
hypercholesteraemic individuals (Spieker et al., 2002). Endothelial function was also 
significantly improved in parallel with insulin sensitivity and HDL profile in type 2 diabetic 
patients treated with the PPAR-γ agonist pioglitazone (30mg/day for 12 weeks) when 
compared to the placebo (Sourij, Zweiker, & Wascher, 2006). The PPAR-α agonist fibrates 
enhances the HDL profile and therefore could also be involved in improving endothelial 
function in diabetic patients (Staels et al., 1998). 
Diabetic kidneys showed significant reduction in CAV-1 and eNOS when compared to 
nondiabetic ones (Komers et al., 2006). CAV-1 is co-localised with eNOS in bovine aortic 
ECs (H. Wang et al., 2009), and eNOS showed a similar distribution as TRPV4 and CAV-1 
in naïve aortic ECs (Figures 58a3, 60a3, and 62a3), thereby revealing the co-localisation of 
those three essential elements in the plasma membrane of ECs. eNOS furthermore showed 
significant downregulation in STZ-diabetic aortic ECs (Figure 62 and 72). Diabetic-induced 
eNOS and CAV-1 downregulation might thus be attributed to the inhibited PI3K-Akt 
pathway since the PI3K inhibitor wortmannin inhibited eNOS and CAV-1 translocation to the 
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plasma membrane (H. Wang et al., 2009). HMG-CoA reductase inhibitor cerivastatin 
(0.15mg/day for 3 days) improved endothelial function by enhancing flow-induced 
vasodilation in elderly diabetics (Tsunekawa et al., 2001). Such endothelial function 
enhancement might be attributed to improved eNOS expression, since human saphenous vein 
ECs treated with ox-LDL (50mg/ml) showed significant endothelial dysfunction associated 
with eNOS mRNA and protein levels. However, simvastatin (1mM) and lovastatin (10mM) 
significantly enhanced eNOS expression by approximately fourfold, which was associated 
with improved endothelial function  (Laufs et al., 1998). 
When STZ-diabetic ECs were treated with insulin for 5 days, TRPV4 expression, 
distribution, and function improved significantly (Figures 58 and 68). Such TRPV4-restored 
expression and distribution were in parallel with CAV-1 (Figure 60c&d) and eNOS-restored 
expression and distribution (Figure 62c&d).  As explained by  H. Wang et al. (2009), insulin 
induces the PI3K/Akt pathway to stimulate eNOS and CAV-1 translocation toward the 
plasma membrane. It also induces eNOS and CAV-1 palmitoylation and thus translocation 
toward the plasma membrane (Hernando et al., 2006). At the same time, eNOS 
palmitoylation increased CAV-1 coupling by tenfold, a process that is required to optimise 
eNOS activity (Shaul et al., 1996). 
Previous researchers have explored the importance of CAV-1 and TRPV4 co-localisation to 
maintain the TRPV4 Ca2+ influx required for EDHF and NO generation and potassium 
channel activation (Rath, Dessy, & Feron, 2009; Saliez et al., 2008; Serban et al., 2010). 
Therefore, TRPV4–CAV-1–eNOS co-localisation might provide a cooperative functional 
complex. ECs constitutively secrete NO through L-arginine oxidation via eNOS, which can 
be induced by blood flow shear stress (Cines et al., 1998; Lüscher & Barton, 1997). Increased 
blood shear stress activates membrane-bound PLA2, which generates AA from the membrane 
cholesterol followed by a series of reactions that generate EET, a direct TRPV4 activator 
(Inoue et al., 2009). Therefore, TRPV4 plays a pivotal role in regulating vascular tone and 
function by sustaining endothelium Ca2+ entry that induces NO, PG, and EDHF generation 
(Inoue et al., 2009; Serban et al., 2010; Watanabe et al., 2008). 
L-NAME partially inhibited TRPV4-induced vasodilation (Figure 27), thereby demonstrating 
that NO is not the only vasodilation contributor in the aorta and that EDHF might provide an 
additional vasodilation pathway (Garland et al., 1995; McCulloch et al., 1997). Furthermore, 
elevated [Ca2+]i as a consequence of TRPV4 activation activates Kca channels, especially 
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BKca, which induces endothelium hyperpolarisation, which is in turn propagated through gap 
junctions into VSMCs and vasodilation (Edwards et al., 2010). 
The BKca blocker iberiotoxin (10nM) significant suppressed 4-αPDD-induced vasodilation 
(Figure 30), which supports what was concluded by Earley et al. (2005): that TRPV4 forms a 
signalling complex with BKca to generate VSMCs hyperpolarisation and vasodilation. 
Moreover, TRPV4 mediates Ca2+ influx through cooperative gating in MEPs that activate the 
BKca to exert VSM hyperpolarisation and, in turn, vasodilation (Bagher & Garland, 2014). 
Since the removal of endothelium showed a significant reduction in TRPV4-induced 
vasodilation (Figure 33), TRPV4 has been suggested to induce vasodilation in endothelium-
dependent and -independent ways (Bagher & Garland, 2014). ASMCs’ TRPV4 expression 
was also studied, since TRPV4 showed partial endothelium-independent vasodilation (Figure 
33), and aortic endothelial TRPV4 was downregulated in STZ-diabetic rats (Figures 58 and 
59). A significant reduction in TRPV4 expression was shown in primary ASMCs (Figure 87), 
which suggests that TRPV4 downregulation contributes to the impairment of both 
endothelium-dependent and -independent TRPV4-induced vasodilation. 
8.5. Lack of association between STZ-induced diabetes and TRPM8 
dysfunction 
Pre-contracted diabetic aortic rings became relaxed through icilin CRC without any 
significant difference from nondiabetic aortic rings (Figure 54). Fura-2 Ca2+ imaging studies 
did not show any significant difference in TRPM8-mediated [Ca2+]i elevation in primary ECs 
isolated from either naïve control or STZ-rats’ ECs (Figure 72). These findings of unaffected 
TRPM8-induced vasodilation in diabetes stress promise in managing diabetic endothelial 
dysfunction, since the TRPM8 vasodilatory pathway seems to be NO-independent (Figure 
28). Alternatively, NO-dependent TRPV4 and muscarinic vasodilatory pathways were 
affected in diabetes. 
The co-expression of TRPM8 and TRPV4 channels in the aortic vasculature was concluded 
as novel Ca2+ entry pathways that might control systemic circulation (X. R. Yang et al., 
2006). EDHF provides another vasodilation system in addition to NO and prostacyclin 
(Garland et al., 1995).  
TRPM8-induced vasodilation was significantly compromised when BKca was blocked with 
iberiotoxin (1nM), as shown in Figure 31. Previous studies have concluded that 
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lysophosphatidylinositol is an extracellular mediator and intracellular messenger that affects 
numerous ion channels, including BKCa and TRPM8 (D. A. Andersson et al., 2007; 
Bondarenko et al., 2011a; Bondarenko et al., 2011b). Therefore, BKca might form a 
signalling complex with TRPM8 via lysophosphatidylinositol, which suggests that TRPM8, 
TRPV4, and muscarinic pathways might share BKca as a common vasodilatory downstream 
target in the vasculature.  
TRPM8 and TRPV4 might act along different pathways. Muscarinic receptors are known to 
stimulate PLC, an enzyme that hydrolyses the membranous PIP2 into IP3 and DAG, by 
which IP3 is capable of activating TRPV4 and binding to endoplasmic reticulum’s IP3-R to 
induce stored Ca2+ release and depletion (Everaerts et al., 2010). However, TRPM8 was 
activated through TRP-domain-bound PIP2; therefore, upon the activation of muscarinic 
pathways and subsequently TRPV4, TRPM8 might be inhibited since its cytoplasmic 
activator, PIP2 level, is reduced by way of PLC activation (B. Liu & Qin, 2005; Rohács et al., 
2005). Therefore, endothelial TRPM8 might act chiefly as an inducer of hyperpolarisation, 
since it showed BKca-dependent and NO-independent vasodilation. 
Some diabetic patients with polyneuropathy experience Raynaud’s disease-like symptoms of 
compromised peripheral circulation and cyanotic skin, especially in the fingers (Fries, 
Shariat, von Wilmowsky, & Böhm, 2005). A previous study showed that transcutaneous 
nerve stimulation enhances the peripheral blood flow with a significant temperature rise from 
24°C to approximately 34°C in T2DM patients (Kaada, 1982). A more recent study 
concluded that topical menthol gel (0.04–8.0%) showed a dose-dependent increase in skin 
blood flow in cutaneous microvasculature that was mediated by EDHF (Craighead & 
Alexander, 2016). At the same time, menthol and icilin clearly activate TRPM8 channels (D. 
A. Andersson et al., 2007). Since icilin-induced vasodilation and icilin-induced [Ca2+]i 
elevation are not significantly affected in diabetes, applying the TRPM8 agonist (i.e., 
menthol) peripherally might provide a therapeutic option for mitigating compromised 
peripheral circulation associated with diabetes. 
8.6. Short-term effects of MGO-induced TRPM8-mediated vasodilation 
NA-constricted aortic rings spontaneously relaxed when incubated with MGO (1 or 100 µM), 
as Figures 90 and 100 show. Furthermore, as Figure 94 shows, AMTB significantly 
counteracted the MGO-induced loss of contractility persistence, but not due to the removal of 
the endothelium. In support, r-TRPM8 FlexStation studies showed significant [Ca2+]i 
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elevation in a time- and MGO dose-dependent manner (Figure 98). MGO-induced [Ca2+]i 
became significantly reduced through AMTB (5 and 10 µM) incubation (Figures 99, 101, and 
103), thereby revealing TRPM8 as a possible target for MGO. Moreover, untransfected CHO 
cells showed a far smaller MGO-induced [Ca2+]i rise (Figures 100, 102, and 104) and, when 
incubated with AMTB (5 µM), showed a significant reduction in MGO-induced [Ca2+]i 
(Figure 100, 109, & 111). Previous studies revealed that TRPM8 channels might contribute to 
Ca2+ release from ER cellular stores, even by way of intracellular TRPM8-independent ER 
Ca2+ stores, though the topic requires further investigation (Mahieu et al., 2007; Thebault et 
al., 2005). Nevertheless, MGO might induce vasodilation through ECs Ca2+ pulsars that 
activate the MEPs’ Kca (Bagher & Garland, 2014). Accordingly, in addition to showing its 
pathological role when elevated in diabetic serum, MGO might act as a redox-based cell 
signalling regulator (Chang et al., 2005; X. Jia & Wu, 2007). 
8.7. Conclusion 
This research has demonstrated that the STZ-induced diabetes model mimics several key 
features of diabetes in humans and is therefore an experimentally applicable and useful model 
of diabetes. It moreover revealed for the first time the downregulation of TRPV4 in 
association with CAV-1 and eNOS downregulation in primary diabetic ECs, thereby 
revealing a possible functional complex of TRPV4 and CAV-1 with eNOS, which is 
significantly impaired at several levels in diabetes and restored through insulin treatment. By 
contrast, TRPM8 does not seem to be part of the TRPV4, CAV-1, and eNOS functional 
complex and was thus not affected by diabetes or chronic MGO treatment. 
This study is also the first to link hyperglycaemia with both MGO and ox-LDL elevation and 
to correlate MGO elevation with TRPV4 downregulation via an STZ-induced diabetes model 
for treating primary nondiabetic ECs with MGO ex vivo. It moreover for the first time 
demonstrated an MGO-induced loss of contractility persistence in a whole tissue model, 
which highlighted that MGO is a TRPM8 agonist and could be an acute MGO signalling 
function. 
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8.8. Future work 
8.8.1. Immunoprecipitation of TRPV4, CAV-1 and eNOS in intact human blood 
vessels to translate the downregulation of these three protein found in STZ-
diabetic rats. 
8.8.2. Using CAV-1 knockout model (CAV-1-/-), to investigate whether CAV-1-/- 
would influence the integrity of TRPV4 and eNOS in the endothelium. 
8.8.3. RT-PCR analysis for TRPV4 expression to examine whether the TRPV4 
downregulation is due to transcription, translational or post-translational alteration 
in diabetes. 
8.8.4. Semi-carbazide sensitive amino oxidase (SSAO) is elevated in diabetics plasma, 
which is the responsible enzyme for the bioconversion of aminoacetone into MGO 
and H2O2 (Kalapos, 2013). Moreover, Uribarri et al. (2007) detected significant 
reduction in eNOS expression and activity which was associated with increased 
VCAM-1 expression when healthy volunteers ingested AGE. Additionally, AGE 
ingestion was shown to induce non-alcoholic steatohepatitis after 39 weeks that is 
detected through elevated AST and ALT (Patel et al., 2012). Moreover, Kalapos 
(2013) stated that 11% of glucose is metabolised through sorbitol pathway that 
involves aldose reductase product, acetal which is converted into MGO through 
CYP2E1, an enzyme which is highly elevated in diabetic endothelium, and hence 
exacerbates OS through inhibiting NADPH due to elevated acetone and 
aminoacetone derived MGO. Therefore, human and rat STZ- diabetic serum MGO 
concentration should be measured and correlated with SSAO, endothelial 
CYP2E1, eNOS and VCAM-1 in addition to hepatic aminotransferases. 
Accordingly, if either hepatic enzymes or both with CYP2E1 are elevated in 
diabetic serum, disulfiram or resveratrol (reversible inhibitor) and other CYP2E1 
inhibitors herbal or chemical might be applied (topically or systemically) for 
reversing vascular or neuronal function (Piver, Berthou, Dreano, & Lucas, 2001). 
8.8.5. Since fructose is MGO precursor (H. Wang, Meng, Chang, & Wu, 2006), 
therefore, fructose might be responsible for AGE formation and accumulation, 
eNOS, VCAM-1, SSAO and CYP2E1 should be monitored for human volunteers 
(or rats) ingesting fructose or sucrose compared to other ingesting only glucose, 
since R. J. Johnson et al. (2009) stated that 1mM fructose concentration pc (After 
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meal) causes significant endothelial [ATP] decline that might be progressed to OS 
and ischemia. 
8.8.6. S. Jia et al. (2006) concluded that insulin is structurally altered when incubated 
with MGO that is culminated with influence insulin pharmacodynamics and 
pharmacokinetic properties and hence yielding insulin resistance. Therefore, 
comparing insulin structure between T2D, obese and healthy individuals might be 
another good notion to investigate the possibility of freeing insulin from the MGO 
or other ROS that yields insulin molecular alteration. 
8.8.7. Examine the effect of metformin on cell culture and tissues incubated with 
MGO or insulin (fat or muscular cells), in the presence of (high glucose 
concentration; mimicking diabetes) which should enhance the influx of glucose 
and possibly MGO formation. However, since TRPV4 was significantly reversed 
through insulin treatment, metformin-enhanced tissue insulin sensitivity might 
provide beneficial outcomes in diabetic vasculature. 
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